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Abstract
Adeno-associated virus (AAV) infection triggers a DNA damage response in the cell. 
This response is not induced by viral proteins but by the structure of AAV ssDNA 
being recognized by the cell as damaged DNA. The consequence of this is the killing 
of cells lacking p53 activity. We have observed that cells that lack p21 or pRb activity 
are also sensitive to AAV-induced cell death. We report that cells respond to AAV 
infection by activating two DNA damage-signaling cascades. The first activates the 
p84N5 protein, which in turn activates caspase-6, leading to cell death. The second 
cascade activates the p53-21-pRb pathway, which inhibits activation of the p84N5 
protein and thus prevents cell death. The result o f the antagonistic interaction between 
these two pathways is that cells that do not exhibit functional p53-p21-pRb signaling 
undergo apoptosis as a consequence o f AAV infection. Cells with a functional p53- 
21-pRb pathway are refractory to AAV-induced cell death. These results show that 
p53, although a pro-apoptotic protein, together with pRb and p21 proteins, is a 
member of an anti-apoptotic cellular mechanism. As such, these experiments reveal 
features that may be exploited to specifically kill cells that lack the p53-p21-pRb 
pathway, such as cancer cells.
We also consider the role of DNA damage signaling in the restriction of AAV 
replication. We report that helper viruses may inhibit ATM, ATR and DNA-PK 
signaling and that this may be advantageous for AAV replication. Inhibition o f ATM 
and DNA-PK in tissue culture cell lines led to an increase in AAV replication. We 
show that ATM, ATR and DNA-PK may be responsible for the hyperphosphorylation 
of replication protein A (RPA) in response to AAV infection. We speculate that 
hyperphosphorylated RPA may be a fundamental restriction factor for viral 
replication and delineate novel experimental tools to test such a hypothesis. The 
implications of these observations for oncolytic therapy are discussed.
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Section 1 Introduction
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The family of parvoviruses
The virus family of Parvoviridae exhibit a broad host range spanning from 
invertebrates to humans. The family is comprised of the two virus subfamilies 
Parvovirinae. which infect vertebrate hosts and the Densovirinae, which infect 
insects. Here we will focus upon the vertebrate parvoviruses that may be further sub- 
classified into two groups based upon their replication lifestyles. The autonomous 
parvoviruses, which encompasses the genera Parvovirus and Erythrovirus, may 
replicate autonomously and require the host cell to pass through S phase for viral 
DNA synthesis. The second group is represented by the genus Dependovirus. These 
viruses require co-infection with a helper virus for functions that facilitate a 
productive infection. The intricacies of helper virus aided replication have been 
extensively studied, particularly the helper functions o f Adenovirus, and are discussed 
in the following section of introduction.
The initial identification of Adeno-associated virus (AAV) came in 1965 when 20 pm 
particles were discovered in association with several human adenovirus strains and 
with the simian adenovirus, SV 15. Initial observations (178, 183) led to the 
conclusion that the “adeno-associated particles' were related to the adenovirus 
genome and were in fact a structural component derived from the inside of the 
adenovirus particle. At this point AAV strains were to be known as AS Vs; adeno- 
associated satellite viruses. This was based upon the definition of a satellite being a
sub-viral agent composed of nuclei acid molecules that rely upon a helper viral co- 
infection for productive replication and that a satellite virus is one such satellite that 
encodes the coat protein in which its nuclei acid is eneapsidated. It was only later that 
these small adenovirus-associated satellite virus particles were considered as distinct 
viral entities whereupon the name Adeno-associated virus was adopted (12). Although 
at the time, acknowledging AAV as a satellite virus may have seemed appropriate, 
with a better understanding of the biology of AAV we can certainly see that AAV is 
far more independent than being deemed as a satellite virus would suggest.
At the time of its discovery AAV was thought to very closely resemble the smallest 
RNA viruses recognised at that time know as the picornaviruses. It was thus 
suggested by Mayor and Melnick (179) that in keeping with such nomenclature but 
recognising the DNA nature of the viral genome, that these small DNA viruses be 
known as a picodnavirus. At such a time it was believed that unlike helper- 
independent small DNA viruses whose genome had been identified as a single­
stranded DNA molecule; AAV had a double-stranded genome. We can now, with 
hindsight, emphasise that this is not the case but rather AAV demonstrates a single­
stranded genome but it meant that the whole group be known as parvoviruses and thus 
the family of Parvoviridae was born.
The Parvoviridae can be further subdivided into the two subfamilies of Densovirinae 
and Parvovirinae, (278). The Densovirinae subfamily are parvoviruses of 
invertebrates and their subfamily is broken down into three genera; Densovirus, 
Brevidensovirus and Iteravirus, (27). Members of the Densovirinae subfamily include 
viruses that infect an enormously wide range of insect orders from across the globe. 
Together they are characterised by their ability to replicate autonomously and their 
capacity to encapsidate either plus or minus strands of their single-stranded DNA 
genome. Each virus of the family is named in a logically uninspired way whereby 
they can be identified by either a two letter or three letter abbreviation of the host 
name (one letter of the genus and two letters of the species). As such the examples 
AvDNV fom Agraulis vanillae and LdiDNV from Lymantria dispar typify the 
members of this subfamily. These viruses are notably fatal to their hosts, typically 
causing paralysis (266) or tumour lesions of the intestines.
In contrast to the arthropod hosts o f their relatives, the Parvovirinae infect only 
vertebrates. The Parvovirinae subfamily is yet again separated into three distinct 
genera; Erthythrovirus, Dependovirus and Parvovirus. Erythrovirus replication 
predominantly takes plaee in erythrocyte precursors, hence the name. The 
Dependoviruses are classieally perceived to be reliant upon a helper virus for 
replication and hence the name. The Parvoviruses however are capable of efficient 
autonomous replication. The most widely recognised Erthythrovirus as a consequence 
of its widespread pathogenesis is the Human Erythrovirus genotype 1 (formally B19) 
whose main targets of infection are erthrocyte progenitor cells found within the host 
bone marrow. Depending upon the immunological and haematological state o f the 
host human erythrovirus will cause a range of pathological symptoms from transient 
aplastic crisis to chronic anaemia, (35). The autonomous parvoviruses such as minute 
virus of mice, MVM, infect only a limited range of hosts and tissues. However, the 
spotlight here is particularly centred upon the Dependovirus, AAV.
AAV
In 1966 the first four serotypes of AAV were isolated from adenovirus stocks and 
shown to be antigenically distinct by means of antisera reactivity experiments, (122). 
The advent of new serological data meant that seroepidemiological studies could be 
considered. It was shown that in humans the most prevalent serotypes were types 2 
and 3 whereas types 1 and 4 were seen to be simian viruses. Subsequent years have 
yielded two further serotypes, types 5 and 6 (16, 229). Although type 5 demonstrates 
significant \ariation from the others, type 6 very closely resembles AAV type 1 and 
may not be an additional serotype as may be the case for the proposed serotype 
AAV3H, seen to be a genomic variant of AAV type 3, (229). In 1999 Erles et al. 
examined the seroprevalence of IgM and IgG antibodies to AAV-2 by means of 
AAV-ELISA and found that in each of the three different geographical regions 
investigated (Germany. Brazil and Japan) approximately 50% of those tested were 
seropositive (88) in addition to which latent AAV is thought to be found widely 
disseminated throughout both human and non-human primates (99). Despite the 
startlingly high prevalence of AAV within the population it must be emphasised that 
AAV has not been associated with any negative pathology.
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It has been demonstrated that AAV particles are capable o f binding cells via heparin 
sulfate proteoglycans (HSPG) at the cell surface (284). Heparin sulfate is one of the 
most abundant form of glycosaminoglycan molecules at the surface of the cell and has 
been shown to be the initial attachment molecule for several viruses including herpes 
simplex virus (301). The wide distribution of HSPG at the surface of many cell types 
may in part be responsible for the broad host range o f AAV. Indeed cell lines that are 
deficient in their production of HSPG do not favour AAV-binding nor infection. 
However, AAV cellular binding and entry also appears to require co-receptor 
molecules. Two such molecules have been identified, the human fibroblast growth 
factor receptor 1 (216) and av(35 integrin (265). It is thought that HSPG binding and 
co-receptor interactions may mediate efficiency in terms of viral attachment and entry 
respectively. However, for AAV there is not a singular, defined receptor-coreceptor 
interaction. Mutants of AAV-2 for example that cannot bind HSPG are still infectious 
and AAV4 and 5 have also been shown to bind sialic acids during infection, (284). 
Publications on AAV receptor and coreceptor binding have generated a plethora of 
reported interactions as demonstrated in Table 1.1.1. Following receptor binding it is 
thought that AAV is internalised via clathrin-mediated endocytosis (21). It is 
speculated here that HSPG binding may be facilitated by the presence of fibroblast 
growth factor receptor and that internalisation process is facilitated by the presence of 
aV p5 integrin. Internalisation within the marginally acidic early endosome allows 
entry of the virus into the cytosol following which AAV aggregates in a perinuclear 
local. AAV is then capable of penetrating the nucleus and although the manner by 
which this occurs is somewhat unclear it is presumed to be via nuclear pores (232). 
The processes of viral uptake and trafficking are by no means black and white and it 
is perceived that viral capsids may passage through the cell by one of at least three 
different mechanisms (240). Rapid endocytosis of viral capsids into the cytoplasm, 
free diffusion of both the endosome and virus within the cytoplasm and nucleus or 
directed trafficking via cytoplasmic motor proteins and nuclear tubule structures 
constitute these three distinct processes. Once within the nucleus, regardless of the 
permissive state of the cell, initial second strand synthesis is required to allow for any 
subsequent replication or cellular integration into the host genome.
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Table 1.1.1. Reported AAV receptors and co-receptors. Adapted from (284).
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A A Vs linear single-stranded genome is 4,675 nucleotides in length. Strands of either 
plus (+) or minus (-) polarity may be eneapsidated within the viral particle (257) 
though in vivo experiments have demonstrated that AAV transcription only occurs 
from the (-) strand and that this transcription is mediated by host cell RNA 
polymerase II (174).
The AAV genome comprises only two open reading frames (ORF) one of which 
encodes the non-structural proteins (Rep proteins), the other of which encodes 
structural proteins (Vp proteins), (28). The Rep ORF encodes four proteins with 
overlapping amino acid sequences; Rep 78, Rep 68, Rep 52 and Rep 40. Similarly the 
Vp ORF encodes the structural proteins, V pl, 2 and 3 whose amino acid sequences 
overlap also. The single strand of AAV DNA exhibits both 5' and 3' palindromic, 
inverted terminal repeats (ITRs) o f 145 nucleotides in length (257) that are 
considerably self-complementary and lead to the formation of stable, terminal, T- 
shaped hairpin loop structures. Several functions required for the AAV life-cycle 
have been attributed to the viral ITRs. The Rep-dependent origin o f DNA replication 
is contained within these regions and they are also involved in the regulation of gene 
expression. The ITRs are also crucial for the site-specific integration of the AAV 
genome into chromosome 19 during latent infection. They are also necessary for 
rescue from the latent state when conditions are permissive. Finally, they are required 
for the packaging of AAV DNA into the viral capsids (157). Despite only having two 
open reading frames the genome has three promotors known as p5, p i9 and p40. Thus 
there are three transcriptionally active sections all o f which overlap. There is however 
a shared polyadenylation site at position 95 and a splice donor site at position 41 (142, 
280). All three of these transcription units make use of the same splice acceptor site at 
position 48, while transcripts originating from p40 are also capable of using an 
acceptor site at position 47. The generation of both spliced and unspliced mRNAs 
from these three promoters lead to the formation of the four Rep proteins and explains 
their overlap in sequence (184). Similarly, the three capsid proteins originate from 
two mRNAs and also have overlapping sequences. The AAV genome may be small 
but is able to efficiently produce a functionally effective and diverse range of proteins. 
This is schematically represented in Figure 1.1.1, which illustrates the three 
promoters, alternate transcripts and splice variants that yield the seven mature RNAs.
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Figure 1.1.1. Schematic representation of transcription and coding regions for AAV. The p5
promotor initiates transcription of a transcript whose spliced version forms Rep 78 and spliced form 
generates Rep 68. The unspliced transcript originating from the pi 9 promotor yields Rep 52, the 
unspliced species of which creates Rep 40. The p40 pro motor generates all of the Vp transcripts. 
Vpl is generated from a different splicing event whereas Vp2 makes use of the same splice event 
used by the Rep proteins 68 and 40. Vp3 is created from the same mRNA by using a different start 
codon. Adapted from (28).
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AAV transcription is orchestrated by a combination o f viral Rep proteins, helper viral 
proteins and cellular components. How the process of transcription proceeds is 
dictated by the permissive status o f the cell. As would be expected, transcription of 
viral genes is repressed during a latent infection. This is thought to involve the action 
of Rep 78 and Rep 68 proteins, which are capable of efficiently suppressing 
transcription from both the p5 and p i9 promoters (137). Repression occurs by the 
direct binding of Rep proteins to the viral DNA, as demonstrated by Kyostio et al. 
1995 (137). It was shown that a region in between the p5 TATA box motif and 
transcription initiation site represented a binding site from which Rep 68 represses 
transcription from the p5 promoter. Aside from direct interaction with viral DNA, Rep 
proteins contribute to the suppression o f gene expression during latency by interfering 
with the cellular transcription components via protein-protein interactions. 
Suppression in this manner occurs during non-permissive conditions but when 
productive infection is permitted, the Rep proteins act as very powerful activators of 
viral promoters. More specifically Rep proteins may both repress and enhance AAV 
transcription in the presence o f a helper virus (210). Furthermore, AAV Rep proteins 
have been shown to inhibit helper virus replication (Adenovirus for example) and 
repress transcription from helper virus promoters (197).
AAV DNA replication
As is the case for most DNA viruses, the parvoviruses replicate in host cell nuclei but 
unlike many viruses they are unable to promote entry of cells into S phase and yet 
display a heavy dependency on host cell factors for replication. While the autonomous 
parvoviruses are restricted to replicating in cells that by natural course enter S phase 
(274), the Dependoviruses i.e. AAV, require co-infection with helper viruses that will 
promote S phase entry in addition to their virally-encoded helper functions. While 
these other virally-encoded helper function will be discussed in the following section, 
this section will deal with the intricacies of the molecular mechanisms of AAV DNA 
replication, reiterating the importance of genomic structure and sequence.
AAV genome replication occurs by a uni-directional, single strand displacement 
mechanism that demonstrates no requirement for Okazaki fragments and thus no 
lagging strand (275). The AAV ITR structure favours the formation of a 3' self-
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complementary region that acts as a primer for DNA synthesis. This is essential for 
converting the single-stranded viral genome into a double-stranded template for 
transcription and replication. While the structure of AAV ITRs is considered the most 
important aspect of their involvement with replication, the ITR sequence contains two 
motifs that represent the minimal origin for DNA replication; the Rep-binding site 
(RBS) and the terminal resolution site (TRS) (292). Figure 1.1.2 graphically illustrates 
the process of AAV genome duplication. Complementary strand synthesis originates 
from the 3' end of the viral genome that folds over to form the primer region of the 
ITR. This produces a linear duplex molecule in which the 3’ hairpin loop structure is 
covalently closed. The viral Rep 68/78 proteins then nick the hairpin structure at the 
TRS. This creates a 3’ primer region that will allow synthesis of the ITR region 
creating a complete duplex molecule. The folding of one end to form the ITR 
structure generates a substrate for single strand displacement replication again as such 
the duplex form represents a single completed progeny single-strand genome that is 
ready for packaging and another substrate for replication, and so the cycle continues. 
However, figure 1.1.2 does not depict the outcome o f failed TRS nicking and terminal 
resolution (123). If TRS nicking does not occur to facilitate terminal resolution of the 
hairpin region from the linear duplex molecule, the formation of double-stranded 
dimers takes place as a consequence of continued synthesis generating head-to-head 
or tail-to-tail dimmers joined by a single ITR. This highlights the importance of Rep 
proteins in the process of AAV DNA replication.
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Figure 1.1.2 A step by step model of the single strand displacement mechanism by 
which AAV DNA Is replicated. The linear single strand of DNA shown in step 1 does not occur 
naturally but rather the palindromic terminal repeat regions form a stable hairpin loop that 
functions as a primer for step 2. Step 2; elongation occurs from the priming region to form a 
duplex replicative intermediate. Step 3; the hairpin intermediate is nicked at the terminal 
resolution site (TRS). The nick site functions as a primer while the strand generated in step 2 
acts as a template for synthesis to restore the S' end of the parental strand. Strand separation 
may occur as in step 4 whereby the S' terminus is free to fold over to then prime a new round of 
replication. Alternatively duplex dimers may be formed if the original hairpin crosslink is not 
resolved. The monomeric replicative forms (mRF) and duplex replicative forms (dRF) are 
indicated.
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Productive AAV infection
AAV may receive the help that it requires for replication (and thus a productive 
infection) from a number of viruses including adenovirus, human papillomavirus and 
herpes simplex virus. The viruses capable of aiding a productive AAV infection are 
seemingly unrelated and there is no clear common link between the ways in which 
these viruses are able to facilitate AAV replication (200). The ways in which 
adenoviral coinfection elicits the help required for productive AAV infection have 
been well characterised in vitro. Adenoviral early functions involve the proteins El A, 
E lB , E2A, E2B, E3 and E4, all o f which (with the exception of E2B and E3) are 
involved in adenoviral helper functions towards AAV by affecting both cellular and 
AAV gene expression (225). It is of interest that neither adenoviral DNA polymerase 
nor terminal protein are involved in aiding AAV replication. In contrast herpes 
simplex virus-encoded enzymes are involved in AAV DNA synthesis. As a 
comparison, the two cases serve to demonstrate the variability in function of helper 
virus coinfection along side that of AAV.
Despite having described the requirement for helper virus co-infection for permissive 
conditions for AAV replication, productive infections have also been observed in cells 
that would normally be characterised as non-permissive. It has been demonstrated that 
in the absence of a helper virus, certain cell lines may become varyingly permissive 
for AAV DNA replication following the application of genotoxic stress treatments 
(303). A shared characteristic of the treatments that generate permissive conditions for 
productive infection is that they are DNA-damaging agents that are capable o f both 
disrupting cell cycle progression and causing the over-expression of certain cellular 
genes. (304). Yakobson et al. proposed several mechanisms by which UV irradiation 
is able to relieve AAV’s requirement for helper viral coinfection. It is suggested that 
AAV may encode a suppressor of its own replication, that a UV-induced cellular 
protein may competitively inhibit or that an alternative UV-induced protein may act 
as a trans-activator. However, these and other hypotheses depend upon UV- 
irradiation-induced change or expression of positively influencing specific proteins. 
No such proteins have been identified and so the mechanisms by which DNA 
damaging agents such as UV are capable of lifting the AAV replication block remain 
unclear.
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Furthermore it has also been demonstrated that AAV can replicate autonomously in 
an in vitro replica o f a differentiating epithelium, the keratinocyte raft system (185), 
and also in synchronised cell populations (304). While the precise mechanisms by 
which synchronisation or differentiation can provide help have not been clarified it 
would not be surprising if the mechanisms by which UV irradiation, synchronisation 
and differentiation impinge on the same mechanism to generate permissive 
conditions. Indeed mechanisms of synchronisation such as hydroxyurea treatment will 
almost certainly induce DNA damage responses that may be reminiscent of genotoxic 
stress-induced responses following UV treatment. In addition to this, many of the 
proteins that are involved in processes of differentiation and DNA damage responses 
may be the same and these processes may be intertwined.
AAV latency
In the absence of a permissive cell state, latent infection occurs. In such cases, AAV is 
capable of intergrating its genome into the cellular DNA. The AAV virion will enter 
the cell whereupon it is trafficked to the nucleus and uncoating takes place. Shortly 
following uncoating a small quantity of Rep protein is produced, the function of 
which is to suppress any further expression from the AAV genome as discussed. The 
viral DNA genome is then integrated into the host cellular genome in a site-specific 
manner on chromosome 19q (136) and remains there without phenotypically 
detectable effects until such a time that conditions are permissible, (28). In such cases, 
co-infection with a helper virus activates and rescues the integrated viral genome from 
the cellular DNA.
The pre-integration site has been cloned and sequenced and is known as AAVSl. The 
AAVSl site contains the same Rep-binding motif and terminal resolution motif found 
in the viral ITR. Rep protein can simultaneously bind the viral ITR and the AAVSl 
Rep binding site and this facilitates integration by initiating Rep-mediated nicking of 
the AAVSl terminal resolution sequence (298). The model for AAV integration is 
somewhat speculative but following nicking it is proposed that a nick-induced primer 
promotes replication by the assembled cellular replication factors and Rep 68/78, 
which hold a circularised duplex of AAV genomes in close proximity of the AAVSl
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site. The ability of Rep proteins to promote strand-switching during replication as 
suggested in the model of AAV DNA replication provides the basis for the proposed 
mechanism of the replication events that underlie AAV integration though there is 
little evidence for the actual mechanism of integration (158).
Prior to integration the AAV single strand genome must undergo second strand 
synthesis and these duplex forms will frequently circularise (78, 79). While 
integration of AAV DNA represents one long-standing mechanism by which AAV 
can establish persistence in host tissues. It has become clear that wild-type AAV DNA 
can exist for a period of latency via circular episomal forms (237) in agreement with 
previous observations that recombinant AAV vectors achieve latency over extended 
periods in a similar form (236). The circular forms also represent a substrate for 
potential integration and non-circularised forms may only be a very transient state.
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Chapter 2 The Eukaryotic Cell Cycle
• The eukaryotic cell cycle and its regulation
• DNA replication
• Regulation of growth and proliferation 
The eukaryotic cell cycle
The eukaryotic cell cycle revolves around the process of DNA replication. The cell 
cycle is segregated into four phases; G l, S, 0 2  and M phase. S phase represents the 
period of the cell cycle in which DNA synthesis takes place, hence S (for synthesis) 
phase. The process of cellular DNA synthesis requires that each and every 
chromosome is replicated once and only once per cell division. The process of 
chromosomal duplication begins in regions of the DNA known as replication origins. 
A pair of duplicated chromosomes is known as a pair of sister chromatids each of 
which must be segregated into each of the daughter cells during mitosis (M phase). 
Following this, the cell undergoes cytokinesis in which the cell physically divides and 
becomes two daughter cells. Prior to M phase the nuclear membrane dissolves and the 
duplicated chromosomes must be equally segregated into the daughter cells. This 
requires the formation of the mitotic spindle microtubular networks to which sister 
chromatids are anchored. Chromatid pairs are separated to oppiste poles by the 
mechanical pull o f the microtubules. Ultimately the cell then divides into two, each 
containing a complete set of chromosomes.
The 01 and 02  phases are considered as gap phases that separate S phase and M 
phase and provide time for cells to acquire the appropriate cellular conditions and 
context required for DNA replication or division. These gap phases also represent 
important periods for cell cycle regulation to prevent un-timely transitions into 
replication or division. 01 in particular represents a key transition point in terms of 
passage through the cell cycle. Cells pause in 01 until conditions are favourable for 
DNA replication. Cells may also remain in this non-dividing state for a prolonged 
period of time. A prolonged non-dividing state in this phase of the cell-cycle is also 
known as OO.
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When the cell cycle is conceptually reduced down to the four phases of G l, S, 0 2  and 
M it gives the illusion of a simple system. Indeed, the cell elegantly performs the 
process of extremely precise replication o f its genome to produce two identical 
daughter cells with ease. However, this does not emphasise the pivotal importance of 
high fidelity with regards to DNA replication, segregation and division without which 
complex organisms might never survive. In order to achieve such accuracy, a complex 
regulatory network rigorously controls the simple cycle from Gl through to mitosis 
and cytokinesis.
For the purpose of understanding the control o f cell-cycle progression we must 
consider the three major cell cycle transition points. The restriction point, is the point 
at which the cell is considered to enter the cell cycle and occurs in the late stages of 
G l. The G2/M transition represents the point at which entry into mitosis takes place 
and ultimately the final stages of mitosis are controlled at the metaphase-anaphase 
transition. There are several networks that compose biochemical switch-like 
operations to carefully regulate passage through the cell-cycle and regulate transition 
at these three key points. Central to this control system are the cyclin-dependent 
kinases (Cdks) and their regulatory components, the cyclins. The following sections 
will discuss Cdk and cyclin function, regulation and their control of cell cycle 
progression.
The family of Cdk proteins share the properties of being catalytic kinase proteins that 
are regulated by cyclin protein partners. Regulation is such that the activation of Cdks 
requires binding to cyclins. Further regulation takes place at the level of 
phosphorylation as full Cdk activation requires threonine phosphorylation proximal to 
the catalytic site. Upon activation. Cdks cell-cycle progression by phosphorylating 
cellular proteins at serine or threonine residues in a sequence-specific manner. The 
process of cyclin-binding to Cdk partners is able to regulate Cdk activity because the 
active site of the Cdk when it is bound to cyclins. Together, cyclin-Cdk interactions 
are fundamental in being able to govern cell-cycle progression since the oscillating 
changes in the activity of Cdks dictate the phosphorylation status of target proteins 
that affect the cell cycle.
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To achieve oscillating changes in Cdk activity one might imagine that the 
concentrations o f individual Cdk proteins may change in phase with the changes in 
cell-cycle status. This however is not the case. Instead changes in Cdk activity are 
achieved by changes in levels of the cyclins while Cdk concentrations remain constant 
throughout the cell cycle. Different pairs of cyclin-Cdk complexs are formed at 
different stages of the cell-cycle and specifically govern progression from one phase 
to another. In Homo sapiens the nomenclature for cyclin-Cdk proteins is different to 
that of other model systems used for considering the biology of the cell-cycle. The 
simple model in H. sapiens is that the Gl cyclins are predominantly cyclin D l,2  and 3 
in complex with Cdks 4 and 6. Cyclin E and Cdk2 govern the 01 to S phase transition 
(190). Cyclin A and Cdks 2 and 1 regulate S phase and cyclin B in complex with 
Cdkl regulates mitosis. Cdkl is also known within the literature as cdc2.
Although, cyclin-binding is a pivotal determinant in terms of Cdk activation, full Cdk 
activation requires further phosphorylation and de-phosphorylation steps. Cdk- 
activating kinases (CAKs) phosphorylate Cdks at a threonine residue adjacent to the 
catalytic site and may confer full activation to cyclin-Cdk complexes. Such 
phosphorylation however may only take place after the binding of cyclin to Cdk. In 
vertebrates the CAK responsible for phosphorylation of Cdk proteins consists o f a 
trimer formed from Cdk? in combination with cyclin H and M atl. Recent studies 
have also identified a further mammalian CAK protein, p42 (162).
Although threonine phosphorylation of Cdks by CAK is required for Cdk activation, 
this phosphorylation is not used to regulate Cdk activity. O f greater importance are 
two sites of inhibitory phosphorylation. Instead inhibitory phosphorylation of Cdks 
occurs at the conserved tyrosine residue number 15, and additionally in vertebrate 
cells, on the threonine residue at position 14. Phosphorylation of these sites inhibits 
Cdk function (208). The balance between two enzymes; one a phosphatase and one a 
kinase regulate phosphorylation o f Thr 14 and Tyr 15. In vertebrates Weel and Mytl 
control the phosphorylation of these two residues whereby Mytl is the key inhibitory 
kinase, phosphorylating both Thr 14 and Tyr 15 and Weel phosphorylates only Tyr 
15. In addition to which the Cdc25 family o f phosphatases carries out opposing 
dephosphorylation. As such Weel and Mytl are inhibitory toward Cdk activity while 
Cdc25 proteins are stimulatory. The phosphorylation status of the two inhibitory sites
23
on Cdks determined by the balance between Cdc25 and W eel/M ytl protein activity 
facilitates G l/S phase and G2/M phase transitions.
As we have already described, Cdk levels remain unchanged throughout the cell 
cycle. Instead it is changes in cyclin levels and phosphorylation status of Cdks that 
regulate Cdk activity. A further mechanism by which Cdk activity is controlled is by 
Cdk inhibitor proteins (CKIs). These proteins are able to inhibit Cdk activity by direct 
binding to Cdk or cyclin-Cdk complexes. These inhibitors are particularly important 
in terms of checkpoint activation in response to DNA damage or inhibitory 
extracellular signals.
In mammals there are two main groups of CKI proteins that are distinguished by their 
mode of Cdk inhibition. These two families are known as the Cip/Kip family of CKIs 
comprising p2I (C ipl/W afl), p27 (KipI) and p57 (Kip2) and the INK4 family, which 
includes plS'^^'^’’, pl6^^^"^ ,^ p l8 '^ ‘^ ‘^‘^ and Members of the Cip/Kip family
inhibit Cdk activity by physical interaction with Cdk and cyclin-Cdk complexes 
(109). Their primary function is to inhibit the G l/S and S-Cdks but they may also 
activate the cyclin D-Cdk4 complex as will be discussed below. Conversely, the INK4 
proteins interact with Cdk4 and Cdk6 inhibiting their propensity for complex 
formation with cyclin D (109, 247).
The biochemical activity of the Cip/Kip proteins is rather complex. Although they are 
inhibitors of cyclin-Cdk2 complexes, (which are predominantly G l/S and S-Cdk 
complexes) the Cip/Kip proteins also aid in the activation o f the G 1-Cdks; Cdk 4 and 
6. The Cip/Kip proteins aid activation in this scenario by enhancing binding affinity 
and thus promoting complex formation between cyclin D and Cdk4 or 6 (138, 246) 
and may help target these complexes for specific function.
CKI expression is modulated in tune with the cell cycle (247). In Gl the CKIs are 
highly expressed to inhibit progression through the restriction point, into S phase. 
Mitogenic signalling can promote cell cycle entry by promoting D type cyclin 
expression for example. The cyclin D-dependent kinases show substrate affinity for 
pRb and promote its phosphorylation and thus transcription of S phase genes (120). 
I he predominantly inhibitory presence of the CKI proteins must be relieved for cell
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cycle progression and this is achieved by targeted destruction of CKI protein in 
response to Cdk-mediated phosphorylation. Thus, as G l/S  Cdk activity increases then 
so does the destruction of CKI thereby allowing S phase progression. Cell cycle 
progression relies upon the biological switch like activation or inhibition o f Cdks, 
which is strictly governed by several overlapping mechanisms as described. This 
highlights the importance and the role of redundancy in biological systems. To 
guarantee that the system as a whole can survive disruption each part is controlled by 
multiple mechanisms and as such should one or more fail the system as a whole can 
survive.
One of the crucial elements of a switch-like activation is that when activation is 
appropriate is should occur in full without the possibility of partial activation. One of 
the elements of maintaining such switches is the process of proteolytic degradation of 
regulatory elements. This is principally carried out by proteosomal degradation 
following ubiquitin targeting. Ubiquitin-mediated degradation is important not only 
for multiple aspects of cell cycle regulation but also in terms of viral life-cycles and 
many viruses encode their own ubiquitin ligase enzymes as indicated in latter 
sections. As such we will discuss the process of ubiquitination and the enzymes 
involved before highlighting their importance for cell cycle progression. 
Ubiquitination involves the attachment of the small protein ubiquitin to target proteins 
in multiple copies or chains which are then recognised by the 26S proteasome that 
will then process the targeted protein into peptide fragments (Hershko and 
Ciechanover 1998). Ubiquitination is facilitated by a chain reaction that begins with 
the ATP-dependent attachment of ubiquitin to the ubiquitin-activating enzyme E l, 
followed by the transfer of the ubiquitin protein to the ubiquitin-conjugating enzyme 
E2. The ubiquitin-conjugating enzyme E2 in conjunction with the ubiquitin ligase E3 
then co-ordinates the attachment o f ubiquitin to the target protein via the generation of 
a peptide bonds. The E3 enzyme represents the mediator o f target specificity and as 
such the key regulator in this process.
As inferred so far, the process o f ubiquitination is crucial for several cell-cycle 
transitions; particularly the G l/S phase transition and the metaphase to anaphase 
transition. To control these transitions there are dedicated ubiquitin protein ligases 
that target the relevant proteins for degradation. Indeed cyclins and CKls are subject
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to periodical proteolysis during the cell cycle (196). These processes are 
predominantly carried out by the SCF complex and the anaphase promoting complex, 
APC. The multisubunit enzyme, SCF, is made up of Skpl, C ull, F-box protein as 
well as the Rbx protein, which binds the E2 ubiquitin conjugate. The SCF unit 
appears to act as a platform for ubiquitination o f target proteins and the F-box protein 
subunit determines such target specificity (126). The interchangeability of the F-box 
protein allows regulation of protein targeting since each F-box protein has affinity for 
different protein substrates. The binding of the F-box protein to its substrate is 
regulated on a further level since F-box proteins typically only bind to phosphorylated 
substrates. The cell-cycle regulation of SCF function can thus be determined by Cdk 
phosphorylation of F-box target proteins.
The metaphase to anaphase transition is a critical point during mitosis when sister 
chromatid separation occurs. Degradation of proteins that control sister chromatid 
cohesion and mitotic cyclins is carried out by a multisubunit enzyme analogous to the 
SCF complex, known as the APC. The APC is composed of up to 13 different 
components and unlike the SCF is regulated by several mechanisms including the 
involvement of activating subunits (191).
So far we have described how the driving force of cell cycle progression, Cdk 
activity, is regulated into oscillations of activity via (a) protein phosphorylation, (b) 
requirements for subunit binding, (c) CKls and (d) targeted proteolytic degradation. 
However, yet another level of regulation takes place by the control of cyclin gene 
expression. The cell cycle dependent synthesis o f cyclins is of prime importance since 
they contribute to the complex regulation of Cdk activity. Transcriptional regulation is 
at its most pivotal at the key cell-cycle transition points; Restriction point, G2/M and 
mitotic exit. While the regulators o f gene expression and the genes that they control 
are moderately we 11-characterised in other model systems such as yeast, they are not 
fully understood in metazoan systems. One of the most crucial families of 
transcriptional regulatory gene products is the E2F group. E2F transcriptional 
complexes are made up of two subunits composed of one E2F family protein, o f 
which there are six in mammals, and one of the two mammalian DP proteins. E2F 
complexes are activators of transcription and they stimulate the transition from G1 to 
S phase by increasing cyclin E and A expression as well as the expression of many
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factors required for DNA replication and thus S phase progression. Functional 
complex formation of E2F/DP heterodimers is controlled by the RB family of pocket 
proteins pRJB, p i07 and p i30 (37, 47, 55). RB proteins inhibit E2F-DP mediated gene 
expression by direct binding to E2F components. The mode of action of inhibition 
depends upon the specific RB and E2F components. While direct binding o f RB 
proteins to some E2F proteins is sufficient to simply prevent E2F-mediated
transactivation there is evidence to suggest that certain combinations o f E2F and RB 
proteins yield repressor complexes that may actively repress the expression of certain 
genes (295, 296). While pRb protein mediated regulation of E2F complexes is an 
important way in which pRb inhibits cell cycle entry, pRb may also regulate 
transcription by modulation o f chromatin structure (314).
The RB family proteins act as the guardians of entry into the cell cycle since they 
function to inhibit G l/S phase gene expression and thus prevent entry through the 
Restriction Point by direct binding to E2F family members. Progression into the cell- 
cycle can only be made by promoting the dissociation of RB-E2F protein complexes 
and this is mediated through phosphorylation of the RB protein component. RB 
phosphorylation is mediated by Cdk activity and pRB, p i07 and p i30 harbour
multiple sites for Cdk phosphorylation and upon phosphorylation demonstrate
extremely low affinity for E2F protein binding. Phosphorylation may also lead to 
targeted destruction since the levels of p i 30 decrease considerably upon
phosphorylation (253). The pRB protein purportedly has two stages to its inactivation, 
firstly mediated by cyclin D-dependent kinases and then by cyclin A or E-dependent 
kinase activity (188). The activity of each cyclin regulated kinase is thought to 
phosphorylate a subset of available phosphorylation sites. Furthermore it is thought 
that the activity of each Cdk is activated by distinct signalling pathways originating 
from growth factor stimulus such as ras signalling (188) thus directly integrating 
various growth factor stimuli with cell cycle control. While the relationship between 
RB proteins and regulation of E2F is considered to be well understood there are 
several aspects that do not fit into such a philosophy of understanding. Despite the 
fact that RB is considered to principally regulate E2F activity, the proportion o f pRb- 
E2F complex represents a minority o f the total cellular pool of E2F complexes. As 
such there appears to be a gap in our knowledge as to what fully regulates E2F
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activity. Perhaps E2F phosphorylation, subcellular localisation and degradation are 
equally as important in terms of maintaining E2F activity in context.
Furthermore recent studies demonstrate that each of the different RB family members 
regulate E2F in different ways and may be responsible for different aspects o f RB’s 
biological significance (84). As a potent tumour suppressor, much of pRB’s role in 
preventing oncogenesis has been attributed its role in regulating E2F activity. While 
this is nevertheless crucial, it is suggested that E2F activity is not totally deregulated 
by a lack of pRB and furthermore interaction with E2F and DP family proteins 
contributes less than 20% of pRB’s reported protein interactions. It is clear that the 
roles of both E2F and pRB are more complex than may have been first envisaged and 
herein lies the gaps in our understanding of vertebrate regulation of cell cycle 
transitions by transcriptional regulation. To emphasise this we can draw on the recent 
suggestion that E2F may function not only as a potential oncogene but also as a 
tumour suppressor. The role of E2F as oncogene can be easily envisaged since E2F 
activity can promote cell-cycle entry and indeed the overexpression of E2F-1 in mice 
can lead to increased rates of tumour acquisition (211). Conversely E2F-1 knock out 
mice demonstrate a wide susceptibility to a variety of tumour types and as such E2F-1 
must also be considered as a tumour suppressor (305). Several theories attempt to 
reconcile these two observations. The ability of E2F to also act as a tumour 
suppressor is proposed to arise the dual modulation of E2F binding domains in 
functioning toward both activation and repression of gene expression depending upon 
the status of RB proteins as mentioned above. Additionally E2F-1 has been shown to 
possess pro-apoptotic function that may be partially responsible for the perceived role 
of E2F in tumour suppression. Perturbations of RB-mediated growth control are 
considered particularly responsible for activating E2F-1-mediated apoptosis via p53. 
Specifically, E2F-1 is thought to regulate apoptotic signalling through ATM, NBS 
and CHK2 activity (215. 227), demonstrating a role for E2F-1 in relaying defects in 
RB-mediated growth control and DNA damage signalling to induce p53 mediated 
apoptosis.
Many of the proteins described herein as key regulators of cell cycle checkpoints are 
so crucial that it is not surprising they are frequently lost in cancers and similarly
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abused by viruses since their inactivation can promote the ideal environment for viral 
DNA synthesis and progeny production. These interactions will be discussed in more 
detail when we consider viral interaction with cell cycle checkpoints and DNA 
damage response (Chapter 4). The cell cycle is clearly very intricately maintained 
both internally by many check and balance mechanisms and externally in terms of its 
response to extracellular inputs. As such the cell is able to function competently in the 
context of its environment and is ideally honed to respond to neighbouring cells as 
part of a unified multicellular organism. This concept will be considered in more 
detail in section 2.3 once we have discussed the intricate process of DNA replication 
that occurs once a cell has finally been granted the right to move into S phase.
DNA replication
DNA replication must occur with the strictest of order to maintain genomic integrity 
and the process of eukaryotic chromosomal replication is a formidable task. 
Understanding the mechanisms that govern DNA replication is important for our 
understanding of DNA damage responses as well as viral replication and the cellular 
factors required for such processes. Therefore, while other aspects of the cell cycle 
are important to gather a thorough understanding of growth and proliferation, the 
processes that occur during S phase will be considered in considerably more detail.
Once the decision has been made for cells to replicate their DNA the control o f S 
phase progression hinges upon origins o f replication. Such origins represent the 
starting points for DNA replication fork progression and the pivot for the ‘once and 
only once' dogma for origin firing and thus regulated DNA replication that ensures 
daughter cells emerge with the correct measure of DNA. A cell prepares its genome 
for replication during G l. Preparation involves the formation of pre-replicative 
complexes (pre-RCs) at origins of replication in a manner known as licensing and 
may only occur when Cdk activity is low and APC activity is high. In higher 
eukaryotes origins are not defined in a sequence-dependent manner and are thought to 
be in part a product of epigenetic modelling (319). Origin firing during S phase 
involves the transformation of pre-RCs into pre-initiation complexes, which involves 
the preliminary unwinding of DNA and loading o f DNA synthesis components as a 
consequence of S phase Cdk activity. The presence of Cdk activity inhibits the re-
29
licensing of origins and this represents one method by which the cell can attempt to 
ensure that the replication of each region of DNA occurs only once.
The ordered formation of the pre-RC involves licensing the genomic origins and this 
process begins with origin recognition by the origin recognition complex, ORC. The 
mammalian ORC is made up of 6 subunits and binds to replication origins in an ATP- 
dependent reaction that is inhibited by Cdk activity and thus cannot take place outside 
of Gl (67). DNA-bound ORC provides the platform for recruitment, of Cdtl and 
Cdc6. These proteins faciltate the loading of the DNA helicase complex; Mcm2-7 
(64). As described, this process of pre-RC formation is restricted to late mitosis and 
early 01 as a simple consequence of inhibition by Cdk activity and by the activity of 
the APC. The role of the APC involves a protein known as geminin. Geminin 
functions as an inhibitor of pre-RC formation by its ability to bind Cdtl and prevent 
its interaction with ORC. Consequently geminin levels are kept low during Gl by 
APC-mediated ubiquitination and thus proteolytic degradation, to allow pre-RC 
formation. In the absence of APC activity in the moments prior to S phase, geminin 
levels are able to rise and as such Cdtl is again sequestered from facilitating pre-RC 
assembly again until the late stages o f the following mitosis (181). The manner in 
which Cdk activity inhibits pre-RC formation is less well defined. One mechanism 
proposes that Cdk-mediated phosphorylation of Cdtl targets it for SCF-mediated 
ubiquitination (160) while Cdk activity may also inhibit the DNA binding ability of 
Cdtl (263) both of which are independent of geminin interactions with Cdtl. 
Furthermore, unbound Cdc6 may also be a target of cyclin A-CDK2-dependent 
proteolysis (59).
The assembly of the pre-RC in which multiple but inactive complexes of Mcm2-7 are 
bound represents a potential starting point for replication but requires the loading of 
pre-initiation complex components in response to cyclin A-CDK2 and Cdc7 activity. 
Cdc7 acts as a direct activator of origin firing and its activity is cell cycle regulated in 
a similar way to that of Cdk activity regulation by cyclin proteins. Cdc7 requires its 
regulatory subunit Dbf4 for activation and Dbf4 levels are strictly regulated by APC- 
mediated ubiquitination. Inactivation of the APC at the G l/S phase transition allows 
the stabilisation of Dbf4, its association with Cdc7 and the activation of Cdc7 which 
facilitates the activation of replication origins. The positive activity of Cdc7 and S
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phase Cdks leads to the loading of the pre-initiation complex components; Mem 10, 
Cdc45, the D bpll complex and the GINS complex that recruits polymerase enzymes 
and promotes the unwinding of the DNA helix to initiate DNA replication. The 
binding of the pre-initiation complex promotes the displacement o f Cdtl and Cdc6 
and the prevention of them re-binding is pivotal to prevent re-replication. Cdk activity 
promotes the binding of Cdc45 to the pre-initiation complex, which is required for 
binding of polymerase cx-primase (322). The initial primase polymerase synthesises a 
short RNA primer using the template DNA strand. This provides a nuclei acid 3’ end 
to which the more processive DNA polymerase enzymes can add new nucleotides. 
The polymerase a-primase enzyme is displaced by replication factor C (RFC) to 
facilitate loading proliferating cell nuclear antigen (PCNA). The more processive 
polymerase enzymes polymerase ô and 8 can associate with PCNA and conduct rapid 
and continuous synthesis of the leading strand in a process that depends upon the 
presence of the single-stranded binding protein, RPA (312). Simultaneously the 
lagging strand is synthesised by discontinuous synthesis with DNA Okazaki 
fragments. Specialised helicase enzymes such as Dna2 helicase and nuclease remove 
RNA primers. DNA polymerase enzymes continue synthesis until they reach the 5’ 
end of a previously synthesised fragment at which point DNA ligase 1 bridges the gap 
to produce a continuous stretch of DNA. Each region of DNA synthesised from a 
single origin is referred to as a replicon and while replicon size can vary from 30 to 
450 kb, replicons within a cluster of origins tend to be o f similar size. This raises the 
question of which origins fire during mammalian replication since we know that far 
more origins are prepared as pre-RCs than will actually fire (204). The factors that 
determine origin licensing and timing of origin firing are two important questions in 
terms of understanding vertebrate replication. Both o f these areas appear to require 
consideration of chromatin structure. Indeed this may be a contributing factor to 
origin determination but also plays an important part in origin usage. It is recognised 
though not fully understood, that transcriptionally active regions o f DNA replicate 
early in that origins fire prior to the latter origins of more transcriptionally silent 
DNA. The difference between these euchromatic and heterochromatic regions 
respectively is not fully characterised but is undoubtedly shaped by chromatin 
structure. DNA damage responses may also play a part in this regulation since ATR
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and CHK2 (discussed further in seetion 3) are important in determining origin firing 
(244).
Chromatin structure represents the folding and packaging of the DNA of each 
chromosome around histone proteins to form nucleosome structures that compact the 
structure of the DNA to allow its ordered and yet compacted packaging into the 
nucleus. DNA is wound around a protein core known as the histone octomer, which is 
made up two copies of each histone H2A, H2B, H3 and H4. Higher order compaction 
of the chromatin into fibres involves interactions between histones in adjaeent 
nucleosomes and non-histone proteins and this largely relies upon covalent 
modifications o f histone tails and the linker histone HI (114), Chromatin structure 
determined by such factors, particularly post-translational modification of histone 
proteins, is a crucial determinant of gene expression and regulation of DNA repair and 
replication. As a reflection of chromatin importance to such processes it is important 
to note that DNA replication during S phase requires not only the precise replication 
of the cellular genomic sequence but also the chromatin structure. As such histone 
synthesis and nucleosome assembly are highly regulated during S phase to allow 
accurate epigenetic inheritance (116).
The result of S phase is a cell with a nucleus that contains a duplicate set of 
chromosomes that are ordered into tightly associated pairs by sister-chromatid 
cohesion. The accurate duplication of the vertebrate cell requires that sister 
chromatids be separated and segregated into two separate daughter cells via mitosis. 
Mitosis is rigorously controlled and cells should not enter into cell division unless any 
aberrancy that arises during S phase has been resolved, similarly mitosis must 
continue to completion if at all and as such the entry into and exit from mitosis 
represent important checkpoints in vertebrate cells. The temporal organisation of 
mitosis is divided into phases; early metaphase, prophase and metaphase involving 
centrosome separation and spindle assembly and nuclear envelope breakdown as 
sister chromatids attach to the spindle and align along the central, metaphase plate. 
The latter stages of mitosis involve anaphase and dissolution of sister chromatid 
cohesion and separation of sister chromatids into opposite spindle poles and 
contractile ring formation to facilitate daughter cell cleavage occurs during telophase, 
the final stage of mitosis. The reformation of nuclear envelopes around separated
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chromosme sets in daughter cells and cytokinesis mark the end of mitosis. The G2/M 
transition and the metaphase to anaphase transition are most important in terms of 
entry and exit. Progression through mitosis is controlled by cyclin A and B and the 
activity of the M phase Cdks is regulated by W eel and Cdc25. The events o f early 
prophase are initiation by cyclin A-Cdk activity since unlike cyclin B-Cdkl, these 
complexes are active and within the nucleus at this stage and they may contribute to 
the activation of cyclin B-Cdk complexes (98). The profile o f cyclin Bl-Cdk activity 
corresponds to the entry of cyclin B1 into the nucleus in mid-prophase and is required 
to stimulate centrosome separation, nuclear envelope breakdown and spindle 
assembly. Levels of the nuclear cyclin A and associated Cdk2 activity rapidly fall 
during mid-prophase in concert with the complete and irreversible activation of cyclin 
B-Cdkl. The inhibitory phosphorylation o f Cdkl restrains cyclin B-Cdkl complexes 
in an inactive state by the inhibitory phosphorylation activity o f the Weel family 
proteins, Mytl and Weel kinases. The activity of these kinases falls rapidly during 
mitosis and as such provides the opportunity for the activation of Cdkl by the Cdc25 
phosphatase enzymes of which there are three isoforms; Cdc25A, Cdc25B and 
Cdc25C (203). Together these three isoforms contribute to the robust on-off switch 
transition for Cdkl activation. The rapid activation of Cdkl during prophase is a 
consequence of the sudden increase in Cdc25A and Cdc25C activity with the 
concomitant decrease in Weel and Mytl activity as a consequence of changes in 
phosphorylation status of all of these proteins. Positive feedback loops lie at the heart 
of Cdkl activation, which is in part catalysed by its own activation of Cdc25 iso forms 
and inactivation of its kinase inhibitors. Changes in the subcellular localisation of 
cyclin B l-Cdkl also govern its activation as does the localisation of Cdc25C whose 
nuclear translocation during prophase is governed by phosphorylation. While Cdk 
activity is certainly pivotal in regulating entry into mitosis, the polo like kinases (Plks) 
are particularly important in the regulation o f mitotic exit though they also retain 
some function in early mitosis. They and the aurora kinase enzymes are important in 
controlling spindle assembly and sister chromatid segregation (Barr et al 2004). 
However, spindle assembly and sister-chromatid separation can only occur in the 
correct conditions to progress through the metaphase-anaphase transition. The 
metaphase to anaphase transition is driven by the activity of the APC with Cdc20 
activator subunit as described earlier and as such any spindle defects will inhibit or 
block the activation of APC^^^^^ and thus mitotic exit.
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Successful DNA replication and cytokinesis to produce identical daughter underlies 
the process of proliferation. O f course for a single cell to become two requires growth 
in concert with replication and division. The processes of growth and proliferation, 
particularly in multicellular organisms, must be controlled and such control must be 
dynamic to support development and complex form. Having summarised various 
aspects of cell-cycle control and the concept o f the cell cycle in general, it is now 
appropriate to introduce the mechanisms that regulate growth and proliferation, at the 
heart of which is the cell cycle.
Control of ceil proliferation and growth
Start, or the restriction point as it is known in mammals, represents the point at which 
a cell becomes committed to entering into the cell cycle and completing a round or 
replication and cytokinesis. In multicellular organisms, such proliferation is strictly 
governed and cells do not proliferate in the manner that we may be accustomed to 
seeing in a tissue culture context. As one can imagine there are differences between 
developmental phase and cell type that require changes to rates of proliferation. It 
would be unfeasible for cells of a multicellular organism to proliferate continuously. 
For multicellular organisms, rates of cellular proliferation depend upon both tissue 
specific genetic programming and signals from the extracellular environment, 
including other cells. The extracellular signals that stimulate cell cycle entry are 
known as mitogens. Mitogenic signalling influences the rate of cell division by their 
effects on the regulators of the G l/S transition, which embodies the restriction point. 
Once we have described the elements that regulate this transition past the restriction 
point, we can approach the mechanisms by which mitogens and developmental 
programming can affect these regulators.
Mitogens are small soluble proteins or peptides that stimulate intracellular signalling 
following binding to extracellular receptors. Mitogen binding promotes receptor 
dimérisation and then phosphorylation of tyrosine residues of the mitogen receptors 
via the kinase domain. The phosphorylated tyrosine residues recruit different SH2- 
domain containing proteins, prompting several signalling cascades. Ras and Myc 
pathways are involved in several mitogenic signalling cascades. Activation of the 
membrane bound GTPase Ras promotes the activation of the MAP kinase pathway.
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Signalling via the MAP kinase pathway results in translocation of MAP kinase 
(MAPK) into the nucleus to phosphorylated proteins that facilitate transcription of 
immediate-early genes such Fos. Immediate-early proteins such as Fos can assemble 
with other factors to yield the transcription activator complex AP-1 to stimulate the 
transcription of genes encoding proteins such as cyclin D l, which is extremely 
important for promoting pRb phosphorylation and entry past the Restriction Point. 
Myc is another immediate-early gene product that stimulates progression through the 
Restriction Point by stimulating various Gl and G l/S cyclin-Cdk components (2).
An alternate pathway that is activated by mitogenic signalling is phosphoinositide-3- 
kinase (PI3K) signalling. PI3K signalling via the phosphorylation of membrane bound 
phospholipids can promote Akt protein kinase activity, which can directly control 
aspects of Gl-Cdk activity. Since cyclin D activity is one of the principle 
requirements for progression through G l/S  transition, it is intuitive that several 
mitogenic signalling cascades promote cell cycle entry by promoting cyclin D 
activity. Cyclin D levels and activity are typically elevated by mitogenic signalling by 
both increased expression and by promoted active complex assembly. The Ras MAP 
kinase pathway is thought to promote cyclin D activity by both of these methods via 
AP-1 mediated transcription of cyclin D l, while Myc induces transcription of cyclin 
D2 and Cdk4. As discussed previously the Cip-Kip Cdk inhibitors are involved in the 
activation of cyclin D-Cdk4 and it is suggested that the assembly of cyclinD-Cdk4- 
p27 requires a MAP kinase-activated assembly factor (50). Mitogenic signalling can 
also stabilise cyclin D levels by inhibiting the activity o f glycogen synthase kinase 3(3 
(GSK3p). which normally functions to promote the nuclear export and proteolysis of 
cyclin D in the cytoplasm (71). This pathway for cyclin D stabilisation requires PI3K 
and Akt activity, and by promoting nuclear retention of cyclin D-Cdk complexes, it 
enhances their activity toward RB proteins.
The activation of cyclin D-Cdk complexes is extremely important for entry into the 
cell cycle. Mitogens promote cell cycle entry in part by enhancing and stabilising 
cyclin D protein. Although the Cip-Kip Cdk inhibitors function to activate cyclin D- 
Cdk complexes, the INK4 Cdk inhibitors are potent inhibitors of cyelin D-Cdk4 and 6 
complex formation. INK4 family inhibitors play an important role in the other side to
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mitogenic signalling via anti-mitogens, which function to inhibit cellular progression 
through the restriction point. One such anti-mitogen is transforming growth factor |3 
(TGFp). TGpp can induce an increase in the levels of the INK4 family inhibitor 
pj i^NK4b pj-omoting Gl arrest (6). As with so many aspects o f cell cycle regulation 
and cell biology the balance between anti-mitogenic and mitogenic signals determine 
whether a cell will progress into cycle.
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Chapter 3 DNA Damage Response in Eukaryotes
• Sensing DNA damage
• Transmitting a DNA damage response
• Transcriptional response to DNA damage
• The regulation of cell fate in response to DNA damage
• Cell-cycle deregulation and genomic instability in cancer
• The molecular basis of cancer and cancer therapy
In order to understand how DNA damage responses influence the cell cycle it is 
important to first thoroughly understand the unperturbed regulation of cell-cycle 
progression. As such this detailed discussion o f DNA damage responses is positioned 
after the description of cell-cycle regulation. However, these two chapters are 
essentially inseparable and should be considered as a whole in order to hold in 
perspective a view of a cell cycling through time. This section gives some insight into 
how cell cycle progression and regulation is manipulated in response to DNA 
damage. Predominantly this involves understanding the concept of cell-cycle 
checkpoints and the manner in which cellular transcription is influenced in response 
to DNA damage to facilitate arrest and repair. We will also consider the regulation of 
cell fate in response to irreparable damage by discussing programmed cell death, 
namely apoptosis.
Sensing DNA damage
As discussed in the previous chapter there are several regulators that over-see the 
progression of the eukaryotic cell cycle through G l, S phase, 0 2  and mitosis. Of 
pivotal importance are the Cdk proteins and their regulation by association with the 
cyclins. We have already considered how Cdk subcellular localisation and catalytic 
sub-unit phosphorylation can modulate their activity and thus speed of transition 
while regulation of cyclin synthesis is of prime importance in this process.
When a cell senses the occurrence of DNA damage, sensor protein signalling 
facilitates cell-cycle arrest. Cells pause at one of the key cell-cycle transition points
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i.e. G l/S or G2/M hence why these transitions are often known as checkpoints. Since 
cyclin-Cdk regulation represents a key mode of regulation for cell-cycle progression it 
is not surprising that signalling to trigger checkpoint activation usually impinges upon 
cyclin/Cdk regulation in some manner. In subsequent sections we will discuss the 
observations that AAV infection can cause cell cycle arrest via DNA damage 
signalling and thus it is relevant here to discuss mechanisms via which cell cycle 
arrest in the event of DNA damage is achieved. To understand how cell-cycle arrest is 
achieved, it is important to understand how damage is sensed in the first instance.
Signalling, which relays the presence of DNA damage to the system that regulates 
checkpoint activation, originates from sensor proteins that function in close proximity 
to DNA lesions themselves. There are several key sensor proteins that will be 
discussed here as general sensors o f DNA damage. Maintaining genomic stability 
requires careful monitoring of DNA replication and as such there are dedicated 
damage sensor systems that function during S phase, these S-phase specific sensors 
will also be considered.
One group of proteins central to the sensor system is the phosphatidylinositol-3 
kinase-like kinases (PIKKs). This group o f proteins comprises the ataxia 
telangiectasia mutated protein (ATM), ATM and Rad3 related protein (ATR) and the 
catalytic sub-unit of DNA protein kinase (DNA-PKcs). These proteins appear to sense 
DNA-damage in a lesion-specific manner and as such will be considered individually. 
ATM is a ubiquitously expressed protein localised predominantly in the nucleus, 
which despite its homology to the PI3 kinases, is a protein kinase (228). One of the 
first important demonstrations of ATM’s ability to phosphorylate proteins in vivo was 
the observation that ATM phosphorylated p53 at serine 15 in response to DNA 
damage (15). This is also one of the first premises upon which one can surmise that 
ATM acts as a damage sensor. Unlike many proposed sensor proteins ATM does not 
appear to have a dedicated interacting partner that directly binds to DNA. However, 
the MRN complex, composed of Mrel 1, Nbsl and Rad50 proteins has been shown to 
be important for ATM activation (145). Since the MRN complex displays various 
DNA-binding capabilities including an ability to assemble linear single-stranded 
DNA fragments together with ATM to form signalling complexes (57), it is likely that 
the MRN complex provides the DNA-binding platform for the sensor activation of
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ATM in response to DNA damage. However, ATM has been shown to possess some 
DNA binding propensity with a preference for double-strand breaks (267). In the 
absence of cellular stress, ATM molecules exist as dimers or multimers that are 
catalytically inactive. It is considered that ionising radiation for example causes some 
manner of changes to chromatin structure that in turn activates ATM. Activation 
involves the intermolecular phosphorylation o f serine 1981 causing the disruption of 
dimer molecules, and takes place within minutes o f DNA damage. Dimer dissociation 
releases ATM molecules whose catalytic domains are no longer concealed and are 
thus liberated to phosphorylate ATM’s many downstream substrates (18). These 
downstream substrates include proteins involved in co-ordinating cell-cycle arrest, 
DNA repair and apoptosis.
ATR is somewhat distinct from ATM in function since it appears to be important in 
the regulation of responses to UV irradiation or replicative stress (Abraham 2001, 
Shiloh 2001) as oppose to ionising radiation-induced strand breaks. Furthermore, 
unlike ATM, ATR is not maintained in a catalytically inactive state by dimérisation. 
However, ATR does appear to have a dedicated DNA-binding partner protein known 
as ATR-interacting protein, ATRIP. In mammals ATRIP colocalises with ATR into 
nuclear foci upon DNA damage or inhibition o f replication, and is phosphorylated by 
ATR (56). The single-stranded binding protein, replication protein A (RPA) is 
required for ATRIP to bind irradiation-induced sites of DNA damage and as such the 
recruitment and activation of ATR is thought to require regions of single-stranded 
DNA (320).
There are two further potential sensor complexes thought to function in sensing 
damage outside of S phase; the 9-1-1 complex made up of RAD9, RADI and HUSl 
and the RAD17-RFC complex. The presence o f RPA on ssDNA is thought to promote 
RAD17-RFC binding to gapped and primed ssDNA and subsequently facilitate the 
binding of the 9-1-1 complex (321).
For simplicity we frequently discuss the sensors o f DNA damage and indeed their 
signalling targets as acting independently, with one sensor for a discrete lesion type 
for example. However, it is undoubtedly the case that there is cross talk between 
sensors, which will affect downstream signalling events. In some respects it is not in
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our favour to attribute very definite roles to these proteins as it may hinder our 
understanding of their roles as more information becomes available but the 
complexity of DNA damage signalling is such that it is important to establish some 
order for descriptive purposes
The above discussion of sensors o f DNA damage does not encompass our 
understanding of surveillance of replication during S phase. During S phase the 
cellular genome is perhaps at it’s most vulnerable to damage particularly from 
replication fork inhibition or collapse and it is o f prime importance that the cell be 
prepared to arrest and be primed for repair. There are several specific mechanisms 
that allow for replication to be completed even in the presence of damage known as 
damage tolerance pathways both of which require properly co-ordinated replication 
arrest. Sensors facilitate the initiation of two types of replication arrest following 
damage during S phase. The G2/M checkpoint, which prevents entry into mitosis in 
the presence of unreplicated or damaged DNA and the intra-S phase checkpoint, 
which represents the slowing of DNA repliaction by the inhibition of further origin 
firing (207). Several of the sensors already discussed are important in terms of 
generating S phase arrest. The MRN complex in particular is important for S phase 
arrest caused by ionising radiation but not UV irradiation-induced S phase arrest 
(155). ATR has also been shown to directly interact with replication forks and may, in 
concert with RPA, survey replication to facilitate rapid checkpoint signalling in the 
event of replication stress (63). It is also true that replication lesions may be converted 
into strand breaks for instance that may be recognised by the sensor mechanisms 
already discussed. There is also evidence for S phase-specific damage sensors 
dedicated to monitoring replication fork progression and co-ordinating arrest. 
Although much of this evidence comes from observations made in yeast there have 
been suggestions of a sensing role of interaction between both TopBPl and RAD9 
and between polymerase e and RADI 7. This is similar to the potential role of the 9-1- 
1 complex and RAD17-RFC already implicated in damage sensing (170, 214).
As is the case for much of the field of DNA damage research there are always 
discrepancies between the many model organisms from yeast to Xenopus through to 
humans. Despite this, a picture does emerge for eukaryotic damage sensing. This 
picture portrays a myriad of sensor proteins that may have their specialities but also
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demonstrate considerable cross talk and interaction. It is quite spectacular to consider 
the many levels at which this suggests a cell may be prepared for the considerably 
diverse forms of damage that may be encountered. It is of importance to note that 
some of the most profound pathologies o f disorders relating to DNA damage 
responses such as Ataxia telangiectasia involve loss or mutation of key sensor 
proteins. It is not surprising that efficient surveillance and this very first step of 
damage signalling is of pivotal importance and that any impairment in our ability to 
sense damage will be detrimental in the extreme.
Transmitting a DNA damage response
Sensing DNA damage represents the first step of a DNA damage response that will 
ultimately lead to arrest, repair or even death. To reach any or all of these outcomes, 
the cell relies on the process of signal transduction from sensors to the key regulators 
of cell cycle progression. This transduction can be simply described stepwise as the 
activation of effector protein kinases by phosphorylation originating from sensor 
inputs. Inputs from sensor proteins are thought to be conveyed to effectors by 
mediator proteins. In humans two of the most prominent effector proteins of DNA 
damage are the protein kinases CHKl and CHK2, and their role in generating a 
transmissible damage signal will be discussed here.
CHK2 protein structure is highly conserved and consists of a key regulatory domain 
known as an activation loop and at least one SQ/TQ residue-rich domain, which 
represents the favoured residue combination for ATM/ATR-dependent 
phosphorylation (17). CHK2 also possesses a ‘fork head associated’ (FHA) domain, 
which is involved in phosphopeptide recognition and is thought to facilitate a 
conditional interaction based on phosphorylation status of an interacting protein 
partner (82). For example this may allow the preferential formation of a platform for 
signal transduction in response to DNA damage-induced phosphorylation o f sensor 
proteins.
DNA damage or the inhibition of replication leads to the rapid phosphorylation of 
CHK2 (177) by ATM. This is then followed by further auto-phosphorylation 
facilitated by the FHA domain (144). There is considerable importance for the FHA
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domain in terms of the phosphorylation of CHK2. As such it is speculated that there is 
a mediator protein involved, which must be recognised by the FHA domain. The 
'mediator of DNA damage checkpoint’ protein, M DCl, is thought to play this role 
though evidence also exists for the importance of 53 BP 1 as mediator and in fact the 
two bear several similarities. Both MDCl and 53BP1, first identified as a p53 
interacting protein (124), are phosphorylated by ATM. Both proteins demonstrate 
physical and functional interaction with phosphorylated H2AX; (phosphorylated form 
denoted by yH2AX) the phosphorylation of which is ATM-dependent following 
ionising radiation, and ATR-ATRIP-dependent following UV irradiation. Strong 
support of 53B Pl’s mediatory role comes from the fact that in response to ionising 
radiation, 53BP1 binds ATM and this binding is necessary for subsequent ATM- 
dependent phosphorylation of CHK2 (73). M D C l’s role may be somewhat more 
complex since MDCl also interacts with the MRN complex and strengthens ATM 
binding to double-strand break lesions (166). In addition to the potential role of 
MDCl and 53BP1 in feedback loops to increase ATM activity in response to DNA 
damage, there are clear positions for these protein in mediating signal from sensor to 
effector i.e. ATM to CHK2.
CHKl is the second effector for signal transmission from ATM and ATR to cell cycle 
regulatory substrates. Experiments suggest that CHKl plays a pivotal role in 
coordinating a G2/M checkpoint and may be important in replication fork recovery 
and monitoring origin firing (93). CHKl appears to be the principle recipient o f ATR 
kinase activity, and human claspin is thought to play the part of mediating the signal 
from ATR (51). Following DNA damage or replication stress, claspin associates with 
ATR, the 9-1-1 complex and CHKl, and is required for CHKl phosphorylation. 
Ultimately the effector roles of CHKl and CHK2 may overlap but they display 
individual characteristics of function that are distinct from one another. For the sake 
of simplicity, it is more important here to highlight the hierarchy of signalling that 
takes place to generate a transmissible signal.
Firstly, sensor proteins recognise DNA damage. Activation of PIKK proteins occurs 
via mediator proteins and chromatin modifications. Ultimately signal amplification 
facilitates effector kinase activation. At this point we need to consider the downstream 
targets of these streams of signalling, which regulate cell cycle progression and DNA
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repair processes. These two aspects depend upon and are very much intertwined with 
transcriptional regulation in determining cell fate. One of the key elements in the 
process of transcriptional regulation in relation to DNA damage is p53. The 
relationship between DNA damage sensing and activation of downstream signalling 
components such as p53 are highlighted in figure 1.3.1. As a key target of cell cycle 
checkpoint pathways, an understanding of p53 function is pivotal to our 
understanding of how cell signalling of DNA damage can be transduced from the 
point of effector activation.
Simple statistics demonstrate the importance of p53 in maintaining genomic stability. 
A staggering proportion of cancers have been linked to mutations of p53 with 
between 50 and 70% of lung, colorectal and breast cancers, exemplifying why p53 is 
one of the most renowned tumour suppressors discovered. First and foremost, p53 is a 
transcriptional activator of genes that contain p53-responsive elements but p53 can 
also function as a transcriptional repressor o f genes that do not (134). Understanding 
p53’s role as a transducer of a DNA damage signal requires an understanding of how 
p53 is regulated. The functional domains o f the p53 protein and various sites o f the 
post-translational modifications of relevance to p53 regulation are summarized in 
figure 1.3.2.
As a transcriptional regulator, the levels of p53 are of prime importance to its function 
but do not solely dictate its activity. Indeed the levels of p53 and its ability to function 
as a transcriptional activator are predominantly regulated by a considerable array of 
post-translational modifications. Phosphorylation, acétylation, méthylation, 
sumoylation and ubiquitination all play important roles and the extensive possible 
modifications reflects the importance of p53 in integrating signals from many sources 
in order to govern a celTs response to a variety of stress signals, not merely DNA 
damage.
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Figure 1.3.1. DNA damage leads to the cell-cycle arrest, apoptosis, DNA 
repair, damage induced transcription and chromatin remodelling via 
complex signal transduction. DNA d a m a g e  m a y  b e  c a u s e d  by a  p le th o ra  of 
bo th  e n d o g e n o u s  a n d  e x o g e n o u s  m e a n s .  T h e  e x a m p le s  h ighlighted  h e re  
include  UV irradiation, rep lica tive  s t r e s s ,  ionising rad ia tion  a n d  te lo m e r e  
e ro s io n .  Tw o of th e  prim ary  DNA d a m a g e  s e n s o r  protein  k in a s e s  involved in 
th e  recognition  of DNA d a m a g e  a r e  ATM a n d  ATR. ATR func t ions  in c o n c e r t  
with th e  ATR in terac ting  protein , ATRIP, w hich  is p h o s p h o ry la te d  by ATR a n d  
c o lo c a l i s e s  with ATR in in tra n u c le a r  foci following DNA d a m a g e  a n d  
replicative s t r e s s .  D oub le  s t r a n d  b r e a k s  (D S B s)  m a y  b e  r e s e c te d  yielding
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s ing le  s t r a n d e d  s e c t io n s  th a t  b e c o m e  b o u n d  by  RPA. C o n c o m ita n t ly  th e  
R A D 17-R F C  c o m p le x  lo a d s  th e  9-1-1 c o m p le x  a t  t h e  d o u b le - s t r a n d e d ,  s in g le ­
s t r a n d e d  junction . In s u c h  a  c on figu ra t ion  A T R  in te ra c ts  with t h e  t a r g e t  
p ro te in s  RA DI 7 o r  RAD9. A lterna tive ly  ATM r e s p o n d s  to  D S B s  via in te rac t ion  
with th e  MRN co m p le x .  T h e  NBS1 c o m p o n e n t  of t h e  M RN c o m p le x  b e c o m e s  
p h o s p h o ry la te d  by ATM a n d  fac i l i ta te s  t h e  in te rac tion  of ATM with o th e r  
t a r g e t s  s u c h  a s  h is to n e  H2AX. ATM a n d  A TR a r e  know n  a s  initiating k in a s e s  
th a t  initiate th e  s igna l  t ra n s d u c t io n  p a th w a y s  th a t  c o n s t i tu te  t h e  DNA d a m a g e  
r e s p o n s e .  T h e  m ed ia to r  p ro te in s  c la sp in ,  BRCA1 a n d  p e r h a p s  o th e r s  
including M D C l (a s  d i s c u s s e d  in t h e  text) facili ta te  th e  ac tiva tion  o f  th e  
e ffec to r  k in a s e s  C h k l  a n d  Chk2 . C h k l  a n d  C h k 2  h a v e  bo th  o v e r la p p in g  a n d  
u n iq u e  func t ions .  C hk2  is a  t a r g e t  o f  ATM signa lling  p re d o m in a n t ly  in 
r e s p o n s e  to  D S B s  th o u g h  A T R  m a y  co n tr ib u te .  C h k l  is a  s u b s t r a t e  for 
p h o sp h o ry la t io n  by both  ATM a n d  ATR. A ctivation  by p h o sp h o ry la t io n  l e a d s  to  
C h k l  a n d /o r  C h k 2  d e p e n d e n t  p h o s p h o ry la t io n  of d o w n s t r e a m  ta r g e t  p ro te in s  
lead ing  to  o n e  or  s e v e ra l  o u t c o m e s  th a t  m a y  fac ili ta te  t h e  rep a ir  of DNA 
d a m a g e  a n d /o r  a r r e s t  or a p o p to s i s .  M any  o f  t h e s e  t a r g e t s  of DNA d a m a g e  
r e s p o n s e  signalling  (and  o th e rs )  a r e  d i s c u s s e d  in m o re  de ta il  in th e  m ain  text.
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Figure 1.3.2. A summary figure of the functional domains of the p53 protein, 
various protein interactions and examples of post-translational modifications.
T he  t ransac t iva t ion  dom ain of p53  s p a n s  th e  N te rm ina l  region from  re s id u e  1 to 4 2 .  
T h e  m ore  centrally lo ca ted  reg ion  of th e  protein , th e  DNA binding dom ain , is loca ted  
within r e s id u e s  102-292 . T h e te t r a m e r i s a t io n  dom ain  s p a n s  r e s id u e s  3 2 3 -3 5 6  within 
which th e  n u c le a r  export  signal is lo ca ted .  T h e  regu la to ry  dom ain  o c c u p ie s  th e  C 
te rm in u s  b e tw e e n  re s id u e s  363  a n d  393 . T h e  r e p o r te d  protein in te rac t ions  with t h e s e  
p53 protein d o m a in s  a re  e x ten s iv e ,  s o m e  of which h a v e  b e e n  d i s c u s s e d  to  s o m e  
d e g re e  in th e  m ain  tex t  an d  a re  in d ica ted  in th e  lower part  of th e  f igure. T h e  p53  
protein u n d e rg o e s  c o n s id e rab le  p o s t- t ran s la t io n a l  modification via phospho ry la tion , 
acéty la tion , m éthylation, ubiquitination. N E D  Delation an d  sum oyla tion . S o m e  of 
t h e s e  m odifications occur in r e s p o n s e  to  n o n -geno tox ic  s t r e s s e s  su c h  a s  osm otic  
s t r e s s  bu t p53 is p redom inan tly  m odif ied  in r e s p o n s e  to geno tox ic  s t r e s s  s u c h  a  s  
replicative s e n e s c e n c e .  UV a n d  DNA b r e a k s  a s  a  result  of ionising radiation. Only a  
few  of t h e s e  m odifications a re  in d ica ted  h e re  in a c c o r d a n c e  with th o s e  re fe rred  to  in 
th e  tex t  T h e  key  k in a s e  e n z y m e s  involved in th e  phosphory la tion  of p 5 3  a r e  C h k l . 
Chk2, ATM. ATR. OAK. p300 . T h e  pos t- t ran s la t iona l  modification of p 5 3  in r e s p o n s e  
to such  s t r e s s  r e g u la te  both t h e  leve ls  a n d  activity of p 5 3  a s  a  t ra n sac t iva t iona l  
activator.
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In terms of levels of p53 protein, the most important interactions are between p53 and 
MDM2 and ubiquitination since these two factors essentially maintain the normal, 
low cellular levels of p53 that are essential for normal cell cycle progression (307). 
MDM2 is an E3 ubiquitin ligase that acts predominantly as a negative regulator of 
p53’s transcriptional activator function by binding to and facilitating the 
ubiquitination of p53 protein. At low levels, MDM2 protein binds to and causes the 
monoubiquitination of p53, which results in translocation and degradation of p53 in 
the cytoplasm while at higher levels, MDM2 catalyses the polyubiquitination of p53 
and its degradation in the nucleus (150).
It is clear that the interaction between MDM2 and p53 must be regulated in the event 
of DNA damage to allow p53 to function as a transcriptional activator. While certain 
covalent modifications (some of which will be discussed later) directly inhibit the 
binding of MDM2 to p53, MDM2 levels are themselves subject to degradation 
following DNA damage (260). The disruption of the MDM2-p53 interaction that 
occurs in response to DNA damage does not necessarily prevent ubiquitination but 
does inhibit p53 degradation leading to stabilisation o f p53 levels.
Phosphorylation is another key determinant o f p53 activity and there are over 20 
characterised phosphorylation sites. The MDM2 binding region in particular contains 
several residues that are phosphorylated in response to DNA damage, of particular 
interest are serines 15 and 20. Serine 15 phosphorylation has been reported to 
positively influence the transactivation capability of p53 (81)while other reports 
suggest an inhibition of MDM2-mediated cytoplasmic export of p53 and thus 
inhibition of degradation (315). Reports suggest that ATM and ATR are the primary 
kinases responsible for serine 15 phosphoryltion in response to both UV and ionising 
radiation, while DNA-PK activity has also been implicated (15, 148, 277). Serine 20 
phosphoylation is reportedly mediated by CHKl and CHK2 in response to UV, 
ionising radiation and reactive oxygen species damage (46, 248). The outcome of 
serine 20 phosphorylation appears to be the inhibition of the MDM2-p53 interaction. 
Discussion of only these two phosphorylation sites does not cover the breadth of 
knowledge with regards to kinases implicated in p53 phosphorylation. However, it 
does demonstrate how DNA damage signalling can impinge upon p53 from various 
levels i.e. both sensor and effector kinase activity. Various other protein modifications
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can be made to p53, such as acétylation, which may depend upon previous 
modification by one or more of the mechanisms discussed above. Ultimately, we see a 
complex picture of modifications that influence p53-regulated genes via p53 
activation. The transcriptional targets of p53 underlie p53’s role in orchestrating both 
G l/S and 02/M  phase cell cycle arrest in response to DNA damage. The steps 
involved in co-ordinating these two cell cyele checkpoints will be discussed and the 
factors downstream of p53 activation will be highlighted.
Although p53 activity is important for both G l/S  and G2/M phase arrest it is clear that 
above all p53 activity is pivotal for G l/S  phase arrest since abrogation of the p53 gene 
entirely prevents Gl arrest in response to ionising radiation. One of the most 
important targets of p53 transcriptional activation in generating G l/S arrest is p21. As 
described in earlier sections, the transition from Gl to S phase requires cyclin-Cdk 
complex formation and kinase activity. O f particular significance is cyclin E-CDK2 
complex formation in progression from G l. As a promiscuous Cdk inhibitor, p21 
disrupts a broad range of Cdk proteins and their activity but pertinent to the role of 
p21 in maintaining a G l/S phase arrest is the inhibition of cyclin E-CDK2 (85). 
Inhibition of cyclin E-CDK2 promotes G l/S  phase arrest by ultimately impinging 
upon the activity of the retinoblastoma tumour suppressor protein pRb. The function 
of pRb is so crucial to cell cycle progression because it governs the activity of the E2F 
transcription factors, the activity of which is to promote S phase by the transcription 
of proteins required for replication. When pRb is phosphorylated it is no-longer able 
to bind E2F and thus E2F is free to conduct it’s transcriptional activities. 
Phosphorylation of pRb is a product of both CDK4/6-cyclin D and CDK2 and cyclin 
E complex kinase activity and since p21’s activity as CDK inhibitor inhibits such 
phosphorylation we see p21 promoting a hypophosphorylated state for pRb, thus 
inhibiting cell cycle progression into S phase (19). There are additional proposed 
mechanisms for prevention of entry into S phase and inhibition of concurrent S phase 
progression but the role of p53 and the p53 transcriptional targets remain of 
paramount importance.
While the role of p53 and hence the role of transcription in generating cell cycle arrest 
is indisputable it is also true that a transcriptional response represents a 'slow ’ 
mechanism of modulating any immediate signalling system. Indeed, in addition to the
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p53-dependent process delineated above there is also a proposed system for a rapid 
response following DNA damage to achieve G l/S  phase arrest involving both the 
degradation of cyclin Dl (4) and the inhibition o f CDC45 binding to the origin (ORI) 
recognition complex (58). The destabilisation of cyclin Dl inhibits cell-cycle 
progression because during normal progression, p21 binds and activates the cyclin 
D1-CDK4 complex allowing cyclin E-CDK2 to promotes entry into S-phase. 
Degradation of cyclin Dl releases p21 and allows p21 to bind and inactivate cyclin E- 
CDK2. The inhibition of CDC45 ORI binding is the eventual result of signalling 
originating from DNA damage-induced activation of ATM and ATR. The resulting 
phosphorylation of CHKl and CHK2 promotes the phosphorylation of CDC25A thus 
targeting it for ubiquitination and eventual degradation by the SCF proteasome. 
Without the phosphatase activity of CDC25 the inhibitory phosphate groups are not 
removed from CDK2 and without cyclin E-CDK2 activity CDC45 will be unable to 
bind to the ORI and thus origin firing is inhibited.
As suggested earlier the G2/M checkpoint response following DNA damage relies 
less heavily upon p53, though a G2/M arrest is a prominent cell-cycle checkpoint. As 
is the case in terms of G l/S phase arrest there are essentially two arms to the 
regulation of the G2/M checkpoint involving the transcriptional activator potential of 
p53 on one hand and the regulation of CDC25 phosphatase on the other. There are at 
least two key targets of p53 transcription that are involved in maintaining G2/M 
arrest. The increased transcription of p21 functions in part to inactivate CDKl via its 
broad range Cdk inhibitor activity. CDKl inactivation also requires the p53- 
dependent transcription of 14-3-3a protein. In this case 14-3-3a promotes the nuclear 
export of CDKl and cyclin B into the cytoplasm thus preventing the activation of 
CDKl required for the onset of mitosis (117). Inactivation and sequestration of CDKl 
and cyclin B is pivotal to maintenance of G2/M arrest and thus prevention of mitotic 
catastrophe, the process of fatal entry into mitosis in the presence of DNA damage 
following the failure of cell cycle checkpoints (44). The transcription of 14-3-3a also 
promotes a positive feedback loop since it blocks the MDM2-dependent 
ubiquitination and nuclear export of p53 thus promoting p53 stabilisation and in turn 
augmenting its own transcription (306). The additional facet to G2/M arrest is the 
prevention of CDC25 phosphatase-mediated removal of the inhibitory phosphate
fie*?,
49
group from CDKl. There are three isoforms of CDC25 and there is some controversy 
as to the isoform of functional importance in this aspect of checkpoint signalling. 
Despite controversy the important model is that the phosphorylation of either 
CDC25A or CDC25C by CHKl inhibits the binding of CDC25 phosphatase to CDKl 
or promotes destabilisation of CDC25 (169, 209) via cytoplasmic sequestration by 14- 
3-3 binding (note the alternate isoform, not the 14-3-30 isoform).
While the G l/S and G2/M transitions represent the most clearly characterised 
checkpoints, there is also evidence for both an S phase checkpoint and an M phase 
checkpoint. S phase arrest most likely involves the inhibition of origin firing. Further 
to this is the role of the structural maintenance o f  chromosomes protein, SM Cl, as a 
substrate for phosphorylation by both ATM-MRN and BRCA1-dependent pathways 
in response to ionising radiation, UV radiation and hydroxyurea treatment (131, 132). 
The precise mode of function of SMCl in generating S phase arrest remains 
unknown. As part of the cohesion complex, which functions to maintain sister 
chromatid cohesion following fork progression, it is possible that phosphorylation 
somehow affects its function in cohesion and perhaps in turn fork progression. 
Similarly the Fanconi anemia product protein, FANCD2 is phosphorylated in an 
ATM-dependent reaction that is also required for S phase arrest though the 
mechanism is not clear (273). Further to these pathways of S phase arrest is the 
anticipated role of replication protein A (RPA) in slowing S phase in response to 
DNA damage. RPA not only plays some roles in detecting DNA damage but may also 
be the recipient of checkpoint signalling during S phase. RPA is essential for DNA 
replication and plays a part in repair and homologous recombination. The function of 
RPA is modulated by phosphorylation (30). In particular hyperphosphorylation of the 
34kDa subunit of RPA mediated by PIKK protein kinase activity is thought to inhibit 
RPA’s function in replication and promote function in repair processes. This may be a 
consequence of hyperphosphoryltion excluding RPA from replication origins (282).
The existence of an M phase checkpoint remains highly speculative and much 
research into this potential checkpoint comes from the study of yeast. In mammalian 
cells DNA damage during mitosis does not necessarily cause arrest though may cause 
a delay in exit from mitosis (254). A potential checkpoint involved in mitotic integrity
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is the mitotic spindle checkpoint which signals diminished centromere function 
following considerable DNA damage (186).
After an extensive discussion of cell-cycle arrest in response to DNA damage it is 
important to consider the potential benefits o f such arrest. It is clear that repair 
mechanisms are likely to be important if  resolving DNA damage is a possibility and it 
emerges that checkpoint signalling may influence the transcription of repair proteins, 
their intracellular localisation and such factors may also be the target of effector 
kinase activity. These concepts will be considered in more detail in the following 
section in which we will describe some of the outcomes of sensing, and then 
transmitting a DNA damage signal as the transcription response to DNA damage.
Transcriptional response to DNA damage
It is not surprising that the vertebrate transcriptional response to DNA damage is 
enormously complex. It involves not merely the transcriptional regulation of genes 
involved in DNA repair processes but also growth factors or growth factor receptors 
and proteins more commonly associated with tissue injury and inflammation (119), all 
of which are extremely interesting when we consider the response of the organism as 
a whole to the presence of DNA damaged cells for example the role of the immune 
system. In fact the pathways that are activated by DNA damage are extremely diverse 
and differs considerably from that of prokaryotes such as bacteria that can summon a 
defined repair response, the SOS response, following DNA damage. This likely 
corresponds to the obvious difference in organism complexity since the vertebrate 
response is not only undoubtedly cell type specific to some degree but must also 
integrate extracellular cues and manage the outcome of a balance between promotion 
of growth and survival with signals of arrest and apoptosis. Compounding this is the 
point that DNA damage is not the only form of cellular stress that proteins such as 
p53 respond to. Furthermore even in the case of DNA damage, a response is not only 
lesion-specific but also modulated in concert with dose.
We have already emphasised the importance of the transcriptional activation 
properties of p53 in relation to the generation o f cell cycle arrest. p53 is also
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important in terms of translational regulation of proteins and processes involved in 
repair mechanisms. In many respects p53 co-ordinates cell-cycle progression in 
concert with repair and cell death, acting very much as the integrating factor of the 
complex system depicted above. It is important to reiterate the point that while 
enhancement of transcription is a very significant property of p53, the repression of 
transcription has also been mentioned as an additional factor in p53-mediated 
translational modulation (316, 317). However, our aim here is to summarise some of 
the understood p53-dependent as well as independent transcriptional responses to 
damage signalling, many of which also involve repair processes.
When we consider repair mechanisms it is important to remember that repair 
processes are largely lesion-specific and of course lesion type is often a reflection of 
DNA damaging agent. In light of this, p53 plays a role in co-ordinating repair of 
various lesion types in response to diverse DNA-damaging insults. First we might 
consider the role of p53 in double-strand break repair such as that resulting from 
exposure to ionising radiation. The process o f double-strand break repair involves 
both non-homologous end-joining (NHEJ) and homologous recombination (HR). One 
component to the involvement of p53 in double-strand break repair is the p53 target 
gene, p53R2, a ribonucleotide reductase. The role o f p53R2 in response to DNA 
damage is thought to be that of supplying the dNTPs that are urgently required for 
repair. It may not only function in the maintenance of the dNTP pool but also directly 
in the protein repair complexes (272). There is also implication for p53’s interaction 
with components of the NHEJ and HR repair pathways (100), though these direct 
protein interactions may not dictate the functional importance of p53 in terms of 
repair.
One of the important repair mechanism employed by cells to repair lesions such as 
those introduced by UV radiation is that of nucleotide excision repair (NER). 
Evidence has come to the fore that implicates p53 in the regulation of NER. In one 
respect p53 appears to directly influence the transcription of proteins involved in 
nucleotide excision repair such as XPC and DDB2, whose roles in global genomic 
repair have not been thoroughly elucidate (3). The contribution of p53 to NER may 
also be by the modulation of chromatin accessibility. The p53 responsive gene 
product GADD45a may in part facilitate this by binding damaged DNA (40).
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GADD45a and b may also contribute to G2/M arrest by regulation of the CDKl- 
cyclin B1 complexes (313). On the other hand p53 may also have a direct role in 
DNA repair processes. p53 has been reported to be able to recognise and bind to 
regions of damaged DNA in a mode distinct from its sequence-specific 
transactivational DNA binding activity (146, 221, 299). p53 has also been shown to 
posses exonuclease activity that may have role in DNA repair (194).
The regulation of cell fate in response to DNA damage
Thus far we have discussed the sensing of DNA damage, the modulation of cell cycle 
progression, changes to the cellular transcriptional profile and DNA repair. Although 
mutation is the driving force of evolution, gross damage to the cellular genome cannot 
be tolerated. If DNA damage cannot be resolved, that is, repair mechanisms are 
insufficient and/or damage is too great, the likely outcome for a metazoan cell is cell 
death. Cell death may manifest itself from one of several processes, but the essential 
mechanistic form of cell death is that of programmed cell death, apoptosis. Cells may 
enter into the cell cycle in the presence o f DNA damage, by the process of adaptation 
but this will frequently end in what has been termed as unregulated cell death, or 
mitotic catastrophe (42). Adaptation in the absence of death is almost certainly the 
prequel to cancer. Although this is generally perceived as a passive mechanism, there 
is data from studies on Drosophilia to suggest that it may indeed be an actively 
regulated system to prevent genomic instability (269), perhaps depending upon CHK2 
activity. In vertebrates it is generally perceived that this form of cell death is unusual 
since apoptotic mechanisms will generally prevail.
However, if DNA damage can be resolved, checkpoint signalling should cease and 
allow the cell cycle to resume. Perhaps when DNA damage no-longer persists there is 
no-longer an activating signal and thus cells are able to overcome cell-cycle 
checkpoint arrest. Perhaps understanding the process of adaptation will teach us 
something about the more favourable process of recovery following successful DNA 
repair and indeed the mechanisms behind both may well overlap. One mechanism that 
is proposed to be significant to recovery from checkpoint arrest following double­
strand breaks involves DNA-PKcs (106). The manner in which this takes place has
53
not been clarified but the dephosphorylation of DNA-PK by protein phosphatase 5 
may well be one such mechanism (293).
The role for p53 in response to DNA damage may extend to the process of recovery 
since several pathways that negatively regulate p53 function appear to be involved in 
the course of recovery; this is not surprising since we have already discussed how p53 
functions so strongly in activating checkpoints. Proposed factors implicated in 
recovery include c-Jun and MYC protein. The mechanism of c-Jun-mediated cell 
cycle re-entry is thought to involve repression o f p53-mediated transactivation and 
thus inhibition of p21 induction (242). MYC protein, more commonly recognised as 
the product of an oncogene, may also function to inhibit the upregulation of p21 in a 
similar mechanism to that of c-Jun via inhibition o f p53 through the protein Mizl 
(118).
However, repair is not always possible and for the safety of the whole organism the 
cells of multicellular organisms have the ability to commit themselves to a cell death 
programme, apoptosis. In many respects apoptosis represents the ultimate fail-safe 
mechanism. We have considered the many pathways that run in parallel to sense 
damage, propagate a signal and give a cell the best opportunity to repair any 
abnormalities in the light of DNA damage. Many of these pathways are at least semi- 
redundant since the cell appears ready for at least one or more pathway to fail and 
ultimately the cell is prepared with a complex array of pathways to ensure that 
emerging aberrant cells cannot perpetuate.
Apoptosis involves the co-ordinated disintegration of the cell by protease and 
nuclease enzymes. An apoptotic cell will typically shrink and the cell membrane will 
bleb out. Chromosome condensation is followed by internucleosomal endonuclease 
activity to yield DNA fragmentation (176). Apoptosis takes course by one of two 
well-characterised pathways, the extrinsic and the intrinsic pathways. Activation of 
the extrinsic pathway involves an extracellular stimulus whereas the intrinsic pathway 
is stimulated from within the cell; as such many of the components of either pathway 
are fairly distinct though they may ultimately converge upon similar effectors. Of 
particular importance are the caspase enzymes, which play a pivotal role in apoptotic 
cascades. The family of caspase enzymes are cysteine proteases that facilitate the
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proteolytic cleavage of cellular proteins upon activation of an apoptotic programme 
(226). The caspases are broadly grouped into two classes, the initiator and the effector 
caspases. In humans the initiator caspases include caspase-2, -8, -9, and -10, while 
the effector caspases are -3 , -6 and -7 . The initiator caspases are auto-activated 
triggering downstream caspase cascades.
The intrinsic pathway responds to intracellular signals and instigates cell death in a 
mode that involves the cytoplasmic release of proteins from the intermembrane, 
mitochondrial space. Cell death stimuli is transduced to the mitochondria via the 
BH3-only domain proteins BID and BIM while the pro-apoptotic BCL-2 family 
members such as BAX, BAK and BOK influence the release of mitochondrial factors 
probably by influencing mitochondrial membrane integrity. There are also anti- 
apoptotic members of the BCL-2 family and these two may interact such that a pro- 
apoptotic member can inhibit the anti-apoptotic activities of the other. Many pro- 
apoptotic proteins are products of genes that contain p53 responsive elements 
including BAX, PUMA, PIGs (p53-induced genes), NOXA, FAS, APAF-1 and 
PERP, many of which impose their pro-apoptotic ability by localising to the 
mitochondria and inducing membrane potential changes that lead to the cascade of 
events that begins with cytochrome c release (285). In particular the PIGs are redox- 
regulating enzymes that control membrane integrity by the formation of reactive 
oxygen species that damage mitochondrial membranes (213). The expression of 
several anti-apoptotic proteins has been shown to be repressed by p53 including Bcl- 
2, MAP4 and survivin (195). The ability of p53 to function at the level of DNA- 
binding and transcription is not the only device at hand for p53’s pro-apoptotic 
function. On one level p53 appears to be directly imported into mitochondria and 
functionally interact with both BAK and BAX to induce membrane potential 
destabilisation (52, 149).
Various pro-apoptotic proteins are released from mitochondria including SMAC 
(second mitochondria derived activator of caspases) and DIABLO (direct inhibitor of 
apoptosis binding protein with low pi), which function to prevent the activity of the 
inhibitors of apoptotic proteins (lAPs). The release o f cytochrome c is of fundamental 
importance however since it promotes the activation of APAF-1 by allowing binding 
of ATP and the formation of the apoptosome, which results in the activation of
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initiator caspase-9. The activation of pro-caspase-9 by the apoptosome leads to the 
activation of the effector caspase 3 and subsequently a collection of downstream 
components that function to dissemble chromatin and encourage DNA fragmentation.
One of the better-studied modes of extrinsic activation involves the tumour necrosis 
factor (TNF) receptor family member, FAS. The binding of FAS ligand to the FAS 
death receptor results in the multimerisation o f the intracellular portion of the receptor 
known as the death domain. Multimerisation allows binding of the FAS-associated 
death domain (FADD) adaptor, which facilitates the recruitment of the initiator 
caspase, caspase 8. This large complex is known as the death inducing signalling 
complex (DISC) and its formation leads to the autocatalytic cleavage of caspase 8 and 
thus its activation. Caspase-8 activation leads to activation of the effector caspase-3 
and a cascade of caspase activation ensues. It is possible that the extrinsic pathway 
can activate the intrinsic pathway via caspase-8 mediated cleavage of BID to facilitate 
release of mitochondrial proteins. A brief summary of the extrinsic and intrinsic 
pathways of apoptosis is described in figure 1.3.3.
It is important to emphasise that both the intrinsic and extrinsic pathways can be of 
significance to DNA damage-induced cell death even though one might imagine that 
DNA damage would be purely sensed by intrinsic mechanisms. For example, DNA 
damage increases the expression of FAS receptor and ligand (130), and UV-induced 
cell death may be mediated by death receptor pathways in some instances (223). 
However it is intuitive that in the majority of cases, it is considered that apoptosis in 
response to DNA damage involves the mitochondrial pathway and that p53 is the co­
ordinator of DNA damage-induced cell death.
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Figure 1.3.3. Schematic representation of the extrinsic and intrinsic pathways to 
apoptosis. T h e  left s id e  of th e  d iag ra m  s h o w s  th e  extrinsic apoptotic  pa thw ay . T h e  
extrinsic apopto tic  pa thw ay  is initiated w h e n  d e a th  rec e p to rs  at th e  cell su rfa c e  
e n c o u n te r  specific  ’dea th  ligands'. L igand  binding in d u c e s  th e  form ation of t h e  d ea th  
inducing signalling com plex  (DISC), which in turn c le a v e s  a n d  ac t iv a te s  th e  initiator 
c a s p a s e s .  which in turn ac tiva te  a  s e c o n d  group  of c a s p a s e s  known a s  e ffec to r  
c a s p a s e s .  which c o n d u c t  th e  ap o p to t ic  p r o c e s s  via t h e  d eg rad a tio n  of key intracellular 
s u b s tra te s .  T h e  right h a n d  s id e  of th e  d iag ram  r e p r e s e n t s  t h e  intrinsic p a th w a y  of 
a p o p to s is  though  it is im portan t to  n o te  th a t  th e  distinction b e tw e e n  intrinsic an d  
extrinsic is purely descr ip tive  a n d  th e r e  is c ro ss - ta lk  b e tw e e n  both  p a th w a y s .  T h e  
intrinsic p a th w ay  of a p o p to s is  c e n t r e s  a ro u n d  th e  m itochondria  a n d  m o re  importantly  
th e  p r o c e s s  of mitochondrial o u te r  m e m b r a n e  pe rm eab il isa tion .
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Several of the kinase proteins involved in checkpoint responses also play a role in 
apoptosis. Their regulation of transcription factors (in addition to p53), may mediate 
the observed requirement for these proteins in DNA damage-induced cell death. For 
instance CHK2 can modulate the preference of E2F-1 for the transcription of pro- 
apoptotic genes by direct phosphorylation (258) while RAD9 of the 9-1-1 complex 
can directly bind to and induce transcription from p53 responsive elements, though 
the role of this in terms of prevention or induction of apoptosis remains to be 
determined (310). There are also the large sub-nuclear structures known as PML 
bodies, which represent aggregates of promyelocytic leukaemia protein, which also 
play a role in the DNA damage response, particularly the response to double-strand 
breaks and may also be involved in regulating apoptosis (291). PML bodies not only 
localise to sites of double-strand breaks but as supercomplexes also contain the DNA 
damage response proteins including the MRN complex and TopBPl as well as p53. 
These PML bodies can influence the acétylation status of p53 and its ability to bind 
MDM2 and thus may be directly involved in sensing and signalling DNA damage 
(66).
In totality the potential pathways that converge to activate and / or repress DNA 
damage-induced apoptosis is beyond the scope o f review but it is hoped that many of 
them have been addressed in summary here, with some emphasis on the importance of 
p53.
Cell-cycle deregulation in cancer
In 2000 Hanahan and Weinberg (111) provided the field with a comprehensive 
evaluation of the changes that must be required for a cell to become a cancer cell. 
Several key features of cancer cells were put into the spotlight as ‘the hallmarks of 
cancer’. These properties include the ability of cancer cells to evade apoptosis, 
insensitivity to anti-growth signals, a limitless replicative potential and self- 
sufficiency in growth signals. We know that the manner in which a cancer cell 
achieves such properties is via a process o f accumulation of both genetic and 
epigenetic changes to genes that regulate such processes. As a consequence of their 
pivotal importance to normal cell existence, many of the genes that are frequently 
mutated in human cancers are known as oncogenes or tumour suppressors and are
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almost always involved in the processes described as hallmarks of cancer, such as 
replication, growth and proliferation, cell cycle checkpoints and apoptosis.
There are various mechanisms by which oncogenes may be activated from their 
normal ‘proto-oncogenic’. Gene amplification, classic mutation and chromosomal 
rearragments all play roles in some of medicine’s most well characterised forms of 
cancer specifically associated with oncogenes such as Burkitt’s lymphoma in which 
the MYC gene undergoes chromosomal translocation. MYC whose function is as a 
regulatory factor during mitogenic signalling is rearranged to be under the control of 
an immunoglobulin gene regulatory element that results in excessive and abnormal 
expression of MYC. Many of the other commonly mutated oncogenes are involved in 
mitogenic signalling such as RAS, EGFR and PDGR. Conversely the disruption of 
tumour suppressors typically involves their inactivation and the mutation of tumour 
suppressor genes usually requires inactivation mutation of both alleles of the gene. 
The list of tumour suppressor genes is inseparable from the cancer pathology that 
their absence promotes, such as ATM and ataxia talengiectasia, BRCAl and 
hereditary breast and ovarian cancer, pRB and retinoblastoma.
Of course not all cancers are associated with disruption to chromosomal structure or 
sequence. O f particular pertinence are the many cancers associated with viruses such 
as cervical cancer and the causative agent, human papillomavirus (HPV). As is the 
case for many virally-initiated cancer states, the process frequently involves 
mechanistic inactivation of tumour suppressor proteins. In the case of HPV, this at 
least involves the viral-induced inactivation of p53 and pRb via interaction and 
degradation by the viral proteins E6  and E7 (74).
When we consider the process o f cell cycle and checkpoint deregulation in terms of 
cancer it is important to bear in mind the idea that for a cell that is a member of a 
multicellular organism, proliferation is not the default. These cells do not undergo 
continuous proliferation and only proliferate when given the correct series of stimuli 
from extracellular mitogens, growth and survival factors. We know that one of the 
classic ‘hallmarks' o f cancer is indeed a loss of dependency upon these signals for 
proliferation. As such it follows that cancer cells frequently acquire oncogenic 
mutations in aspects of mitogenic signalling such as MYC, as exemplified above, or
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even cell-surface mitogen receptors. Ultimately mitogenic signalling is integrated into 
cell cycle control and cancer cells frequently carry mutation that affects cell cycle 
entry and thus G l/S phase gene expression, which is usually regulated by the E2F 
family of transcription factors. All cells, regardless of their tissue origin, must activate 
cyclin-CDK complexes to progress into cycle via phosphorylation of pRB and 
ultimately activation of E2F. Frequently, cancer cells display mutations that are 
associated with pRB’s regulatory role in the G l/S phase transition and affect pRb’s 
ability to restrain E2F’s transcriptional capabilities (245). Potential mutations affect 
the cyclin-CDK complexes that phosphorylate pRb either by overproduction of cyclin 
or CDK subunits or by mutation that renders CDK molecules refractive to CDK 
inhibitors or tumours actually lose a gene required for CDK inhibition such as 
pj^iNK4a less frequent than mutation of the CDK4/cyclinDl- p l 6 *^ *^ '^  ^ -pRb
pathway, which is deficient in high frequency in human cancers ( 172) pRB may itself 
be lost or compromised (2 0 1 , 2 1 2 ).
Multicellular organisms are typically o f a particular size and shape because the tissues 
that constitute the organism are carefully regulated in their size by restriction to 
growth and proliferation while tumours represent cell populations that have lost their 
normal growth restrictions. Growth factors stimulate growth in part by P13 kinase 
activation, which stimulates P1P3 synthesis and in turn leads to Akt activation. Akt 
activation stimulates the protein kinase TOR, which promotes protein synthesis and 
growth in part by increasing the production o f ribosomes (175). To achieve a state 
that forgoes growth inhibition, cancer cells frequently harbour mutations of the P13 
kinase-Akt signalling pathway (230).
While growth factors and mitogenic signalling herald the potential to actively 
encourage growth and proliferation, we know that survival factors function to 
suppress apoptosis and thus grant cells survival in the appropriate context. Cancer 
cells frequently do not require such pro-survival signalling if they have mutations of 
apoptotic apparatus such as over-production of anti-apoptotic mediators such as Bcl-2 
family or loss of the FADD adaptor Apafl.
Unlike cancer cells, normal cells would not respond to constitutively active mitogenic 
signalling but rather this would induce cell-death or permenant withdrawal from the
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cell-cycle, i.e. senescence via upregulation of ARF (156). This response is
known as the hyperproliferation response and is of course frequently suppressed in 
human cancers either by the over-production of survival signals such as Bcl-2 or 
inhibition of pro-apoptotic devices. Since ART signalling in response to 
hyperproliferation promotes cell death via p53, we highlight another reason why loss 
of functional p53 is beneficial to cancer. The loss of p53 is of profound importance to 
human cancer and almost warrants an acknowledgement as a defining ‘hallmark’. As 
a crucial hinge between life and death in response to diverse stress stimuli, not merely 
DNA damage, it is clear how the disruption of p53 function alone can promote 
genomic instability.
The concept of genomic instability essentially represents that way in which we 
perceive the process that drives tumorigenesis. It designates a state of increased 
genetic mutation, loss or rearrangement and potentially arises from an initial phase of 
spontaneous mutation. Several forms of instability may contribute to genome wide 
instability arising from defects or mistakes in various processes. The DNA damage 
responses are of particular importance to this concept since mutations in aspects of 
DNA damage responses and checkpoint signalling frequently predispose genomic 
instability such as loss of p53 or ATM. One form of instability is known as 
microsatellite instability and manifests itself as an increased number of point 
mutations in microsatellite regions of DNA i.e. regions of repetition in DNA 
sequence. This form of instability arises from defects that affect the mismatch repair 
machinery. Defects in mismatch repair leave the genome vulnerable to the 
accumulation of point mutation. Components o f this pathway and the analogous repair 
process of base excision repair are not usually associated with defects that promote 
genomic instability. However the hereditary disease, xeroderma pigmentosum, is 
characterised by a high predisposition to cancer as a consequence of defective 
nucleotide excision repair and thus inadequate repair of UV-induced DNA lesions. 
Despite the involvement of these processes in generating genomic instability, one of 
the most significant paths is via chromosomal instability arising from defects in 
chromosome number or structure i.e. when regions from one chromosome may be 
exchanged or attached to another chromosome. Chromosomal instability is thought to 
arise from DNA damage response defects, telomere erosion as well as defects in 
chromosomal segregation and cell division. O f course not all rearrangements that
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arise from breakage-fusion events will be viable and in many cases such translocation 
and recombinations will be lethal; it is in the few instances when cells survive with 
gross reassortments that chromosomal instability becomes a significant cancer risk.
Defects in the cellular response to double-strand breaks such as MRN and BRCAl 
deficiencies can lead to chromosomal instability via failures in the process of 
homologous recombination. Additionally, telomere defects that allow the emergence 
of chromosome ends unprotected by the telomere cap, will facilitate the fusion of 
broken ends between chromosomes, or following replication, between sister 
chromatid ends (11). This will frequently result in the production o f dicentric 
chromosomes that will undoubtedly be broken by opposing spindle pole bodies during 
division, yielding further broken ends. This represents the model of breakage-fusion- 
bridge cycles that can promote the loss or amplification of large portions of 
chromosome. While the shortening o f telomeres during cell division is important in 
preventing unrestrained proliferation, eroded telomeres can promote the form of 
chromosomal instability described above when p53 defects abrogate the mode by 
which eroded telomeres would normally signal the onset of apoptosis or senescence 
(94).
It is not unusual for cancer cells to harbour unusual (aneuploid) numbers of 
chromosomes and frequently this arises as a consequence of the accidental generation 
of a tetraploid state (four copies of each chromosome) through abnormal cell division 
for example. Subsequent chromosomal segregation may result in uneven and irregular 
chromosomal distribution, expression from which may result in abnormal protein 
expression profiles. Furthermore cancer cells may not harbour the correct numbers of 
centrosomes for segregation and division and this is frequently associated with 
alterations to the spindle checkpoint system such as Mad2 and Bubl (135).
Frequently, the described chromosomal instabilities are accentuated by defects in p53 
and our understanding of how DNA damage repair mechanisms and checkpoint 
signalling overlap and potentiate gross instability is part of how understanding 
tumorigenesis may progress in the future. Understanding how combinations of defects 
and deficiencies manifest themselves in human cancer supports our ability to treat
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tumours. Indeed, many of our weapons against cancer abuse the very factors that 
promote cancer manifestation itself.
The molecular basis of cancer and cancer therapy
Thus far we have discussed how normal cells control their cell cycle, growth and 
proliferation and how DNA damage responses are intimately linked with these control 
mechanisms. We have summarised how DNA damage can be sensed and 
communicated to effectors of cell-cycle arrest, repair and cell death and described the 
important mechanisms that drive tumorigenesis. Finally it is important to consider 
how our molecular understanding of cancer evolution can aid our efforts to minimise 
cancer mortality and target tumours.
The ideal world for cancer therapy would be the complete eradication of all tumour 
cells leaving normal cells unscathed. Our current methods for cancer treatment are 
comparatively barbaric when we consider such an ideal. While surgical removal of 
primary tumours can, in many cases be successful, surgery is frequently not an option 
and in such cases radiotherapy and chemotherapy are the alternatives.
In traditional radiation-based therapy, the molecular basis of cancer is exploited by 
modulation of both dose and frequency to utilize the potential differences between 
tumour cells and normal cell radiosensitivity. The basis for this lies in understanding 
how genotype might predict resistance to both radio and chemo therapeutic agents as 
cancer cells are frequently more sensitive to DNA damaging agents such as radiation 
and drugs that inhibit DNA synthesis or directly damage DNA (108). For example a 
loss of p53 results in genetic instability as a result o f loss of cell cycle checkpoints. 
Flowever loss of p53 can also promote increased survival and radiation-resistance 
since the pro-apoptotic activities of p53 are also abrogated. As such the activation o f 
alternative apoptotic pathways that are independent of frequently abrogated tumour 
suppresors such as p53 is an important therapeutic research focus (108).
The manipulation of checkpoint responses is a further strategy for consideration to 
widen the susceptibility window for treatment. Broad range inhibitors of checkpoint 
kinases such as caffeine and CHKl inhibitors are currently of interest in the
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sensitisation of p53-deficient cells to cell death (318). Another strategy is combination 
therapy devised to trigger DNA damage checkpoints in normal cells to protect them 
from the secondary agent thus making the secondary drug more selective. For 
example the tubulin modifier Taxol that disrupts spindle function is lethal to cells in 
mitosis. Low dose DNA-damaging agents will cause arrest in normal cells that still 
retain normal checkpoint function while cancer cells that are frequently checkpoint 
deficient will continue to cycle thus rendering them more susceptible to subsequent 
Taxol treatment (31).
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Chapter 4 Viral Interactions with the DNA Damage Response
• DNA viruses and the DNA damage response
• Retroviruses and the DNA damage response
• Tumour viruses and cell cycle checkpoints
• Oncolytic viruses
• Thesis Aims
DNA viruses and the DNA damage response
Aside from the various interactions that viral proteins have with cellular factors and 
the potential genomic instability that they may cause (as discussed in more detail in 
section 4.4), there is a fundamental level upon which viruses may interact with the 
DNA damage response. This is because o f the nature of viral DNAs and their 
replication intermediates, which appear as abnormal structures that may potentially 
induce a DNA damage response. As such many viruses have evolved ways 
counteract such responses, which might otherwise prevent or inhibit productive viral 
replication. Furthermore, some viruses may well benefit from such responses.
The DNA damage responses do not constitute our traditional perceptions o f anti-viral 
responses such as the interferon response. Indeed more recently this traditional 
understanding of anti-viral interferon responses was observed to feed into DNA 
damage responses as one of its antiviral mechanisms (270). The DNA damage 
surveillance mechanisms are so well honed through evolution that it seems almost 
natural that this system, so adept at recognising aberrant DNA structures, would be 
employed as an anti-viral defence. Furthermore since DNA damage responses 
function with great efficacy as effectors toward DNA substrates, it is not unlikely that 
the various systems that we recognise as contributing toward cellular defence to viral 
pathogens integrate on many levels and also revolve around DNA damage networks.
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The past decade has seen a considerable increase in our appreciation of viral 
interactions with DNA damage responses and the literature is now teeming with 
reported interactions. In many cases these interactions are not always associated with 
a known function (249) but several other such interactions highlight the importance of 
inactivating the DNA damage response to permit a successful viral life-cycle. 
Alternatively some viruses do appear to benefit from a DNA damage response and 
these too will be discussed below. There are very few instances in which viral RNA 
interactions with DNA damage responses have been reported. Viral RNA interactions 
are more thoroughly considered at the level of retroviruses and as such integration and 
these interactions will be discussed in the following section (4.2). This section will 
attempt to address some of the reported interactions of DNA viruses with the DNA 
damage responses and will specifically deal with experiments that more completely 
demonstrate a well-understood story.
The Adenovirus lifecycle represents one o f the best-characterised examples of how 
viruses may elicit a DNA damage response that can be detrimental to viral 
reproduction. Adenovirus harbours a double-stranded DNA genome with flushed 
ends. These DNA ends are recognised by the cellular repair machinery, which 
attempts to join these ends in a repair-like manner. This is detrimental to the virus 
since it results in circular concatemers of newly replicated genomes that cannot be 
packaged into viral capsids. As such Adenovirus has evolved mechanisms to evade 
the DNA damage repair machinery. The ability o f wild-type Adenovirus to evade the 
cellular repair machinery usually masks the actual DNA damage response. As such, 
much of the work that has alluded to the cellular response to Adenovirus comes from 
the use of mutant viruses that are unable to produce the viral proteins that are required 
to derail the cellular response.
When the E4 protein-encoding region of Adenovirus is deleted and mutant viruses 
produced and used to infect cells, the activation of a response reminiscent of the 
cellular response to double strand breaks is observed. In particular, the formation of 
viral replication centres coincides and colocalises with the accumulation of activated 
ATM and the MRN complex (261). The MRN complex functions as a platform for 
ATM activation in response to cellular DNA damage. The observation that MRN 
complex colocalises with these replication foci suggests that the MRN complex
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recognises some structures present as viral replication intermediates as damaged 
DNA. As the replicative cycle of these mutant viruses continue it was observed that 
replicated viral genomes are joined together to form concatemers that cannot be 
packaged and thus in many respects this represents an unsuccessful productive 
infection since progeny viruses are not produced despite replication taking place. The 
process of joining of these viral genomes appears to involve cellular repair 
mechanisms, particularly the non-homologous end-joining (NHEJ) pathway for DNA 
repair and particularly, DNA-PKcs and ligase IV activity, both of which function as 
important components of the NHEJ response to double strand breaks (33, 261).
The mechanism by which this takes place involves the co-ordinated effort of two 
proteins; the E4orf6 and E4orf3 proteins. These two viral proteins disrupt MRN 
complex activity. E4orf3 expression prevents the accumulation of M rell to 
replication centres and promotes the redistribution of MRN complex components into 
aggresome-like structures (9). While redistribution of MRN prevents concatemer 
formation, the direct degradation o f Mrel 1 by the complex of E1B-55K and E4orf6 
attenuates DNA damage signal transduction thus ablating ATM activation, while 
simultaneously removing the catalyst for viral genome joining (41, 261).
The manipulation of DNA damage signalling and DNA repair mechanisms by the 
Adenoviral oncoproteins E4orf6 and E4orf3 represents an important part of the 
adenoviral life cycle. These aspects of interaction with the cellular DNA damage 
machinery are not the limits of adenoviral manipulation of such responses and further 
aspects of oncoproteins function are considered below in the context of tumour viral 
interactions with cell cycle checkpoints and control.
Viral interactions with PML bodies are also considered to be significant with regard 
to viral replication since several viruses have been seen to influence these intranuclear 
structures also known as NDlOs and PODs. PML bodies are composed of PML 
protein and many other diverse proteins involved in transcriptional regulation, 
apoptosis and cell cycle control. PML bodies are thought to play a role in DNA 
damage responses including apoptosis and chromatin modification as well as gene 
expression and p53 function. PML bodies are considered to function as part of the
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cellular anti-viral defence and as such it makes evolutionary sense that several viruses 
appear to have the ability to manipulate PML body structure and function (199, 222).
Herpes Simplex Virus 1 (HSVl) and Adenoviral interactions with PML bodies have 
been considerably investigated while Epstein-Barr Virus (EBV), SV40 and AAV also 
have reported interactions (89, 96) though for AAV this lies in the context of helper 
viral co-infections. HSV1 and PML body manipulation has been extensively 
investigated and will be used as an example here to explore the concept of viral- 
mediated changes to PML body structure and function. Addition features of the HSV 
lifecycle in terms of viral-induced changes to DNA damage and repair protein 
localisation will also be considered.
PML nuclear bodies are not considered to be particularly mobile structures within the 
nucleus but they are thought to be relatively dynamic in nature in that it is imagined 
that these bodies represent pools o f various proteins that can be readily manoeuvred to 
required sites for function such as regions of DNA damage as proposed in previous 
section 3.2. In the case of HSV for example it is suggested that proteins associated 
with PML bodies become localised adjacent to incoming viral genomes (91). For 
several DNA viruses one also observes the recruitment of DNA damage response and 
repair proteins to viral replication centres. In some cases as described previously (for 
Adenovirus) this may not be beneficial. In a similar way to Adenovirus, HSVl has a 
liner double-stranded genome. However, in the case of HSV 1 the recruitment of the 
MRN complex and activation of subsequent DNA damage responses is considered to 
be advantageous for viral replication since when M rell is removed, viral replication 
is less efficient (153). Conversely, HSVl must disrupt PML bodies for optimum viral 
replication. For HSV-1 the principal protein involved in PML body remodelling is the 
E3 ubiquitin ligase, ICPO. ICPO activity promotes the proteasome-dependant 
degradation of PML (90). If PML-remodelling is inhibited by disruption of ICPO 
expression, viral gene expression is repressed and lytic infection suppressed.
In addition to the degradation of PML protein, HSV ICPO protein also degrades DNA- 
PKcs, which is thought to be beneficial to HSV replication for several reasons relating 
to the role of DNA-PKcs, which includes processing and repair of double strand 
breaks. On one hand it is thought that ICPO maintains the HSV genome in a
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configuration that is optimal for viral replication by inhibiting circle formation and it 
is thought that ICPO may in part achieve this by the degradation of DNA-PKcs (205). 
The latency aspect of HSV infection is an important facet o f herpesvirus pathology 
and relies upon the circularisation o f the viral DNA to promote its dormancy. As 
described, it is considered that HSV may also benefit from some aspects of DNA 
damage signalling and in terms encouraging viral latency, it is thought that HSV may 
benefit from some aspects of the cellular DNA repair machinery. Hence ICPO’s 
degradation of DNA-PKcs is beneficial for the productive, replicative element o f the 
HSV lifecycle when DNA circularisation is not an optimal configuration (125).
The exemplification of adenovirus and herpesvirus interactions with DNA damage 
responses highlights several similarities in terms of the recruitment of DNA damage 
response proteins to replication centres and disruption of PML nuclear bodies. 
However these two viruses are generally perceived to reside at opposite ends of a 
scale with regards to benefits gained from DNA damage signalling, with Adenovirus 
seemingly inhibited by such responses and Herpes virus supposedly benefiting (154). 
DNA damage signalling is extremely complex and many pathways interact perhaps 
via a single protein and so while abrogation of one element may hinder viral 
replication it is not clear what pathways such abrogation would have blocked. A 
balance of benefit versus detriment is entirely artificial and perhaps DNA damage 
signalling as a process is too complex and intricate to make such a distinction, as are 
viral infringements upon such signalling. However, the lessons that can be taken away 
from viral interactions with cellular DNA damage processes and cell cycle mechanics 
may be enormously beneficial to our understanding of cellular processes.
Unlike HSV and Adenovirus, the parvovirus AAV is a non-autonomous virus. Viral 
transcription is minimal in the absence of a helper virus and yet the potential 
interactions of AAV with the cellular DNA damage response is enormously 
significant. Unlike the majority o f DNA viruses reported to have interactions with 
DNA damage signalling, AAV is a single-stranded DNA virus. In the absence of 
permissive conditions the AAV genome can be integrated in a site-specific manner 
into the human genome. As such the AAV genome can exist in different forms; as a 
single-stranded DNA with double-stranded ends, as an independent double-stranded 
molecule, as a, integrated DNA or as a circular double stranded form. These different
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configurations may act as substrates for different elements of DNA damage 
signalling. Indeed in the absence o f any viral transcription, AAV infection results in 
the activation of various DNA damage signals. The infection of various human cell 
lines with AAV reveals the generation of a G2/M arrest (220). This G2/M phase arrest 
is dependent upon the activation of an ATR-dependent response that results in the 
activation of Chkl. Ultimately, this culminates in the inhibition of the cyclinB/cdc2 
complex by the degradation of CDC25C. The observed cell-cycle arrest occurs in 
parallel to the formation of intranuclear foci composed of various DNA damage 
related proteins that colocalise with AAV DNA. It is proposed that RPA, Rad51 and 
DNA polymerase delta are involved in the initial recognition of the single-stranded 
AAV DNA molecule (129). The hypothesis follows that if polymerase delta cannot 
progress along the DNA, a signalling complex reminiscent of a stalled replication fork 
is recruited consisting of ATR and the 9-1-1 complex, which may facilitate the ATR- 
dependent recruitment of BLM protein. The adaptor proteins TopBPl and Brea I 
promote the ATR kinase-mediated activation of Chkl and subsequent G2 arrest.
More recently it has also been shown that using recombinant AAV that viral genome 
processing into circular double-stranded species requires both ATM and DNA-PKcs 
(53). Recombinant AAV is frequently used as an experimental model since 
considerable interest is placed in the development of recombinant AAV vectors for 
use in gene therapy. These vectors resemble wild-type AAV in terms of the single­
stranded genome and terminal repeat structure but of course the viral genes are 
replaced with genes of interest and relevant promoter elements. While some genomes 
will integrate into cellular chromosomes it has been recently observed that both wild- 
type and recombinant AAV can persist in a circular, episomal form (236, 237). It has 
previously been suggested that DNA-PKcs is involved in promoting the formation of 
episomal forms, without which i.e. in the context of SCID mice, linear molecules 
persist that are not usually observed in normal tissues (80, 255), and that DNA-PK 
may inhibit the integration of AAV DNA (256).
The ability of AAV genomes to persist in tissues is one of the most important factors 
for consideration in terms of gene therapy development. The implication that host cell 
repair factors are involved in the process of circularisation and concatemerisation that 
is seemingly required for episomal persistence has lead to the in-depth consideration
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of the cellular pathways that govern such processing. The AAV terminal repeat 
structures represent the substrate for genome processing. The double-strand break 
repair pathway is the predominant recombination mechanism involved in AAV 
genome processing. Using transgenic mice and mutant tissue culture cell line systems, 
several proteins were implicated in being significant for AAV genome recombination 
though the significance of each protein differed somewhat between systems. 
Collectively it was shown that ATM, DNA-PKcs, M re ll, N bsl, BLM and WRN 
proteins were important while the activity of Nbsl was only significant in tissue 
culture cells and DNA-PKcs only in transgenic animals. These differences were 
attributed to the proliferative nature of cell lines. The previously characterised roles of 
these proteins in various aspects o f non-homologous end-joining (NHEJ) and 
homologous recombination (HR) led the authors to propose that NHEJ mechanisms 
were of prime importance for AAV genome processing in quiescent cells and HR 
mechanisms in dividing cells. In particular the authors speculate a role for the single­
strand annealing mechanism of HR, a homology dependent mechanism of double 
strand break repair that requires only small regions of homology, which are aligned 
and intervening sequences are removed (25).
The described interactions of AAV DNA with DNA damage response and repair 
pathways focus entirely upon the cellular responses to AAV DNA as a substrate and 
do not infer a role for any AAV gene products. There are however some reports of 
the AAV Rep gene products in modulating cell cycle progression. Of particular 
interest is the observation that the Rep78 protein elicits a complete S phase arrest 
(233). The study of AAV’s potential oncosuppressive properties has brought to the 
fore AAV’s anti-proliferative activity. In particular there is a strong implication that 
Rep gene expression suppresses helper viral oncoprotein-mediated cellular 
transformation as well as DNA replication and it is likely that these observations 
purvey some cell cycle modulatory role for the Rep gene products. As such, the 
activities of AAV proteins in regulating cell-cycle checkpoints will be discussed here, 
along side our introduction to viral DNA interactions with DNA damage responses.
Rep 6 8  and Rep 78 both induce cell cycle arrest though at different phases o f cell 
cycle progression. Rep 78 can cause complete S phase arrest while Rep 6 8  promotes 
arrest at both G1 and G2 phases of the cell cycle. The apparent difference in activity
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resides in the zinc finger domain of Rep 78, the role of which may be to promote the 
accumulation of hypophosphory 1 ated pRb. The mechanism behind the ability of Rep 
78 to evoke an unusual S phase arrest involves two modes of action. The Rep 78 
protein is able to directly induce DNA damage by nicking of the cellular DNA leading 
to an ATM-CHK2 dependent DNA damage response. The endonuclease activity of 
Rep 78 is not sufficient to generate complete S phase arrest, and it is observed that the 
zinc finger domain is also required. The zinc finger domain promotes the interaction 
of Rep 78 with the cellular protein phosphatase CDC25A resulting in stabilisation of 
the protein but preventing it from activating CDKl and CDK2 thus suppressing its 
cellular activity (29). Whilst these two activities are inseparable in terms of their 
requirement for generating S phase arrest, it remains unclear how these activities may 
be reconciled to result in such arrest. It is proposed that the ability of Rep 78 to 
promote the accumulation of active pRb (233) is relevant to the ability of Rep 78 to 
sustain S phase arrest. It is speculated that the combined endonuclease activity and 
CDC25A inhibition is sufficient to cause the complete activation of cellular pools of 
pRb (29). The authors propose that Rep 78 can activate pRb to such a degree that this 
alone is capable of preventing S phase progress. This is supported by the observation 
that pRb a complete S phase arrest can represent ‘chronic’ pRb-mediated arrest (8 ). 
This is likely mediated by a lack of expression of replication factors, leading to a 
senescence-like programme that is molecularly distinct from a pRb-mediated pause in 
S phase.
The ability of AAV Rep proteins to induce cell cycle arrest in and around S phase is 
undoubtedly a contributing factor to the potential anti-proliferative effect of AAV 
infection. In addition to these interactions it seems that AAV Rep proteins can also 
directly inhibit the ability of tumour virus proteins to cripple the cell cycle checkpoint 
system. It has been shown that AAV Rep proteins can bind and stabilise p53, 
preventing ubiquitin-mediated proteolytic degradation (24). Rep 78 is perceived to 
conduct this activity by direct binding to p53 and is considered to be the principle Rep 
protein responsible for preventing p53 degradation by tumour viruses such as 
Adenovirus. Furthermore, Rep 78 has also been shown to protect the pRB family of 
pocket proteins (pRb, pi 07, pi 30) from inactivation by the Adenoviral El A protein 
(22). It appears that this is achieved by the binding of Rep proteins to E l A thus 
preventing its association with the pRB proteins and rescuing them from targeted
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disruption. It is also postulated that AAV Rep proteins may induce expression of the 
pRB family proteins and thus contribute to their elevated levels via transactivation of 
transcription in addition to direct protection in the presence of Adenovirus. Rep 78 
may also actively suppress E2F-1-mediated transcription providing an additional 
mechanism to suppress cell cycle progression and DNA replication (23). This tri­
partite rescue of cell-cycle checkpoint and DNA damage control proteins represents 
an important facet to how AAV Rep proteins mediate anti-proliferative and indeed 
anti-oncogenic properties.
Retroviruses and the DNA damage response
Contrary to DNA viruses, retroviruses harbour an RNA genome and there have been 
few reports of RNA viral interactions with DNA damage responses. This may be due 
to the counter-intuitive nature of searching for such interactions since RNA substrates 
are not considered to be as important in terms of activation of cellular DNA damage 
responses. However, as we probe deeper into the complex world of DNA damage 
signalling it is becoming clear that RNA processing and transcriptional control 
signalling may play a significant role and be integrated into the DNA damage 
response. As such perhaps forthcoming research will uncover a deeper role for DNA 
damage signalling responses for RNA viruses.
Retroviruses however have a complex element to their life cycle whereby reverse 
transcription of their viral RNA ultimately leads to the formation of a duplex DNA 
molecule that is then integrated into the host cellular genome. As such we can see that 
retroviruses present not only an RNA substrate but also a DNA substrate to the cell, 
which furthermore requires recombinogenic mechanisms to integrate into host DNA. 
In this guise there have been several discoveries that highlight the importance of 
cellular DNA damage repair mechanisms for retroviral life cycles.
Retroviral integration is extremely important for viral persistence but given the 
efficiency of surveillance of cellular DNA integrity it is not surprising that in the 
process of retroviral integration, cellular DNA damage proteins may become 
involved. There are several phases to the process of retroviral integration, which may 
prompt a cellular DNA damage response. The process of retroviral integration
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involves a version of a viraily-encoded integrase enzyme, which facilitates some end 
processing of the viral DNA complex, which itself represents a substrate for DNA 
damage signalling. This is followed by the concerted nicking of cellular DNA with 
ligation into the genome. This process causes localised chromatin structure disruption 
and the momentary introduction of a double-strand break that if not sealed at either 
end of the viral insertion via post-integration repair, may emerge as more complex 
lesion.
The process of post-integration repair is extremely important in terms of avoiding the 
generation of further DNA breaks that might trigger a potent DNA damage response, 
which could lead to perceived irreparable damage and cell death, which is not 
beneficial for retroviral persistence. It is observed that the process of post-integration 
repair is mediated by a host of cellular repair proteins, not virally encoded factors. 
The process and enzymes involved in non-homologous end-joining are considered to 
be required for post-integration repair and as such successful integration. Cells that 
are deficient in the non-homologous end-joining repair pathway appear to be more 
susceptible to cell death following retroviral infection and that retroviral transduction 
is reduced by up to 90% in non-homologous end-joining deficient cells (60, 62). It is 
speculated that cell death is a consequence o f unsuccessful integration leading to 
DNA strand breaks. Biochemical analysis using specific PIKK protein inhibitors 
points to a significant role for DNA-PK and perhaps ATM in the process o f successful 
retroviral integration though the genuine relevance of DNA-PK in the process of 
retroviral integration is strongly contested ( 1 0 , 13).
Despite the controversy regarding the role of DNA-PK in terms of retroviral 
integration it seems that there is some agreement for the importance of the other PIKK 
proteins ATM and ATR in terms of signalling DNA damage during retroviral 
integration and it is clear that the process of retroviral integration does generate a 
DNA damage response. One of the primary indicators of DNA damage signalling and 
indeed changes to chromatin structure is the phosphorylation of histone H2AX. The 
generation of y-H2AX is indicative of an active DNA damage response and has been 
shown to occur in response to retroviral integration (62). While phosphorylated 
histone H2AX is not required for retroviral integration and post-integration repair, its 
phosphorylation suggests the activation of the upstream kinases for which H2AX is a
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substrate, such as ATM, ATR and DNA-PK. It has been shown that retroviral 
integration activates an ATR-dependent DNA damage response (61) and an ATM- 
mediated DNA damage response (141). Such responses are considered beneficial to 
retroviral integration and may aid the process of repair since caffeine treatment (a 
broadly effective inhibitor of PIKK activity) inhibits retroviral transduction 
efficiency. Indeed, ATM inhibitors, caffeine and caffeine-related substances are 
currently being considered for their potential in terms of inhibition of retroviral 
transduction and particularly in terms of HIV therapy (141, 202).
It is clear that the process of integration represents the key point during retroviral life 
cycles at which they are at the mercy of the host cell since cellular DNA repair 
response factors are so crucial to successful integration. Other factors pin-pointed in 
terms of having significant roles in this process are proteins known to be of 
significance to homologous recombination and trans-lesion synthesis, Rad52 and 
Radis. The HlV-1 integrase enzyme is seen to associate with R adi8  and it is thought 
that the trans-lesion synthesis repair pathway may be involved in the process of 
retroviral integration (193).
It is surprising that so many DNA damage response pathways might be stimulated by 
retroviral integration and in totality be of benefit to retroviral transduction. The 
presence of numerous free cDNA retroviral genomes in the nucleus and the lack of 
detrimental DNA damage signalling suggests that retroviruses have evolved to 
predominantly benefit from responses that for many viruses inhibit productive life­
cycles. However, it seems the case that the homologous recombination repair 
component Rad52 does act in detriment to retroviral integration (140). In a Rad52 null 
background, an increase in retroviral integration is observed. It is not considered that 
homologous recombination pathways are inhibitory in general but rather Rad52 
presents a hurdle for retroviral integration by binding of the afore mentioned cDNA 
genomes. The proposed mechanism of inhibition involves the competition between 
Rad52 binding, which does not promote integration; with the dedicated integration 
complexes required for successful integration events.
The wealth of host DNA repair factors implicated as having retroviral interactions, 
and the clarification of their roles in viral life cycles has provided much hope for the
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development of retroviral therapeutics. When we consider the purpose of striving to 
understand viral interactions in general with DNA damage responses it might be said 
that elucidating novel targets for the generation of viral therapeutics is one of the main 
goals of such fields. In the light o f such a purpose one might say that the identification 
of retroviral DNA damage response and repair interactions represents one of the more 
significant success stories of this field with several clinical trials revolving around 
such observations. This may be seen as somewhat ironic when we consider that the 
field emerged with the expectation that DNA viruses would dominate the field.
Tumour viruses and cell-cycle checkpoints
We have already considered at length what constitutes normal cell-cycle progression 
and the key co-ordinating factors that ensure regulated growth and proliferation in the 
correct context for multicellular organisms. However, for viruses the cellular milieu is 
of pivotal importance to viral replication. Though this may not be the same for every 
virus there are some similarities in the general requirement of a cellular context that is 
relevant for replication and the viral life-cycle. In the process of generating such an 
environment some viruses may kick-start a process that may lead to tumorigenesis. 
These viruses are consequently known as tumour viruses because of their unequivocal 
association with cancers, some of which are of considerable relevance to human 
disease.
As described, viruses require cells to be prepared to replicate so that a virus can use 
some of the vital components of replication that it cannot provide itself. To do so a 
virus must force a cell into cycle and to do so a virus must manipulate both cell cycle 
and checkpoint control proteins. To achieve this a virus must encode its own tools, the 
relevant proteins. We have already considered the events that are required to 
overcome cell-cycle checkpoints and promote proliferation in the guise of 
tumorigenesis. Viruses of course reach the same objective by the targeting of the same 
proteins. The viral proteins that facilitate such activity are often referred to as viral 
oncoproteins since the occasional outcome of their activity is cancer.
While the list of viral oncoprotein targets is fairly considerable and includes both 
cyclin, CDKs as well as CDK inhibitors such as p21 and p i 6 , there are two proteins
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whose viral inactivation almost certainly promotes genomic instability and/or 
tumorigenesis; p53 and pRb. Since tumour viral interactions with these two proteins 
are so very important the two will be considered separately in conjunction with the 
relevant viral interactions.
HPV and Simian virus-40 (SV40), inhibit p53 by direct interaction. On the part o f the 
SV40 this takes place via the viral large T antigen (SV40 T-ag), the mechanism of 
which appears to depend in part on the ability o f SV40 T-ag to bind p53 and promote 
sequestration that prevents its function (239). The HPV E6  viral oncoprotein appears 
to hold similar activity to that of the SV40 T-ag in terms of inhibition of p53 activity 
by complex formation with E6 , in addition to which HPV E6  facilitates the 
degradation of p53 via ubiquitin-targeted proteosomal degradation (234).
The adenovirus type 5 proteins ElB-55k and E4orf6 are also considered to inhibit p53 
transactivation via direct binding (309) and targeted degradation (217, 218). The 
human T-cell leukaemia associated virus HTLV-1 can also functionally inactivate p53 
via the viral protein Tax though the mechanism by which this occurs is uncertain. In 
each of these cases the end result o f viral oncoprotein interactions with p53 is the 
inhibition of p53’s tumour suppressor activities. In addition the Kaposi’s sarcoma 
herpes virus (KSHV) encoded latancy associated nuclear antigen (LANA) also 
interacts with p53, suppressing its transactivational activity and disrupting its ability 
to induce apoptosis (97). Further to the role of the KSHV LANA protein in disrupting 
p53 properties it also binds to pRB proteins and promotes E2F transcriptional activity 
(219). As we have extensively discussed a lack of functional p53 activity is a 
fundamental determinant of genomic instability and thus cancer. These viruses have a 
profound influence on genomic stability by their negative regulation of p53 via 
disruption of cell cycle checkpoints and apoptosis.
Viral oncoproteins also target the tumour suppressor protein pRb. As a fundamental 
brake on cell-cycle entry it is intuitive that viruses might be required to manipulate 
pRB activity. As we have already described, pRb is one of several proteins all of 
which bare considerable structural homology (p i07 and p i30 being the further family 
members). Most importantly, they all share the 'pocket’ domains that are responsible 
for their important functional interactions. Of particular significance being
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transcriptional factor binding and inactivation to prevent entry into S phase (294). 
The polyoma viruses encode the large and small T antigens, which constitute versatile 
oncoproteins that have been extensively studied. SV40, BK virus (BKV) and JC virus 
(JCV) are the most comprehensively eonsidered in terms of their interactions with 
pRb (38, 189). The HPV E7 protein has also been widely investigated for its part in 
pRB inactivation and carcinogenesis. The adenovirus E l A protein has considerable 
history with the RB family of proteins sinee the RB group of pocket proteins were 
identified as a consequence o f their binding to adenovirus El A (112).
The adenovirus El A protein targets pRB via the B-Box domain of the protein via the 
LxCxE motif of the El A protein (250) in a way analogous to that of HPV E7 
proteins’ pRB interaction. It is thought that interaction of these viral proteins with 
pRb prevents the binding of other interacting partners that also contain the LxCxE 
sequence motif, sueh as D-type cyclins (192). The E2F group of transcription factors 
do not contain the LxCxE binding motif but it is thought that viral oncoprotein 
binding via the LxCxE domain displaces E2F-pRB binding through competition for 
binding within the pocket region. Ultimately, displacement of E2F from pRB leads to 
the activation of E2F target gene transeription and drives cells into S-phase.
The high risk HP Vs are so named for their oncogenic potential and are clinically 
associated with the majority of cervical cancers. The E7 protein of high risk HPV is 
capable of binding RB family proteins and also eausing the release of E2F. 
Furthermore these E7 proteins target pRb for ubiquitin-mediated degradation, and 
ultimately proteolytic degradation is primarily responsible for E7’s oncogenicity 
(103). Several mechanisms including E7s ability to bind directly to the proteasome 
are considered relevant for E7’s ability to destabilise RB family proteins (26).
The three Polyomaviruses mentioned above, SV40, JCV and BKV are the only 
Polyomaviruses though to have some role is certain human cancers. While JCV and 
BKV are rather common throughout the population, the number of individuals 
serotypically positive for SV40 infection is considered low. As already mentioned, the 
Polyomaviruses encode oncoproteins known as T antigens that are essential for 
replication in the early stages o f infection. The large T antigens of SV40, JCV and 
BKV bare considerable sequence homology and all possess the LxCxE domain that
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provides a binding motif for interaction with pRb and the related pocket proteins p i 30 
and p i07.
Tumour viral interactions with both p53 and RB family proteins are predominantly 
responsible for much of their tumorigenicity and despite being rather different viruses, 
the many viruses described here have evolved exceptionally similar ways to 
counteract p53 and RB protein function to activate the cell cycle. However for many 
of these viruses, p53 and RB interactions are not the limits of their manipulation of 
cell-cycle regulatory mechanisms. Though some of these interactions are not as 
significant with regard to their contribution toward carcinogenesis they are 
nevertheless probably contributing factors to the overall progress of cellular 
transformation. These alternate mechanisms for cell-cycle deregulation are primarily 
based upon the disruption of cyclin-CDK complexes and function. Since the catalogue 
of tumour viral interactions of this nature is extensive, the fundamental strategies 
employed will be considered and examples o f viruses and/or the relevant oncoproteins 
will be considered.
The principles of cyclin-CDK manipulation by tumour viruses involves three main 
approaches all of which function toward the same goal, functional activation of 
cyclin-CDKs. The principles of tumour viral cyclin-CDK activation include (a) the 
inhibition of both classes o f CDK inhibitor, (b) prevention o f the increase in CKI 
expression, (c) stabilisation o f cyclin and CDK proteins and (d) the expression of 
'viraT cyclins that are homologous to their cellular counterparts. For the Cipl/W afl 
class of CDK inhibitors the HPV oncoproteins E6  and E7 act proficiently to inhibit 
p21’s activity. On one hand, E6  appears to reduce the transcription of p21 mRNA 
probably via the previously described p53 disruption, while E7 counteracts CDK 
inhibition by direct competition for p21 binding sites for cyclin-CDK complexes (127, 
128). E7 can also cause the cellular redistribution of p21 and thus can inhibit its 
binding to cyclin-CDK complexes. The INK4 class of CDK inhibitors are also 
susceptible to viral oncoprotein disruption and the HTLV-1 Tax protein is a 
prominent example. Tax appears to be capable o f directly inhibiting the expression of 
pj^iNK4B pjg iNK4c^  pj^iNK4d ^]Q|^ R is also able to bind p l 6  and prevent
cyclin/CDK inhibition (268). With regard to stabilisation of cyclin and CDK protein 
levels. Tax protein stimulates cyclin D expression and by direct protein-protein 
interaction encourages cyclin D-CDK complex formation (110). However, one
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innately simple and yet exceptionally effective mechanism is the viral expression of 
‘viral’ cyclins (187). Essentially this involves viral proteins that bear considerable 
sequence similarity to cellular cyclins. The viral cyclin proteins function in a similar 
way to their cellular homologues and essentially this represents a simple and self- 
sufficient mechanism for enhancing cyclin expression and activity. Approximately 
eight viruses have been shown to encode viral cyclin homologues many of which are 
herpes viruses, KSHV as an example (187).
The viruses described here and their encoded oncoproteins disrupt the cell cycle and 
inactivate cell-cycle checkpoints to achieve a host cell environment in which they can 
thrive. It is probable that one consequence of this is cancer, a state that is probably 
rather beneficial to many viral lifecycles since it means not only continual, 
inappropriate proliferation but also a resistance to cell-death. Since, viruses are 
obligate parasites that require a host cell for replication and indeed a proliferating cell 
for essential replicative factors, these are undoubtedly evolutionarily relevant 
functions.
Oncolytic viruses
The generation of oncolytic viruses perhaps represents one way in which our 
developed understanding of what constitutes cancer cells and understanding the 
defects that define them meets our understanding of viral replication. Considering 
oncolytic viruses is very much the flipside to understanding tumour virus biology. 
Moving from the poise o f how viruses might instigate a cancerous state we will now 
discuss how viruses might be engineered to selectively kill cells with tumorigenic 
potential.
Viruses represent an exceptionally efficient nucleic acid delivery system. Once 
introduced to a susceptible host, a virus will propagate itself within host cells to 
produce progeny that will be transmitted from cell to cell. Ultimately viral replication 
may cause considerable tissue damage as a virus and its progeny spread through a 
susceptible cell population. As such one can envisage harnessing such efficient 
powers of delivery and destruction to target cell populations that may be detrimental 
to a host such as cancer cells. We have considered the mutations commonly
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associated with cancer cells and we know that cancers are essentially clonogenic. As 
such if it were possible to engineer a virus to exploit specific flaws in a cancer cell 
population to yield selective replication in cancer cells whilst leaving normal cells 
unscathed, we would have a highly refined and efficient biotherapeutic agent. If such 
therapy were feasible it may be that one might imagine that in the future a virus could 
be specifically tailored in a patient-specific manner to target specific tumour type with 
in the therapeutic time frame. These concepts are essentially the philosophy behind 
developing oncolytic viruses.
When we consider ‘tailoring’ viruses, the fundamental points are that the virus should 
selectively infect and / or replicate in cancer cells as oppose to normal cells. There are 
several ways in which viruses can and have been manipulated to yield such 
characteristics by engineering key aspects of the virus life cycle to increase specificity 
in this regard.
One of the key mechanisms for engineering specificity for tumour cells is to 
manipulate the virus so that one or several o f the key viral genes are only expressed in 
tumour cells and as such completion of the viral life cycle may only oecur in such 
cells. This method of engineering has been employed to produce oncolytic 
adenovirus, herpesvirus and parvovirus derivatives (5, 7, 171). Oncolytic viruses 
manipulated in this way are regarded as transcriptionally regulated and this typically 
involves the regulation of viral early gene products via tumour-specific enhancer and 
promoter elements (133).
A second method of viral manipulation is to exploit the cellular interferon response by 
preventing viral subversion of interferon defences. Viruses typically evoke a type 1 
interferon response, which has the propensity to signal neighbouring cells to halt 
protein synthesis and as such inhibit virus replication. Many viruses encode proteins 
that can prevent an interferon response from being generated by cells in response to 
viral infection and cancer cells typically have defective interferon responses. As such 
if viruses are manipulated to no longer possess interferon suppression properties then 
normal cells will inhibit their replication by an active interferon response while cancer 
cells will remain susceptible and support viral replication (259). On a similar notion 
viruses can be altered in their ability to prevent induction of apoptosis. Cells typically
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respond to viral infection by attempting to induce an apoptotic response and viruses 
have evolved ways to prevent or delay this. We know that cancer cells frequently lose 
their ability to regulate apoptosis and as such if  viruses are manipulated such that they 
can no longer prevent apoptosis they should only propagate in susceptible cancer cell 
populations.
Viruses naturally display tissue and cell tropisms determined by the surface antigens 
that dictate their receptor specificity. Since the virus itself encodes viral capsid 
proteins, these proteins can be modified such that a virus displays the desired receptor 
specificity. Recombinant viruses can be generated that can only infect via cell surface 
receptors that are exclusively found on tumour cells for instance (198). Viruses can be 
made to express proteins on their surface that will be exclusively recognised by 
tumour antigens such as single-chain antibodies or polypeptide-binding ligands such 
as growth factors. As such these viruses are described as being re-directed since they 
are specifically targeted to cells expressing the relevant associated ligand.
Ultimately these factors can be manipulated to produce a virus that is considered to be 
capable of harbouring specificity to kill cancer cells. However, several other factors 
determine how efficiently any such virus can act as an oncolytic therapy in vivo. As a 
realistic therapeutic agent, oncolytic viruses must not only selectively propagate in 
cancer cells leaving normal cells healthy, but to do so they must be able to evade 
innate immune responses that will hinder the efficacy with which a virus can gain 
access to the tumour site, and adaptive immune responses that develop after 
subsequent rounds of treatment. Furthermore, viral propagation within a tumour must 
be able to sufficiently eliminate cancer cells before an immune response attempts to 
eliminate viral load. Several viruses naturally possess multiple serotypes and as such 
the neutralising antibodies that may be generated against one serotype as a 
consequence of an immune response may not be successful neutralising agents against 
the other serotypes. It may be possible to evade immune responses for sufficiently 
long to offer a suitable therapeutic window by switching serotypes for each round of 
therapy (14). Many immune evasion attributes are beyond the scope of manipulation 
of viral genes and proteins and require consideration of therapeutic regime and 
particularly combination therapy to increase efficacy of either therapeutic agent or 
artificial modification of these bioreagents. The process of coating viruses in a
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polymer substance may be one such method of artificial manipulation to evade 
immune responses. It is thought that by coating viruses in a polymer that disguises 
antigens that would otherwise be recognised by the immune responses, one can 
prolong the period o f time in which the virus can avoid sequestration by host 
immunity. It is not surprising that while polymer coating disguises viral ligands from 
meeting the immune system, it also restricts them from meeting there prospective 
partner receptor on the target cancer cell. As such it has been necessary to insert the 
antigens required for target cell binding into the polymer coat. Not surprisingly this 
leads to a vicious circle o f attempting to find the balance between immune invasion 
and sufficient targeting and infection (105).
Alternatively traditional immunosuppressant drugs can be used to achieve direct 
suppression of host immune responses. When administered at the appropriate time 
certain drugs can be extremely effective in eliminating both B and T cell-mediated 
host antiviral responses. Additionally one can reduce the levels of antibodies that may 
facilitate an immune response by antibody depletion prior to the introduction of virus. 
Several mechanisms can be employed to this end and it may be less detrimental to the 
patient than immunosuppression. Alternative methods to avoid immune responses that 
are innately associated with viral infection appear to defeat the object of using viruses 
as a specific delivery tool. Mechanisms employed involve the direct delivery of viral 
genomes to target cells or by the delivery of viruses within cells to target regions. 
Both of these mechanism may avoid initial immune responses but with the case of 
direct genome delivery risks off-target destruction of healthy tissue. These 
mechanisms are of course short term in that they only disguise the virus for the initial 
step before virus meets target tissue at which point viral replication may evoke 
immune responses (39).
Further to the issue of what constitutes a good oncolytic therapy one must consider 
the ability of the virus not only to specifically infect and replicate within tumour cells 
but to be able to access the entirety of a tumour mass. It is important that a virus be 
able to efficiently move from blood vessel to tumour mass and as such many 
oncolytic viruses have been engineered to express not only ligands for tumour cell 
receptors but also for endothelial receptors to promote more efficient transfer from
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blood vessel to tumour whilst maintaining specificity for specific transfer and 
propagation within the tumour mass.
However, what are the clinical implications o f immunosuppressants at a point when 
cancers have already established? Can the long-term safety o f patients be guaranteed 
with regard to cancer recurrence or progression in the face of an 
immunocompromised system in addition to the susceptibility of patients to potential 
off-target viral effects? These questions can only be answered by extensive clinical 
trials to determine the realistic potential of oncolytic viral therapy. These are some of 
the many questions yet to be answered regarding the suitability of viruses as cancer 
therapy. The nature of viruses as evolutionarily competent entities makes it difficult to 
predict safety in short term studies since one the most significant of fears is that viral 
evolution and recombination will lead to the propagation of potentially uncontrollable 
biological agents. If oncolytic therapy can progress as a reality it is pivotal that the 
many questions regarding their biosafety be addressed. While several viruses are 
currently in phase I and II clinical trials the acceleration of focus into oncolytic 
therapy has been surpassed by a plethora of agents whose biosafety can be more 
easily assessed. The use of viruses in gene therapy and the unexpected losses of lives 
in such clinical trials have perhaps stunted enthusiasm in this area (161, 180).
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Thesis Aims
The introduction covers a considerable breadth of various fields sinee the aims 
described below straddle several sectors o f biological research. The core observations 
from which these aims stem are described below and it is hoped that the topics of 
introduction provide some insight into the concepts discussed in later chapters.
In 2001 Raj et al. highlighted the ability o f AAV viral DNA to cause a DNA damage 
response. This response was shown to result in the killing of cells lacking p53 
activity. It was established that in the presence o f functional p53, cells may undergo a 
transient G2 arrest characterised by stabilisation of p53 and subsequent increase in 
p21 and the targeted degradation of CDC25C while a lack of functional p53 resulted 
in a cells susceptibility to AAV-induced cell death. The mechanism by which an AAV 
induced DNA damage response may result in targeted cell death has not thus far been 
established. One of the primary aims o f this work was to establish the mechanism by 
which selective cell death in the absence of p53 might be achieved. This aim is 
addressed in the first section of results.
Furthermore, subsequent publications have examined the ability of AAV DNA to 
induce G2 arrest (129). Such data has further highlighted the observation that AAV 
DNA may be recognised by an infected cell as damaged DNA. Stemming from these 
observations and those of others that we have introduced and have shown the 
detrimental effect of DNA damage response with regard to viral replication we also 
wanted to consider the role of DNA damage responses in restricting AAV replication. 
This aim is addressed in the second section of results.
The potential clinical implications for our furthered understanding of AAV DNA- 
induced DNA damage responses in terms of cell death and for AAV replication are 
later discussed.
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Section 2 Materials and Methods
Chapter 1 Materials 
Suppliers of reagents
Except where specified, including below, reagents were obtained from Sigma-Aldrich 
Company Ltd. (UK), BDH Laboratory Supplies (UK) or Fisher Scientific (UK).
Suppliers of commonly used reagents are listed below:
Agarose, ammonium persulfate (APS), ethidium bromide, sodium dodecyl sulfate 
(SDS) and N,N,N,N ' -tetra-methy 1-ethylenediamine (TLMLD) were obtained from 
Bio-Rad (UK). Ultra Pure ProtoGel Acrylamide was obtained from National 
Diagnostics (UK). Complete Protease Inhibitor Cocktail Tablets were obtained from 
Roche (UK). Marvel was obtained from Premier International Foods (UK). Fetal calf 
serum (FCS) was obtained from Perbio Science Ltd. (UK). Dulbecco’s modified 
Eagle’s medium (DMLM) was obtained from Invitrogen (UK). All primers were 
produced by Sigma-Genosys (UK).
Media and buffers
Table 2.1.1 Buffers and reagents
2 X Laemmli’s buffer 4 % (w/v) SDS, 20 % (v/v) glycerol, 0.1 
M DTT, 0.12 M Tris, pH 6 .8 , containing 
a trace of bromophenol blue
10 X loading buffer 50 % (v/v) glycerol, 0.5 % (w/v) 
bromophenol blue, 0.4 % (w/v) xylene 
cyanol
LB broth 1 % (w/v) tryptone, 0.5 % (w/v) yeast 
extract, 8 6  mM NaCl
LB agar LB broth + 2%  (w/v) Bacto agar
PBS 0.17 M NaCl, 3.3 mM KCl, 10 mM 
Na2HP0 4 , 1.8 mM KH2PO4, pH 7.4
TAL 0.04 M Tris-acetate, 0.001 M LDTA, pH 
8 . 0
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trypsin-versene 0.14 M NaCl, 2.7 mM KCl, 8.5 mM 
Na2HP0 4 , 1.5 mM KH2PO4, 0.27 mM 
EDTA, 0.13 % (w/v) trypsin, 0.001 % 
(w/v) phenol red, pH 7.6-7.8
pen/strep stock (cell culture antibiotics) 0.6 % (v/v) penicillin, 1 % (v/v) 
streptomycin
SDS electrophoresis buffer 25 mM Tris base, 192 mM glycine, 0.1 % 
(w/v) SDS
transfer buffer 30 mM Tris base, 240 mM glycine, 20 % 
(v/v) methanol
Antibodies
Primary and secondary antibodies were used for western blotting and / or 
immunofluorescence in accordance with supplier instructions.
Table 2.1.2 Primary antibody supplier information
Antibody Supplier Catalogue number
Actin Santa Cruz SC-1616(l-9)
ATM Abeam Ab78-100
ATM serine 1981 p Calbiochem DR1002
ATR Santa Cruz SC-1887
Caspase-3 Cell Signalling 9662
Caspase-6 Cell Signalling 9762
DNA-PKcs BD pharmingen 556456
FLAG Sigma-Aldrich F3165
p21 Santz Cruz SC-397-G
p53 Novocastra NCL-p53-D01
p53 serine 15p Cell Signalling 9284
p84N5 Abeam ab487
pRb BD pharmingen 554136
RPA-34 Calbiochem NA18
RPA serine 33p Bethyl Labs BL744#A300-246A
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TopBPl BD transduction 611875
Tubulin Santz Cruz SC-5546
Secondary HRP conjugated antibodies for western blotting were purchased from GE 
Healthcare, UK. Secondary Alexa conjugated antibodies for immunofluorescence 
were purchased from Molecular Probes, UK. Antibodies were used in aecordance 
with supplier instructions.
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Chapter 2 Cell culture techniques and manipulation 
Cell lines
The isogenic HCTl 16 cell lines (a kind gift from B. Vogelstein, The Sidney Kimmel 
Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 
Baltimore, MD), Saos-2 and U20S cells were all cultured under the same culture 
conditions as follows. The HCTl 16 cells are immortalised human colon tumour cells 
from which lines lacking either p53 (HCTl 16 p53-/-) or p21 (HCTl 16 p21-/-) have 
been generated (Kholi et al. 2004). Both Saos-2 and U20S cell lines are human 
osteosarcoma lines. The U20S p53DD cell line was generated by K Raj (NIMR, 
London, UK). The cells express the p53DD protein, a C terminal miniprotein that acts 
in a similar manner to full-length mutant p53. It lacks protein residues 12-301 and 
causes a reduction in sequence specific DNA binding of wild-type p53 (243). <E>NXA 
cells are a retroviral packaging cell line, kindly supplied by (a kind gift from G. 
Nolan, Department of Microbiology and Immunology, School of Medicine, Stanford 
University, Stanford, CA). 293T human embryonic kidney cells immortalized by 
SV40 large T antigen.
Maintenance of cells
Cells were maintained in 10 cm tissue culture dishes (Nunc) in 10 ml of DMEM 
(Dulbecco’s modified Eagle’s Medium) supplemented with 10 % (v/v) fetal calf 
serum (FCS) and 1 % (v/v) antibiotics stock (pen/strep). In this study, the 
concentrations of FCS and pen/strep were kept constant at 10 % and 1 % respectively, 
unless otherwise stated, and DMEM supplemented with these reagents is termed 
‘complete DMEM’. Cells were incubated at 37 °C in a 5 % CO2 environment. When 
the cells reached confluency, they were passaged by seeding 10 % of them into a new 
dish (approximately twice a week). To detach the adherent cells from the flask, they 
were washed with phosphate buffered saline (PBS), incubated for 5 min at 37 °C with 
trypsin-versene until they detached from the bottom of the flask and then suspended 
in more complete DMEM. When cells were required to be seeded at a particular 
density, the cells in suspension were counted on a haemocytometer, using a phase 
contrast light microscope (Nikon Eclipse TSIOO, Surrey, UK) to estimate the cell 
concentration.
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Long-term storage of cells
Cells were cultured until confluent and then a suspension of -1x10^ cells was 
prepared as above (using trypsin-versene). They were then pelleted (2500 g, 5 min) 
and then resuspended in 1 ml of freezing medium (90 % (v/v) FCS, 10 % (v/v) 
dimethyl sulphoxide (DMSO)) and transferred to a cryogenic vial. This was stored at 
-80 °C overnight, wrapped in 12-15 layers of tissue paper to slow down the freezing 
of the cells, before being transferred to liquid nitrogen. When required, the cells were 
rapidly defrosted at 37 °C and added to 10 ml o f complete DMEM. The cells were 
pelleted as above, resuspended in 10 ml of complete DMEM and transferred to a 10 
cm dish
Virus production and infection of cells
Wild-type AAV-2 was made using the pDM single plasmid transfection system 
(Plasmid Factory). 293T cells were transfected with the pDM plasmid and cultured 
for 72 hours. Cells were then harvested along with the supernatent by cell scraper and 
pelleted at 1750 RPM for 5 minutes in a centrifuge. The cell pellet was resuspended in 
10 mL PBS and subjected to three freeze thaw cycles in a snap-freeze bath of ethanol 
and dry ice. Cell debris was pelleted once more by centrifugation at 1750 RPM for 5 
minutes. The supernatant was then collected and CsCl salt added to give the refractive 
index of 1.372 as measured using a refractometer. The adjusted solution was 
transferred to ultraclear tubes and balanced using liquid paraffin. These caesium 
chloride gradients were spun at 50,000 RPM for 30 hours at 24°C. A visible band in 
the centre of the gradient corresponding to AAV with a refractive index of 1.372 was 
collected using a fine gauge needle and syringe.
For infection cells were seeded the day prior to infection at 1 x 10  ^ cells per 10cm 
tissue culture dish. Cells were infected with AAV at a multiplicity of infection (MOI) 
ranging between 2,000 and 5,000. For UV inactivation of virus the required volume of 
virus was added to the well of a 4 well tissue culture plate (Nunc) and PBS added to a 
total volume of 10 pL. The lid from the 4 well plate was removed within a UV 
crosslinker and the plate was then irradiated with 2400 J/m^. UV-irradiated virus was 
then resuspended in tissue culture medium and used to infect cells in 10 cm tissue 
culture dishes. Virus was resuspend in 3 ml medium per 10 cm dish and overlayed
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onto cells. After 5 hours, tissue culture medium was added to a total volume of 10 ml 
per plate.
Infection with Ad5, HSV-1 or Vv was as above whereby virus was resuspended in 3 
ml eomplete DMEM and overlayed onto cells. After 5 hours, complete tissue culture 
medium was added to a total volume of 10 ml per plate.
Plasmids and transfection
Plasmids expressing dominant negative caspase-6 and dominant negative caspase-3 
were kindly provided by D.E. Bredesen (Buck Institute, Novato CA). Plasmids 
expressing ATMwt and ATMkd were kindly provided by M. Kastan (St. Jude 
Children’s Research Hospital, Memphis TN). All transfection were performed using 
Effectene (Qiagen) in accordance with the manufacturers supplied protocol. Cells 
were seeded the day prior to transfection at 1 x 10  ^ cells per 10cm tissue culture dish 
or 0.2 X 10  ^ cells per well of a 6 well plate. Cells were transfected with 2.5 pg of 
plasmid DNA per 10cm dish or 0.5 pg o f plasmid DNA per well of a 6 well plate. 24 
hours post transfection the culture media from transfected cells was aspirated and 
refreshed with 10 ml of fresh complete medium. 48 hours post transfection cells were 
selected for antibiotic resistance. Culture media was supplemented with the 
appropriate antibiotic to the following concentrations; 4.5 pg/mL puromyein, 5 
pg/mL blasticidin or 500 pg/mL neomycin. For siDNA-PK or siCONTROL 
transfection, 1 pM siRNA were used to transfect 0.2 x 10  ^ cells per well of a 6 well 
plate.
Vectors and retrovirus production and cell transduction
For shRNA expression silencing of pRb the sequences;
5--GATCCCCGCCACTTGAAATGTTAGTCTTCAAGAGAGACTAACATTTCAA 
GTGGCTTTTTGG A A A-3 ' and
5 ' - AGCTTTTCC A A A A AGCC ACTTG A AATGTT AGTCTCTCTTG A AG ACT A 
ACATTTCAAGTGGCGGG-3 ’ were annealed and cloned into the EeoRI site of the 
pSuper expression vector (kind gift from Thijn Brummelkamp, Whitehead Institute, 
Cambridge, MA). The shRNA insert and promoters were excised from pSuper via
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Xhol and EcoRI restriction sites and ligated into the pRetroSuper retroviral 
expression vector to yield the pRSshRb construct. Once in the context of the retroviral 
expression vector it is possible to generate retroviruses in which the desired vector is 
packaged using a packaging cell line as delineated below.
The packaging cell line known as (j)NXA cells (a kind gift from G. Nolan, Department 
of Microbiology and Immunology, School of Medicine, Stanford University, 
Stanford, CA) were transfected with the pRSshRb vector or a vector containing an 
irrelevant (scrambled) sequence. Virus particles were harvested 48 hours post 
transfection by harvesting the supernatant from transfected cell monolayers. 
Supernatents were filtered using a sterile 0.2 pm filter and syringe. The filtrate was 
then supplemented with 10 pg/ml polybrene and used to infect 10-cm tissue culture 
dishes of cells. 24 hours following infection cells were selected for antibiotic 
resistance with 1.5 pg/ml puromyein.
To reconstitute p21 or pRb protein in Saos-2 cells, the pBabe Puro retroviral vector 
harboring these genes was used to generate retroviruses as above and used to 
transduce Saos-2 cells, which were then subjected to puromyein selection as described 
above.
The p84DDD sequence was excised from the PCR3 and inserted via EcoRI restriction 
sites into the pBabeBlast retroviral vector. ONXA cells were transfected with this 
construct as delineated above to generate retroviruses. Cells expressing the dominant- 
negative construct or the empty vector control were selected using blasticidin (7.5 
pg/ml).
Protein extraction from tissue culture cells
Cells were washed in PBS and harvested using a plastic cell scraper. Cells were 
pelleted and then the pellet resuspended in Reporter lysis buffer (Promega) with a 
cocktail of protease inhibitors (Calbiochem) and incubated on ice for 30 minutes. 
Lysates were centrifuged at 16,000 g for 5 minutes and the supernatent collected. The 
protein concentration of the sample extracts was determined via Bradford assay in 
accordance with manufacturers instructions (BioRad).
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Total DNA extraction from tissue culture cells
Cells were harvested by trypsinisation and pelleted. Cell pellets were washed once 
with PBS. Total DNA extraction was performed using the QIAamp DNA mini kit as 
per the manufacturer’s protocol with the following alterations. Lysis reaction occurred 
at 56°C for 1 hour as opposed to 10 minutes. DNA was precipitated using 230 pi 
100% ethanol as opposed to 200 ul. DNA was eluted from columns using 60 pi 
ddH20 as opposed to 200 pi following 5 minutes incubation at room temperature.
Hirt extraction from tissue culture cells
Cells were trypsinised from tissue culture plates and neutralized with tissue culture 
medium. Cells were counted and the cell concentration was adjusted to 2 x 106 cells 
per ml. 0.5 ml of this suspension was dispensed into an eppendorf tube. 0.5 ml of 2 x 
lysis solution (2% SDS, 2 mM EDTA pHS.O) was added to the eppendorf 
immediately. The eppendorf was then gently inverted 3 times and left to stand at room 
temperature for 15 minutes. 250 pi 5 M NaCl was then added and the tube inverted 3 
times. The tube was then left to stand at 4°C overnight. Tubes were then spun at 
13,000 RPM in a refrigerated benchtop centrifuge at 4°C for 15 minutes. The 
supernatant containing episomal DNA, viral DNA and mitochondrial DNA can then 
be collected. The supernatent was then subject to phenol/chloroform extraction and 
ethanol precipitation by the addition o f I/IO**’ volume of 3M Sodium Acetate pH5.2 
and two volumes 100% ethanol. The tube was vortexed and then left to stand at -20 
°C overnight. The tubes were then spun at 13,000 RPM in a refrigerated benchtop 
centrifuge at 4°C for 10 minutes. Pellets were then resuspended in ddH20.
Fixing and blocking of tissue culture cells for immunofluorescence
Cells were grown as per the experimental conditions in 10 cm dishes on 13 mm glass 
coverslips. Glass coverslips were harvested using forceps by removing individual 
coverslips from dishes and placing them into individual wells of a 4 well dish (Nunc). 
Cells on coverslips were washed in PBS and fixed in 5% paraformaldehyde for 20 
minutes with gentle shaking. Cells were then rinsed twice in PBS and then stored in
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IFF (1% FCS, 2%BSA in PBS) at 4°C for up to two weeks. Coverslips were then 
processed for immunofluorescence or FISH (see chapter 5 below)
Fluorescence activated cell-sorting (FACS) analysis of DNA content
Cells were harvested by trypsinisation and then pelleted by centrifugation at 660g for 
five minutes. Cells were fixed by resuspending the cell pellet in ice cold 70% ethanol 
and then incubated at room temperature for 5 minutes. Cells were then re-pelleted and 
resuspended in one volume RNase A (0.1 mg/ml in PBS) and incubated for 10 minutes 
at 37°C. One volume of 40 pg/mL propidium iodide solution in PBS was then added. 
DNA content was then quantified using FACScan and CellQuest software (Beckton 
Dickinson). A total of 10,000 cells were counted for each analysis.
Methylene blue staining of tissue culture monolayers
Cell monolayers were washed twice with PBS and then a solution o f 1% methylene 
blue in 50% methanol / PBS was overlayed onto them. Dishes were then incubated at 
room temperature for 30 minutes. Staining solution was then decanted from the dishes 
and monolayers were washed extensively with PBS. Dishes were then air dryed in the 
dark.
Drug inhibition of PIKK proteins in tissue culture cells
Caffeine (Calbiochem) was resuspended directly in complete DMEM to the desired 
concentration. Wortmannin and DNA-PK inhibitor 11 (Calbiochem) were resuspended 
in DMSO in a 1000 times stock solution. U 20S cells were plated at 1 x 10  ^ cells per 
plate the day prior to drug application. Manipulations were conducted in the dark 
where possible to avoid light inactivation o f wortmannin or DNA-PK inhibitor. Drugs 
were diluted in 10 ml complete DMEM and overlayed onto cells. Cells were 
incubated with drug for 24 hours prior to infection. For infection 3 ml culture medium 
was removed from cells and used to resuspend virus. The remaining 7 ml culture 
medium was removed and stored at 37°C in the dark. The 3 ml containing virus was 
overlayed onto cells. 5 hours post infection the 7 ml removed from each plate was 
replaced. Cells were cultured for a further 48 hours and then half of each plate was 
harvested for total protein extraction and the other half for DNA extraction.
94
Chapter 3 Molecular biology techniques 
Transformation of E.coli with DNA
The chemical competent E.coli cells, XL 1-Blue supercompetent cells or BL21 Star^^ 
(DE3) cells, were used in transformations. One pi of plasmid miniprep or maxiprep 
DNA (0.1-50 ng of DNA) was added to 50 pi of cells in a pre-chilled 15 ml Falcon 
2059 polypropylene tube. The tube was incubated on ice for 30 min then heat-pulsed 
in a 42 °C water bath for 45 sec. After cooling the tube on ice for 2 min, 1 ml of SOC 
medium (Invitrogen, UK) was added, then the tube incubated at 37 °C for 1 h with 
shaking at 220 rpm. The culture (-250 pi) was spread on an LB agar plate 
(containing 100 pg/ml ampicillin) using aseptic technique and the plate incubated 
overnight at 37 °C. Cultures of any resultant E. coli clones were prepared the 
following day by transferring bacteria from the plate to LB broth using a sterile 
pipette tip and aseptic technique.
Glycerol stocks
E.coli clones were stored at -80  °C as a ‘glycerol stock'. A glycerol stock was 
prepared by transferring 0.8 ml of a fresh mid-log culture (in LB broth) to a cryogenic 
vial and adding 0.2 ml of glycerol. This was mixed and immediately stored at -80  °C. 
Purifying plasmid DNA-miniprep;
Two ml of plasmid-containing E.coli cultures (in LB broth with 50 pg/ml kanamycin 
or 100 pg/ml ampicillin) were grown overnight at 37 °C with shaking at 220 rpm. 
Plasmid minipreps were prepared using the QiaPrep Plasmid Miniprep Kit (Qiagen, 
UK) using the manufacturer's protocol. DNA was eluted using 50 pi o f deionised 
H]0.
Purifying plasmid DNA-maxiprep;
A 5 ml plasmid-containing E. coli culture was grown during the day (for -  6 h) in LB 
broth containing 50 pg/ml kanamycin or 100 pg/ml ampicillin (at 37 °C with shaking 
at 220 rpm). Then, 150-250 ml of LB broth (containing antibiotic) was inoculated 
with the 5 ml culture, and was incubated overnight at 37 °C with shaking at 220 rpm. 
The Hi Speed Maxi Kit (Qiagen. UK) was used to produce plasmid DNA maxipreps 
according to the manufacturer's protocol. DNA was eluted using 1 ml of deionised 
HiO.
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Quantitation of DNA
DNA concentrations were assayed using a 1201 UV-visible spectrophotometer 
(Shimadzu, UK). DNA solutions were diluted 1:100-1:500 and their absorbance at 
260 nm measured in quartz cuvettes. DNA concentrations were calculated assuming 
an A260 of 1 is equivalent to 50 |ig/ml of double-stranded DNA.
TAE agarose gel electrophoresis
To check for the presence or quantity of DNA (for example, mutagenesis PCR 
products, miniprep DNA and RT-PCR products), the DNA was separated on a 1 % 
agarose gel, buffered with TAE, containing 1 qg/ml ethidium bromide. Samples were 
mixed with 10 x loading buffer, loaded into the gel, and electrophoresis was carried 
out at a constant voltage of 70 V, limiting to 200 mA. DNA bands were visualized by 
trans-UV illumination and compared to DNA markers (Invitrogen, UK) of known 
molecular mass. Digital images were captured with a Kodak Image Station 440 and 
Digital Science ID software (Perkin Elmer Life Sciences Ltd., UK).
Southern blotting
DNA was separated by TAE agarose gel electrophoresis as described above. DNA 
was then transferred to nylon membrane (Millipore) over night via capillary action 
using Solution A for transfer (1.5 M NaCl, 0.4 NaOH). For slot-blot analysis, DNA 
was diluted in 100 pi Solution A and applied to a MINIFOLD-II slot blot system 
(Schleicher and Schuell). The DNA was transferred to nylon membrane by suction. In 
both cases the DNA was cross-linked to membrane via 1200 J/m2 UV. Membranes 
were blocked in pre-hybrisation solution for 6 hours. Radiolabelled DNA probes were 
prepared via random priming from the relevant plasmid DNA (as described below). 
Radiolabelled probes were resuspended in hybridisation solution and incubated with 
membrane over night at 42 °C in a rotator oven. Membranes were washed at 48 °C in 
a rotator oven using 8 volumes of pre-warmed wash solution (0.1 X SSC, 0.1% SDS). 
Membranes were then wrapped in saran wrap and exposed to Kodak MXB X-ray film 
(X-ograph imaging systems, UK). Films were developed using a Fujifilm FPM- 
3800A processor (UK). Alternatively, membranes were wrapped in saran wrap and 
exposed to phosphorimager screen for phosphorimager analysis and ImageQuant 
quantification.
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Pre-hybridisation solution composition, 10 ml:
4.5 ml Formamide 
2 ml 20 X SSC
1 ml IM Sodium Phosphate pH6.5 
1 ml 100 X Denhardt solution
1 ml 20 % SDS
0.5 ml Herring sperm DNA (5mg/ml) 
Hybridisation solution composition, 10 ml:
4.5 ml Formamide
2 ml 20 X SSC
1 ml IM Sodium Phosphate pH6.5 
0.1 ml 100 X Denhardt solution 
0.2 ml 20 % SDS
0.2 ml Herring sperm DNA (5mg/ml)
2 ml Dextran sulphate (50%)
Generation of radiolabelled DNA probes
50 ng of DNA in 10 pi were denatured at 100°C for 8 minutes and immediately 
chilled in ice for 8 minutes and then spun briefly. 3 pi dATP, dTTP, dOTP (0.5 mM 
each) were added followed by 2 pi Hexanucleotide mix (Roche), 2 pi a-32P-dCTP 
and 1 pi Klenow enzyme (Promega). After incubation at 37°C for 30 minutes the 
reaction was stopped by dénaturation at 100 °C for 7 minutes and chilled for 5 
minutes.
Generation of fluorescence in situ hybridisation (FISH) probes
For FISH of Ad5, HSV-1 and Vaccinia virus DNA a set of 4 DIG labelled probes 
each were prepared using the PCR DIG Probe synthesis kit (Roche Cat. No. 
11636090910) as per the supplier instructions. The following primers were designed 
for probe synthesis. The template DNA for probe synthesis was Hirt extracted DNA 
from Ad5, HSV-1 or Vaccinia virus infected U20S cells as described above.
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Human Adenovirus Type 5
Primers designed from the sequence from ACCESSION AC 000008 VERSION 
AC 000008.1 01:56160529 from Pubmed nucleotide.
Set 1 -  A = nucleotides 920 to 939, B = nucleotides 1080 to 1099, Fragment size 
179bp
A 5’ -  GATCTTACCTGCCACGAGGC -  3’
B 5 GCCACAGGTCCTCATATAGC -  3'
Set 2 -  C = nucleotides 11,000 to 11,019, D = nucleotides 11,180 to 11,199, 
Fragment size 199bp
C 5  TTGCAAATTCCTCCGGAAAC -  3'
D 5’ -  TTCGTAATCACCATCTGCTG -  3 ’
Set 3 -  E = nucleotides 21,543 to 21,562, F = nucleotides 21,711 to 21,729, 
Fragment size 186bp
E 5' -  TAGACATGACTTTTGAGGTG -  3'
F 5’ -  CGGCAGCTGTTGTTGATGTT- 3 ’
Set 4 -  G = nucleotides 29,995 to 30,014, H = nucleotides 30,196 to 30,215, 
Fragment size 220bp
G 5' -  CATATCTCAGACACCATCCC -  3'
H 5 AGGCTTCGGAAAGATCGCTT -  3’
Human HSV-1 Strain 17
Primers designed from the Human herpesvirus strain 17 complete short unique region 
with partial terminal and inverted repeats DNA, complete cds. ACCESSION L00036 
L00037 M12354 M12355 M12506 M30738. VERSION L00036.1 01:291490.
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Set 1 -  A = nucleotides 3072 to 3091, B = nucleotides 3254 to 3273, Fragment size 
201 bp
A 5’ -  AATAAACAACGCTACTGCAA -  3’
B 5  -  GAGCTGCGGTTCGTGCGCGA- 3’
Set 2 -  C = nucleotides 11,107 to 11,126, D = nucleotides 11,339 to 11,358, 
Fragment size 251 bp
C 5  AACTCCTCCCATCCATTCTT -  3’
D 5 GCCATCGCCGAAGAGTCGGA -  3'
Set 3 -  E = nucleotides 18,382 to 18,401, F = nucleotides 18,557 to 18,576, 
Fragment size 194bp
E 5  -  CCAGACACTTGCGGTCTTCT -  3'
F 5 TTACGCTGGAAACCCCAGAA- 3’
Set 4 -  G = nucleotides 25,655 to 25,674, H = nucleotides 25,821 to 25,840, 
Fragment size 185bp
G 5  -  TGTGTAGCAGGAGCGGTGTG -  3’
H 5 GGTGAAACCAACAGAGCACG -  3’
Vaccinia Virus strain Western Reserve’
Primers generated from the sequence. Vaccinia virus, complete genome ACCESSION 
NC_006998, VERSION NC 006998.1 01:66275797. This is strain ‘western
reserve' analogous to the wild-type CR-19 virus used in our experiments.
Set 1 -  A = nucleotides 107,281 to 107,300, B = nucleotides 107,461 to 107,480, 
Fragment size 200bp
A 5' -  GCGTGTGATTTACTCATTTA -  3’
8  5 ' -  CGGAATTCATTAATAAGTTC -  3'
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Set 2 -  C = nucleotides 117,814 to 117,833, D = nucleotides 117,994 to 118,013, 
Fragment size 199bp
C 5  -  TAATATATGGGCGACTTCTC -  3’
D 5 CCAAATTAAGATCTGGTACT -  3’
Set 3 -  E = nucleotides 16,743 to 16,762, F = nucleotides 16,940 to 16,959, 
Fragment size 216bp
E 5' -  GATAGATGGTCTCATTTCAT -  3’
F 5  -  AGTGTACTCGTTACTAAATA -  3’
Set 4 -  G = nucleotides 133,399 to 133,418. H = nucleotides 133,573 to 133,592, 
Fragment size 193 bp
G 5 TAATTGCTTCGGCCAACATG -  3'
H 5  TTGAATAGGCGTTAGACCTA -  3'
For FISH of AAV DNA, biotinylated AAV specific probes were generated by random 
priming using the Biotin Decalabel DNA labelling kit (Fermentas) as per the supplier 
instructions.
Probes were used for FISH of viral DNA in tissue culture cells. The protocol for FISH 
using these probes is delineated in chapter 5.
Generation of retroviral expression vector harbouring the RPA32A33 mutant
The original sequence for the RPA32A33 mutant was within a bacterial expression 
vector as described in the following reference (30). The sequence was removed by 
PCR to generate BamHl and EcoRI restriction sites at 5' and 3' ends respectively. 
The following primers were used;
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Forward
5 ' CGCGG ATCC ATGGCT AGGC AAGCCG AAAA
Reverse
5 ' CCGG AATTCTTATTCTGC ATCTGTGG ATT
for PCR using the Thermoprime Plus DNA polymerase kit (Thermo scientific) as per 
the suppliers instructions. The PCR product was cleaned using the QIAquick PCR 
purification kit (QIAgen) as per suppliers instructions. The PCR product was cut 
using the BamHI and EcoRI restriction enzymes and ligated into the pBabePuro 
BamHI and EcoRI cloning sites.
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Chapter 4 Protein methods
SDS-PAGE
SDS-PAGE was used to separate proteins according to molecular mass. It was 
performed using Mini Protean II apparatus (Bio-Rad, UK). 1.5 mm spacers were used 
and proteins were resolved on 8%, 10% or 12% gels where appropriate. The 
components for preparing resolving and stacking gels were as delineated in Harlow 
and Lane 1988. The resolving gel solution was prepared, ensuring that the APS and 
TEMED were added just before use. This solution was poured into the caster to 3 cm 
below the top, overlaid with water-saturated butanol and allowed to polymerise for 20 
min. Once the resolving gel was set, the butanol was rinsed away with ddHiO and the 
stacking gel solution prepared (the APS and TEMED were added just before use). 
The stacking gel was poured on top of the resolving gel and a gel comb inserted into 
the stacking gel solution. After 20 min the comb was removed and the gel positioned 
in the electrophoresis tank. The tank was filled with SDS electrophoresis buffer and 
the sample wells rinsed with this buffer.
Protein samples were then prepared for loading by mixing with an equal volume of 2 
X Laemmli's buffer and denaturing by incubating at 95 °C for 2 min. Samples and 
protein standards (dual colour marker, BioRad. UK) were loaded into the wells of the 
gel. The gel was then run at a constant voltage o f 150 V until the desired separation 
of the protein-standards was achieved.
Western blotting
Western blotting was performed to detect proteins that have been electrophoretically 
separated on SDS gels as above. The separated proteins were then transferred from 
the gel to a PVDF membrane, Immobilon™ (Millipore, UK). This was achieved 
using a wet transfer system. Mini Transfer Blot (Bio-Rad, UK; filled with transfer 
buffer), at a constant voltage of 150 V for 90 min.
The membrane was incubated in blocking solution for 1 h at R/T with gentle shaking. 
For most Western blots, the membrane was blocked in PBS containing 5 % (w/v) 
Marvel (Premier Brands UK, Ltd., UK) and 0.1 % (v/v) Tween20. The membrane was 
incubated with primary antibody (see Table 2.1.1 for a list of antibodies) for 2 h at
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R/T with gentle shaking, in PBS, 5 % (w/v) Marvel and 0.1 % (v/v) Tween20. The 
membrane was then washed in PBS with 0.1 % (v/v) Tween20 three times at 15 min 
intervals. The membrane was then incubated for 1 h at R/T with gentle shaking in 
PBS with 5 % (w/v) Marvel and 0.1 % (v/v) Tween20, containing HRP-conjugated 
IgG from the relevant host (GE Healthcare, UK) diluted to 1:2000. Following this, the 
membranes were washed five times as described above. Binding of HRP-conjugated 
antibody was visualized by Enhanced Chemiluminescence (ECL; GE Healthcare, 
UK), with blots being exposed to Kodak MXB X-ray film (X-ograph imaging 
systems, UK). Films were developed using a Fujifilm FPM-3800A processor (UK).
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Chapter 5 Staining and imaging techniques 
Immunofluorescence
Cells were fixed to glass coverslips as described in chapter 1 and stored in IFF at 4°C. 
For immunofluorescence cells were permeabilised with 0.5% Triton-X (Fluka) in PBS 
for 10 minutes at room temperature with gentle shaking. Coverslips were rinsed three 
times in PBS and then blocked for 30 minutes in IFF at room temperature with gentle 
shaking. Coverslips were incubated with primary antibody diluted to 30 pi in IFF in a 
humidity chamber for one hour. Coverslips were then washed three times in PBS. 
Coverslips were then incubated with the appropriate secondary antibody conjugated to 
an Alex Fluor (Molecular Probes). Secondary antibodies were diluted in IFF and cells 
were incubated in a humidity chamber in the dark for one hour with shaking. 
Coverslips were then washed 3 times with PBS in the dark. Coverslips were then 
incubated with a solution of 1 pg/ml DAPI nuclei acid stain (Molecular Probes) in 
PBS for 5 minutes in the dark with gentle shaking. Coverslips were then rinsed three 
times with PBS and once with water and mounted onto Super Frost Plus glass slides 
(Menzel-Glaser) using Citifluor (Agar Scientific).
Fluorescence in situ hybridisation (FISH)
Cells were fixed to glass coverslips as described in chapter I and stored in IFF at 4°C. 
For FISH cells were permeabilised with 0.5% Triton-X (Fluka) in PBS for 10 minutes 
at room temperature with gentle shaking. Coverslips were rinsed three times in PBS 
and then blocked for 30 minutes at 42°C in pre-hybridisation buffer.
FISH pre-hybridisation buffer composition, 10 ml:
5 ml Formamide
1 ml Denhardts solution lOOx
0.5 ml Herring sperm DNA (5mg/ml)
2 ml 20 X SSC
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1.5 ml ddHiO
FISH hybridisation buffer composition, 50 ml:
25 ml Formamide
500 pi Denhardts solution lOOX
5 ml Dextran sulphate 50%
2 ml Herring sperm DNA (5mg/ml)
4 ml 20 X SSC
13.5 ml ddHzO
Probes were resuspended in hybridisation buffer. A combination of all four probes 
specific for either Ad5, HSVl or Vv DNA were diluted 1:25 in a total of 50 pi per 
coverslip. For combined FISH of AAV DNA 2 pi of the random priming reaction was 
added. The 50 pi hybridisation mix was pipetted onto SuperFrost Plus glass slides 
(Menzel-Glaser) and the coverlip overlayed onto the mix avoiding any bubbles. The 
slide was then placed on a heat block (pre heated to 100°C) for 5 minutes. The slides 
were then placed on ice for 10 minutes. Slides were then placed into a dark humidity 
chamber and incubated at 42°C overnight. The following day coverslips were washed 
with two 10-minute washes with formamide wash buffer (50% formamide, 2XSSC, 
0.05% (v/v) Tween-20) at 42°C with shaking. Coverslips were then washed with two 
10-minute washes with 2XSSC at 42°C with shaking.
DIG labelled probes were fluorescently labelled using the Fluorescent Antibody 
Enhancer Set for DIG Detection (Roche Cat No. 1768506) as per supplier protocol. 
Alexa Fluor 594 conjugated streptavidin was used to fluorescently label anti-AAV 
biotinylated probes as per supplier protocol. All reactions were carried out in the dark 
where possible. Coverslips were finally rinsed three times with PBS and once with 
water and mounted onto SuperFrost Plus glass slides (Menzel-Glaser) using Citifluor 
(Agar Scientific). For combined FISH with immunofluorescence the above protocol 
I'or immunofluorescence was carried out prior to mounting after FISH labeling.
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Confocal imaging
Cells were imaged using a Leica DMRXE upright microscope (Leica Microsystems 
Ltd, Milton Keynes, UK) and a lOOx objective lens. Specimens were scanned using 
the following excitation (ex) and emission wavelengths (em): DAPI ex 359 nm, em 
395-520 nm; Alexa-488 ex 488, em 505-685; Alexa 594 ex 568, em 595-710 nm, 
Fluorophores were excited sequentially to reduce cross-channel bleed through and to 
allow maximum emission detection. Specimens were scanned with 20 sections of the 
Z axis with 6 accumulations per frame. Images are presented as an overlay projection 
of all frames resulting in a composite image.
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Section 3 Results
Chapter 1 Cells lacking the p53-p21-pRb pathway are susceptible to 
AAV-induced cell death via p84N5
AAV induces a DNA Damage Response
The AAV-induced DNA damage response leads to cell death in the 
absence of p53 and p21
Elevated levels of p21 cannot rescue Saos-2 cells from AAV-induced cell 
death
An AAV-induced DNA damage response activates pRb 
Expression of pRb alone cannot rescue cells from AAV-induced cell death 
Reconstitution of the p53-p21-pRb pathway in Saos-2 cells is not 
experimentally viable
Abrogation of pRb renders U 20S  cells susceptible to death 
AAV infection leads to caspase activation
Caspase-6 is the principle caspase involved in mediating cell death in 
response to AAV 
AAV activates p84N5
Inactivation of p84N5 relieves susceptibility to AAV-mediated cell death 
AAV induces a DNA Damage Response
When cells undergo DNA damage by exogenous means such as UV irradiation for 
example, proteins involved in detecting, signalling and repairing DNA are recruited to 
sites of damage and form what are known as irradiation-induced, or DNA damage- 
induced foci. The single-stranded DNA binding protein RPA is one of the first 
proteins to form foci at sites of DNA damage. Furthermore, in response to DNA 
damage, RPA becomes hyperphosphorylated. Since AAV infection has been reported 
to induce a DNA damage response, we wanted to know if an AAV-induced DNA 
damage response would also cause the appearance of DNA-damage foci. The data 
described in this chapter involve the use of UV-inactivated AAV. Both wild-type and 
UV-irradiated AAV have been shown to induce the same responses though to a lesser 
degree when not UV irradiated (129). In this section UV-AAV was used to prevent
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any viral transcription and thus eliminate the possibility that virally transcribed 
proteins were responsible for subsequent observations. To visualise AAV-induced 
DNA damage foci, cells were grown on coverslips and infected with AAV. Coverslips 
were harvested and in situ hybridisation techniques were employed to visualise AAV 
DNA in infected cells. In addition to in situ hybridisation for AAV DNA, the same 
coverslips were examined via immunofluorescence using antibodies directed to 
phosphorylated RPA. Figure 3.1.1 A shows that when U20S cells were infected with 
AAV, AAV DNA was readily detectable within the nucleus of the cells via in situ 
hybridisation. The DNA appeared to be found in discrete, punctuate foci within the 
nucleus. When serine 33 phosphorylated RPA was visualised in the same cells, 
punctuate foci, reminiscent of DNA damage-induced foci were visible, and were 
precisely colocalised with foci of AAV DNA. These foci are a visual representation of 
the DNA damage response signalling that takes place as a consequence of incoming 
AAV DNA.
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Figure 3.1.1 A
AAV DNA RPAser33p DAPI merge
no AAV
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Figure 3.1.1 A. Hyperphosphorylated RPA colocalises with AAV DNA in 
AAV-infected ceils. U 2 0 S  c u ltu red  on g l a s s  c ove rs l ip s  a n d  in fec ted  with AAV. 
24  h o u rs  p o s t  infection ce lls  w e r e  f ixed a n d  p r o c e s s e d  for in situ hybridisation 
with a  Dig-labelled anti-AAV p r o b e  th a t  w a s  v isu a l is e d  us ing  a  FITC labe lled  anti- 
DIG sta in ing  kit. H y p e rp h o s p h o ry la te d  R P A  w a s  s ta in e d  us ing  an  an ti-RPA  
an tibody  specific  for t h e  s e r in e  33  p h o s p h o ry la te d  form  of th e  protein  a n d  an  
A lexa 5 94  c o n ju g a te d  s e c o n d a r y  an tibody . R P A  Is sh o w n  in red  a n d  AAV DNA in 
g re e n .  DAPI sta in  h igh ligh ts  DNA in b lue. T h e  s c a le  ba r  r e p r e s e n t s  10 /xm.
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Figure 3 .1 .1  B 
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Figure 3.1.1B. RPAandTopBPI colocalise Into nuclear foci following AAV 
Infection. U 2 0 S  cultured  on g l a s s  c o v e rs l ip s  a n d  in fec ted  with AAV. 24  h o u r s  
p o s t  infection cells  w e re  fixed a n d  s ta in e d  for im m u n o f lu o re s e n c e  u s in g  anti- 
R P A  a n tib o d ie s  a n d  a n t i -T o p B P I  a n t ib o d ie s .  R P A  is sh o w n  in red  a n d  T o p B P I  
in g re e n .  DAPI sta in  h ighlights  DNA in b lue . T h e  s c a le  ba r  r e p r e s e n t s  10 /xm.
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We also wanted to consider other DNA damage related proteins that might be 
recruited to these foci. As such we did co-immunostaining of RPA and TopBPI, 
which acts a recruitment factor for ATR. We observed that following AAV infection, 
both RPA and TopBPI colocalised to punctate intranuclear foci, which we know also 
contain AAV DNA (Figure 3.1.IB).
In response to DNA damage signalling, cells employ cell cycle checkpoints, which 
pause the normally cycling cell to allow for repair and to prevent aberrant replication. 
There are two key transition points during the cell cycle at which cells may arrest; the 
G l/S phase checkpoint and the G2/M transition. In the event of significant damage to 
cellular DNA, cells may undergo cell death by apoptosis or mitotic catastrophe. The 
fine balance between arrest and cell death in response to DNA damage is controlled 
by various protein signalling cascades. One such protein is the p53 protein, whose 
activity has long been deemed The guardian of the genome’ (139). A plethora of 
evidence highlights the means by which p53 preserves genome integrity, 
fundamentally by inducing pro-apoptotic cascades in the event of DNA damage. The 
subsequent experiments documented here stem from the observations made by Raj et 
al. 2001 in which the AAV-induced DNA damage response was seen to culminate in 
death of cells lacking p53 activity (220).
The AAV-induced DNA damage response leads to cell death in the absence of 
p53 and p21
In cells with functional p53, AAV infection results in a DNA damage response that 
culminates in G2 arrest. Arrest is accompanied by the activation of p53 and a 
subsequent rise in the levels of p21 protein, a transcriptional target of p53 activity. 
The p21 protein is a broad range CDK inhibitor and as such inhibits cell-cycle 
progression. As such cells may not progress through the G2/M transition and instead 
arrest with 4n DNA content. AAV-induced G2 arrest of cells with functional p53 is 
shown in figure 3.1.2. Cells were infected with AAV and harvested at various time 
points post infection for tluorescence-activated cell sorting (FACS) analysis of their 
DNA content. U20S cells with functional p53 arrest with 4n DNA content whereas 
AAV-infected Saos-2 cells, which lack functional p53 accumulate with sub-Gl DNA 
content, which is indicative of cell death. Similarly when HCT116 cells with p53
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were infected with AAV, they underwent G2 arrest. However, when the isogenic 
partner cell line HCT116 p21-/-, whieh expresses functional p53 but lack p21 were 
infected with AAV, significant cell death was observed as shown by the increase in 
cells with less that 2n DNA content. These observations previously reported by Raj et 
al 2001 demonstrate that in the absence of p53 or p21, cells are susceptible to AAV- 
mediated cell death. In the presence o f functional p53 and p21 however, cells respond 
to AAV infection with G2 phase cell cycle arrest (220). We show here that this is 
concomitant with the activation o f p53 as demonstrated by the phosphorylation of p53 
on serine 15 and the increased expression of p21 protein, a p53 transeriptional target 
gene (Figure 3.1.3). We sought to establish whether artificially enhancing the levels 
of p21 protein in Saos-2 eells (which lack p53) would be sufficient to protect them 
from AAV-induced cell death.
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Figure 3.1.2
HCTIIt HCTIlt
U20S
(p53+/+) (k*53V) p21*/+) p21-/-)
L . .  Lx. 
Ul I
3 days 
5 days
2n 4n 2n 4n 2n4n 2n 4n
Figure 3.1.2. AAV Induces G2 arrest or cell death In cells lacking 
p53 or p21. A nalyses  of u n in fe c te d  ce lls  (control) a n d  cells  in fec ted  
with AAV a t various  t im e s  a f te r  infection. C ellu la r  DNA w a s  s ta in e d  
with propidium  iodide a n d  a n a ly s e d  b y  F A C S .
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Figure 3 .1 .3
+AAV
days post infection (p i) 
p53 ser15P
p21
actin
Figure 3.1.3. AAV infection of U20S cells leads to the 
phosphorylation of p53 on serine 15 and increased expression  
of p21. (B) W e s te rn  blot a n a ly s i s  of a c t iv a te d  p 5 3  ( a s  s h o w n  via 
ph o sp h o ry la tio n  of s e r in e  15) a n d  p21 from  ly s a te s  of un in fec ted  
U 2 0 S  cells  an d  th o s e  a t  v a r io u s  d a y s  pos t- in fec tion  (p.i) with AAV.
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Elevated levels of p21 cannot rescue Saos-2 cells from AAV-induced cell death
p53’s ability to enhance transcription of various proteins involved in cell cycle arrest 
and apoptosis in response to DNA damage is well documented. For example the 
levels of 14-3-3a are augmented following an AAV-induced DNA damage response. 
However, the presence or absence of 14-3-3a does not dictate the survival of a cell 
following an AAV-induced DNA damage response (220).
To determine whether augmented levels of p21 (such that might occur in the presence 
of activated p53) might rescue Saos-2 cells from cell death upon AAV infection, 
Saos-2 cells were retrovirally-transduced to express elevated levels of p21 protein as 
demonstrated in figure 3.1.4A. As a control, Saos-2 cells were also transduced with 
the empty retroviral vector. These transduced cells were infected with AAV and 
harvested for FACS analysis five days post-infection (Figure 3.1.4B). Dishes of cells 
were also processed via methylene blue staining of adherent monolayer cells to 
further demonstrate cell death (Figure 3.1.4C). FACS analysis demonstrates that 
while uninfected cells preserve a normal profile, AAV-infected cells (both 
untransduced, control transduced and +p21 transduced cells) exhibit a profound 
increase in cells with less than 2n DNA content, indicative of cell death.
The clonogenic assay method of methylene blue staining of surviving cells represents 
a robust way of demonstrating long-term cell survival (34). Such analysis becomes 
more directly relevant in subsequent experiments in which a comparison of relative 
survival is required. In this case there is a very definite distinction between survival 
and death as demonstrated by FACS and this is reinforced by methylene blue analysis.
Although initial experiments demonstrate the importance of p21 in protecting cells 
from death, it is clear that elevated levels of p21 alone are not sufficient to prevent 
AAV DNA-induced cell death. Since the role of p21 is unmistakable, we considered 
factors downstream of p21 in terms of signalling cascades. One of the most 
documented signalling cascades originating from p53 activation is that involving the 
increased expression of p21 and as a consequence of p21's CDK inhibition, the 
maintenance of pRb in a dephosphorylated state that inhibits cell cycle progression.
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As such pRb is a recipient of increased p21 activity and so we considered the possible 
role of pRb in preventing AAV-induced cell death. O f particular relevance here is the 
fact that pRb is not expressed in Saos-2 cells.
An AAV-induced DNA damage response activates pRb
We have thus far demonstrated that AAV infection activates p53 and leads to the 
subsequent up-regulation of p21 expression. We examined AAV-infected U20S cell 
lysates to determine whether pRb status was affected by the presence of AAV DNA. 
Western blot analysis using antibodies directed to pRb demonstrated that upon AAV 
infection, pRb activation takes place as shown by its increased dephosphorylation 
over the course of 72 hours following infection, as demonstrated by species of pRb 
with increased electrophorectic mobility (Figure 3.1.5A and B). The very distinct 
activation o f pRb in U20S cells, which demonstrate resistance to AAV-induced cell 
death, reiterates the potential involvement o f pRb in preventing cell death in response 
to AAV-induced DNA damage signalling.
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Figure 3.1.4 
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Figure 3.1.4. Saos-2 cells with augmented levels of p21 are 
susceptible to AAV-induced cell death. (A) W e s te rn  blot a n a ly s e s  of 
ly sa te s  of S a o s -2  cells  th a t  w e r e  u n t ra n s fe c te d  (c) S a o s -2  tha t  w e re  e ither 
t r a n s d u c e d  with em p ty  v ec to r  (v) or v e c to r  tha t  ca rr ied  a  p21 g e n e  (+p21) 
(8) F A C S  a n a ly s e s  of DNA c o n te n t  a n d  (C) m e th y le n e  b lue  sta in ing  of 
un in fec ted  cells a n d  AAV-infected u n t ra n s d u c e d  an d  t r a n s d u c e d  cells.
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Figure 3.1.5
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Figure 3.1.5. AAV Infection of U20S cells leads to the activation 
(déphosphorylation) of pRb. (A and B) W e s te rn  blot a n a ly s is  of two 
in d e p e n d e n t  ex p e r im e n ts  with a n t ib o d ie s  a g a in s t  th e  p R b  protein of 
ly sa te s  of un in fec ted  U 2 0 S  cells  (c) a n d  AA V-infected U 2 0 S  cells  a t 
v a r ious  h o u rs  post-infection (h p.i).
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Expression of pRb alone cannot rescue cells from AAV-induced cell death
To examine the hypothesis that pRb plays a fundamental role here in preventing cell 
death, we used Saos-2 cells, which do not express pRb and are susceptible to AAV- 
mediated cell death. We reasoned that if pRb was crucial, then the re-introduction of 
pRb protein might confer protection to otherwise susceptible cells. Saos-2 cells were 
transduced with retroviruses bearing the pRb gene or an empty vector. Figure 3.1.6A 
clearly shows that cells transduced to express pRb do indeed express the protein while 
untransduced and control transduced cells do not. However, despite expressing pRb, 
these cells were equally susceptible to AAV-induced cell death as the control and un­
transduced cells. This is demonstrated by FACS analysis and the methylene blue 
staining, clonogenic assay (Figure 3.1.6B and C respectively).
Reconstitution of the p53-p21-pRb pathway in Saos-2 cells is not experimentally 
viable
Experimental evidence thus far demonstrates the importance of p53, p21 and pRb in 
that absence of either of these proteins leads to a cell’s susceptibility to death in 
response to AAV-induced DNA damage signalling. However, cells cannot be rescued 
from such susceptibility by expression o f either one of these proteins alone. As such 
we wanted to reconstitute the full pathway in Saos-2 cells to analyse the possibility 
that the complete signalling pathway be required for cell survival in the event of such 
damage signalling. Saos-2 cells were transfected with a combination of expression 
vectors bearing the genes for p53, p21 or pRb protein. Figure 3.1.7 demonstrates that 
it is possible to achieve the expression of p53, p21 and pRb with a population of cells 
as shown by western blot analysis o f transfected Saos-2 cells prior to selection. 
However, these unselected populations, which are heterogenous by nature, are 
unsuitable for further experiments in which we would be asking the question; will 
these cells survive following AAV infection? If cell death were observed one could 
not be certain that it was not simply a consequence o f unsuccessful reconstitution of 
the pathway. Unfortunately, upon antibiotic selection to obtain a homogenous 
population of Saos-2 cells expressing p53, p21 and pRb, it was found that the 
emerging cells no longer express these proteins in detectable quantities. It is likely 
that reconstitution of this pathway in Saos-2 cells does not allow successful 
proliferation, and subsequently the cells selected for no longer express the proteins.
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Figure 3.1.6
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Figure 3.1.6. Reconstitution of pRb cannot rescue Saos-2 cells from 
AAV-induced cell death, W e s te rn  blot ana lys is ,  us ing  a n tibod ie s  a g a in s t  
pRb, of ex trac ts  from cells  th a t  w e r e  e i the r  t r a n s d u c e d  with an em p ty  v ec to r  
(v) or a  vec to r  bea ring  th e  pR b  g e n e  (+pRb) a n d  u n t ra n s d u c e d  cells  (c). (B) 
FA C S  a n a ly s e s  of DNA c o n te n t  a n d  (C) m eth y len e  blue s ta in ing  of un in fec ted  
cells a n d  AAV-infected u n t ra n s d u c e d  a n d  t r a n s d u c e d  cells.
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Figure 3.1.7
Saos
p53»
p21+
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Figure 3.1.7. The réintroduction of the p53-p21-pRb pathway is only 
possible without antibiotic selection. W e s te rn  blotting of ly sa te s  of 
control S a o s - 2  cells (c). S a o s - 2  ce lls  t r a n s d u c e d  with an  em pty  v e c to r  (v) or 
S a o s -2  cells  t r a n s d u c e d  with p 5 3 ,  p21 a n d  p R b  e x p re s s io n  v e c to rs  
(p53+ p21+ pR b).  Tubulin  is sh o w n  to  d e m o n s t r a t e  e q u a l  loading.
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Abrogation of pRb renders U 20S cells susceptible to death
Despite Saos-2 cells being the ideal system in which to test the hypothesis that the 
complete signalling pathway from p53 ultimately to pRb be required to afford 
protection from AAV-induced cell death, a more experimentally viable approach was 
required. As such we focused upon disrupting the p53-p21-pRb pathway in U20S 
cells which are otherwise resistant to AAV-induced apoptosis. Expression of short 
hairpin RNA (shRNA) against pRb was used to decrease levels of pRb protein in 
U20S cells. Figure 3.1.8A shows that following shRNA transduction, the level of 
pRb protein was considerably decreased. The susceptibility to AAV-mediated cell 
death of these and control cells was examined. Cells were infected with AAV and 
then analysed by methylene blue staining o f surviving, adherent cells 10 days post­
infection. The stained plates clearly show that upon abrogation of pRb expression, 
U20S cells were no longer resistant to AAV-induced cell death (Figure 3.1.SB). In 
combination with our previous observations, emerges the following conclusion; that 
the functional integrity of the complete p53-p21-pRb signalling pathway is required to 
prevent cell death in the event of AAV-induced DNA damage signalling. A table to 
summarise these data and those reported by Raj et al. 2001 (220) is shown in Table
3.1.1.
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Figure 3.1.8
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Figure 3.1.8. Expression silencing of pRb In U20S cells renders 
U20S susceptible to AAV-induced cell death. (A) W e s te rn  blot 
a n a ly s is  of ly sa te s  from ce lls  th a t  w e r e  t r a n s d u c e d  with re t ro v iru ses  
e n co d in g  e ithe r  s c r a m b le d  s h R N A  (sh C )  or pR b-spec if ic  sh R N A  (sh R b ).  
A ntibodies a g a in s t  p R b  a n d  p 5 3  w e r e  u s e d .  MB U pon e x te n s iv e  
e x p o s u re  of th e  blot, re s id u a l  p R b  pro te in  b a n d  is o b s e r v e d  in th e  s h R b  
lane , indicating n o n - c o m p le te  abolition of th e  p R b  protein by th e  sh R N A
(B) M e th y le n e  b lu e  s ta in in g  of AAV in fe c te d  ce lls  t r a n s d u c e d  with 
s c ra m b le d  sh R N A  (shC ) or  p R b -sp e c i f ic  sh R N A  (sh R b ).
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Table 3.1.1
p53
p21
i
pRb
+AAV
U20S U20S
p53DD
U20S
ShRb
HCT116 HCT116p53V-
HCT116
p21V-
Saos-2 Saos-2
+ p21
Saos-2 
+ pRb
+ — + + — + — — -
+ + + + + — + + + +
+ + — + + + — — +
0 0
Table 3.1.1. Perturbations of the p53-p21-pRb pathway render cells 
susceptible to cell death upon AAV infection. T h e  ta b le  s u m m a r i s e s  th e  
result  of AAV infection in all cell ty p e s  u s e d  or g e n e r a te d  a n d  in fe c te d  with 
AAV a s  d e s c r ib e d  in th e  tex t  to g e th e r  with th o s e  r e p o r te d  by Raj et ai.
2001. T h e  ta b le  s h o w s  th e  s t a t u s  in e a c h  line of t h e  p 5 3 -p 2 1 -p R b  p a th w a y  
an d  th e  resu l t  of AAV infection in th e  lower row A skull a n d  c r o s s b o n e s  
ind ica te s  cells  d e a th  upon  infection A c o n tin u o u s  circle in d ica te s  cell 
survival
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We now centred our attention on understanding how signalling via this pathway might 
prevent death. As such it was necessary to try and establish the pathway or pathways 
that promote cell death to understand how p53 signalling to pRb might protect.
AAV infection leads to caspase activation
Caspase proteins represent core mediators of cell death. There are at least 11 known 
caspases in humans and the signature o f caspase protein activation and involvement in 
cell death can yield a lot of information with regard to the signalling pathways 
involved in stimulating cell death (281). Raj et al 2001 have shown previously that 
AAV-induced cell death occurred via apoptosis since cells were positive for Annexin- 
V (220). As such we wanted to characterise apoptotic cell death via caspase 
activation. Saos-2 cells were infected with AAV and whole cell lysates were 
examined for caspase activation by looking for the generation of cleavage products 
since caspase cleavage is indicative o f caspase activation. Figure 3.1.9A shows 
western blot analysis of caspase 3 and highlights the generation of lower molecular 
weight products that correspond to caspase 3 cleavage products. Caspase 3 is one of 
the core executioner caspase molecules activated in cells undergoing apoptosis. 
However, we also observed the activation o f caspase 6, whose activity is associated 
with fewer inducers of cell death. A panel o f cells were examined for caspase-6 
activation (Figure 3.1.9B). Saos-2 cells, U 20S cells and U20S cells transduced with 
shRb were infected with AAV and whole cell lysates were examined via western 
blotting. We observed that while caspase-6 was clearly activated in Saos-2 cells, 
U20S cells did not activate caspase-6 in response to AAV infection. However when 
pRb levels were diminished in U 20S cells via shRb we saw that upon AAV infection, 
caspase-6 activation was observed. The pattern of caspase-6 activation is consistent 
with the cells that we have thus far demonstrated to be susceptible to AAV-mediated 
cell death.
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Figure 3.1.9
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Figure 3.1.9. AAV Infection lead s to the activation of casp ase^ )  
and casp ase-6  In ce lls  su sc ep tib le  to AAV Induced cell death.
(A) C a s p a s e  3 w e s t e r n  b lo t  a n a l y s i s  o f  l y s a t e s  of S a o s - 2  a t  v a r i o u s  
d a y s  p o s t-A A V  in fe c t io n  (B) C a s p a s e  6 w e s t e r n  b lo t  a n a l y s e s  o f  
l y s a t e s  o f  S a o s - 2 .  U 2 0 S  c e l l s  e x p r e s s i n g  s h R b  a n d  w i ld - ty p e  U 2 0 S  
ce l ls .  1 a n d  2 d a y s  p o s t  in f e c t io n  w ith  A A V . U n i n f e c t e d  cell l y s a t e s  
a r e  l a b e l le d  a s  "c".
y
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Caspase-6 is the principle caspase involved in mediating cell death in response to 
AAV
To clarify whether caspase-6 was a fundamental mediator of cell death in response to 
AAV-induced DNA damage signalling as opposed to it’s activation being merely a 
consequence of cell death, we employed point mutant dominant negative caspase 
molecules to inhibit caspase activity. Saos-2 cells were transfected and selected to 
express dominant-negative caspase-6 or dominant-negative caspase-3 protein as 
shown by immunoblotting (Figure 3.1.10A). Saos-2 cells expressing dominant- 
negative caspase-3 protein were infected with AAV and cell survival was assayed by 
methylene blue staining (Figure 3.1.1 OB). Inactivation of caspase-3 in this way 
conferred very little protection from AAV-induced cell death. However, methylene 
blue staining of AAV-infected dominant negative caspase-6 expressing Saos-2 cells 
highlighted almost complete protection from AAV-induced cell death (Figure
3.1. IOC). In an independent experiment to that of the data presented in figure 3.1.10, 
untransfected cells, cells transfected with the empty vector or dominant negative 
caspase-3 or -6  expressing cells were infected with AAV and analysed by FACS and 
methylene blue staining (Figure 3.1.1 IB and C respectively) Following FACS the 
measure of cells with a sub-Gl DNA content were quantified and this is annotated 
against each profile. Following AAV infection between 70 and 90% of Saos-2 or 
Saos-2 empty vector control cells underwent cell death as determined by the 
percentage of cells with sub-Gl DNA content. Conversely, only 20% of cells 
underwent cell death when expressing the dominant-negative caspase-6 protein 
compared with 30% of cells expressing dominant negative caspase-3. Long-term cell 
survival assays and FACS analysis both yielded the same conclusion; that caspase-6 
be the fundamental caspase involved in mediating cell death in response to AAV. 
Since caspase-6 is activated by a more limited group of pro-apoptotic agents our 
search for the pro-apoptotic mediator of AAV-induced cell death could be more 
refined.
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Figure 3.1.10
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Figure 3.1.10. Dominant negative caspase-6 expressing Saos-2 cells are 
rescued from AAV-induced cell death. (A) W e s te rn  blot ana ly s is  u s ing  anti- 
c a s p a s e  3 a n d  a n t i - c a s p a s e  6  of ly s a t e s  from  S a o s - 2  cells th a t  w e r e  e n g in e e re d  to  
e x p re s s  either d o m in a n t-n e g a t iv e  c a s p a s e  6 (DN C6). which p o s s e s s e s  a  tag  
s e q u e n c e ,  or d o m in a n t-n e g a t iv e  c a s p a s e  3 (DN C3). which is a  point m u tan t  of t h e  
s a m e  l e n ^ h  a s  th e  w ild-type p ro te in . (B) D uplica te  m eth y le n e  blue s ta in ing  of 
un in fec ted  S a o s - 2  cells . S a o s - 2  cells  c o n ta in ing  th e  em pty  vec to r  a n d  S a o s - 2  cells 
e x p re s s in g  d o m in a n t-n e g a t iv e  c a s p a s e  3. s e v e n  d a y s  post-infec tion  with AAV. (C) 
Duplicate  m e th y le n e  b lue  s ta in ing  of u n in fe c te d  S a o s - 2  cells. S a o s - 2  cells  
contain ing th e  e m p ty  v e c to r  a n d  S a o s - 2  cells  e x p re s s in g  do m in a n t-n e g a t iv e  
c a s p a s e  6. s e v e n  d a y s  post- infec tion  with AAV.
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Figure 3.1.11
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Figure 3.1.11. FACS analysis of AAV-induced cell death in Saos-2 cells 
expressing dominant-negatlvecaspase 3 / 6. (A) W e s te rn  blotting of ly sa te s  
of u n t ra n s d u c e d  S a o s - 2  cells. S a o s - 2  ce lls  t r a n s d u c e d  with an  em p ty  v e c to r  
an d  S a o s -2  cells  th a t  h a d  b e e n  t r a n s d u c e d  with e i the r  a  d o m in an t  n e g a t iv e  
c a s p a s e - 3  or a  d o m in a n t  n e g a t iv e  c a s p a s e - 6  e x p re s s io n  co n s tru c t ,  ^ p r e s s i o n  
is ind ica ted  by th e  i n c r e a s e  in a m o u n t  of c a s p a s e - 3  or - 6  respec tive ly  
E x p re ss io n  of tubulin is sh o w n  to d e m o n s t r a t e  equa l  loading. (B) S a o s - 2  cells , 
S a o s -2  cells  t r a n s d u c e d  with an  e m p ty  v e c to r  or S a o s - 2  cells  t r a n s d u c e d  with 
the  d o m in a n t  n e g a t iv e  c a p s a s e - 3  or d o m in a n t  n e g a t iv e  c a s p a s e - 6  c o n s tru c t  
w e re  in fec ted  with AAV (+AAV) or m o c k -u n in fe c te d  (c). P la te s  w e re  s ta in e d  
with m e th y le n e  b lue  five d a y s  pos t- in fec tion  to s h o w  surviving a d h e re n t  cells .
(C) In parallel cells  w e r e  h a rv e s te d  for F A C S  an a ly s is  to allow quantif ica tion  of 
relative a m o u n t s  of cell d e a th  following AAV infection by quantification of cells  
with sub -G 1  DNA c o n ten t .
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One protein that has been demonstrated to activate caspase-6 is the pro-apoptotic 
protein p84N5 (77). The activity of p84N5 was o f particular interest since its activity 
has been associated with pRb in that it has been shown that p84N5’s pro-apoptotic 
propensity is inhibited by active, dephosphorylated pRb. As such we considered 
whether p84N5 may be the mediator of AAV-induced cell death in the absence of 
p53-p21-pRb signalling.
AAV activates p84N5
In order to establish if p84N5 played a role in eliciting cell death in response to AAV, 
we examined whole cell lysates from AAV-infected U20S and Saos-2 cells by 
immunoblotting using antibodies directed against p84N5. The limited literature 
regarding p84N5’s activity demonstrated that p84N5-mediated apoptosis coincides 
with the appearance of a lower molecular weight cleaved form of p84N5. As such we 
used this as a marker for any activation. Figure 3.1.12A shows that the cleaved form 
of p84N5 was indeed generated in Saos-2 cells following AAV-infection but not in 
AAV-infected U20S cells. This indicates that in cells susceptible to AAV-indueed 
cell death, p84N5 is active. This concept was examined further by looking at later 
time points post infection in Saos-2 cells, where it was observed that p84N5 activation 
increased over time as demonstrated by the increase in quantity of the cleaved form of 
p84N5, figure 3.1.12B. These data support the hypothesis that p84N5 is important in 
lending susceptibility to AAV-induced cell death and as such we continued to 
approach the question of whether it may be involved more directly.
Inactivation of p84N5 relieves susceptibility to AAV-mediated cell death
In order to examine the functional importance of p84N5 activity with regard to AAV- 
mediated cell death, we examined whether inactivation of p84N5 would prevent cell 
death in Saos-2 cells, which lack the activity of the p53-p21-pRb pathway. The 
p84N5 protein contains putative death domains (77) considered to be of importance in 
terms of the proteins pro-apoptotie activities. We used a retroviral construct to express 
a truncated form of the protein lacking the death domain regions. This mutant has 
previously been characterised and shown to function as a dominant-negative, thus 
inhibiting the activity of the wild-type protein (75). Saos-2 cells were transduced to 
express the dominant-negative protein as shown in figure 3.1.12C. These and control 
cells transduced with the empty retroviral vector were subjected to antibiotic selection
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and subsequently infected with AAV. Results are shown in duplicate in figure 
3.1.12D. Tissue culture plates were stained with methylene blue to highlight surviving 
cells. The results clearly show that while control Saos-2 cells underwent cell death 
upon AAV infection, leaving empty tissue culture plates, Saos-2 cells expressing the 
dominant negative p84N5 protein fully populated the plates following AAV infection. 
These observations support the concept that p84N5 is the pro-apoptotic factor 
involved in promoting cell death in response to an AAV-induced DNA damage 
response in cells that lack the p53-p21-pRb.
As such we surmise the following model, which dictates the outcome of AAV 
infection in terms of cell death or survival. The AAV DNA, as a consequence o f its 
unusual structure, is recognised as a DNA lesion. As such the AAV DNA initiates a 
DNA damage response, which likely involves many biochemical-signalling cascades. 
Here we focus upon two (i) the activation of p53 leading to the increased expression 
of p21 and ultimately the activation o f pRb and (ii) the activation of p84N5, which 
together determine the fate of the cell in response to AAV infection. In the presence 
of a functionally intact p53-p21-pRb signalling pathway, pRb will be successfully 
activated. The activation of pRb by dephosphorylation permits its interaction with and 
inhibition of p84N5 from activation, and as such prevents the initiation of apoptosis. 
However, if pRb activation cannot take place, p84N5 can be activated and cleaved 
leading to apoptosis via caspase-6.
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Figure 3.1.12
A
B
Saos-2 U20S 
C AAV C AAV
-rr— — cleauedp64N5
+ AAV
C 1 3 5 days post irfeclion
_  P84N5
^  mm —  cleaved p64N5 
Saos-2
C V DNp84
> —  p64N5 
' —  DN-P84N5
Saos-2
uninfected
Saos-2 
empty vector 
+ AAV
Saos-2 
DN-P84N5 
+ AAV
Figure 3.1.12. Expression of dominant negative p84N5 rescues Saos-2 cells 
from AAV Induced cell death. (A) W e s te rn  blotting of ly sa te s  of S a o s - 2  or 
U 2 0 S  un in fec ted  (c) cells  a n d  cells  2  d a y s  p o s t  infection with AAV using  
an tibod ies  a g a in s t  p 84N 5  pro te in . (B) p 8 4 N 5  w e s te rn  blot a n a ly s is  of ly sa te s  
from S a o s -2  cells  th a t  w e re  h a rv e s te d  a t  va r io u s  d a y s  post-AAV infection (C) 
W e ste rn  blot ana ly s is  u s ing  a n t ib o d ie s  a g a in s t  p84 N 5  of u n t ra n s d u c e d  cells  (c). 
cells t ra n s d u c e d  with e m p ty  v e c to r  (V) or with v e c to r  e x p re s s in g  dom inan t-  
nega tive  p84N 5  protein (D N p84), which is a  s h o r t e n e d  form  (lacking th e  d e a th  
dom ains)  of th e  wild ty p e  protein. (D) D up lica te  m e th y le n e  blue  s ta in ing  of 
un in fec ted  S a o s - 2  cells , S a o s -2  cells t r a n s d u c e d  with e m p ty  v e c to r  or S a o s -2  
cells e x p re s s in g  d o m in a n t-n e g a t iv e  p 8 4 N 5  pro te in , ten  d a y s  p os t  AAV infection.
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Chapter 2 AAV-induced DNA damage signalling as a potential 
factor restricting autonomous replication of AAV
• Helper viruses promote AAV replication
• Helper viruses disrupt the aggregation of AAV DNA into nuclear foci
• Helper viruses degrade PIKK protein levels
• Biochemical inhibition of PIKK protein function aids AAV replication
• Molecular inhibition of PIKK protein function
• Helper viruses attenuate AAV-induced hyperphosphorylation of RPA
• A mutant form of RPA-34 can act as a dominant negative
Helper viruses promote AAV replication
The data presented in this chapter addresses AAV replication restriction and as such 
all of the viruses used in these experiments were live wild-type AAV, not UV- 
irradiated virus. We wanted to directly examine helper virus-mediated help to AVV 
replication. To do so we took DNA extracts from AAV-helper virus coinfections and 
analysed AAV DNA replication by southern blotting. AAV at a constant multiplicity 
of infection (MOI) of 2000 was used to infect U 20S cells. Simultaneously cells were 
infected with Adenovirus (Ad5), Herpes simplex virus-1 (HSVl) or Vaccinia virus 
(Vv) in increasing MOI s. Infections were cultured for 48 hours following which total 
DNA extractions were performed. Equal quantities o f DNA were loaded onto agarose 
gels and subsequently transferred to nylon membrane for southern analysis. 
Membranes were probed using a radiolabelled AAV DNA probes (Figure 3.2.1). 
Figure 3.2.1 illustrates the pattern of bands observed for the different sized products 
of AAV replication intermediates. The lower band corresponds to the single-stranded 
(ss) AAV DNA. The middle band corresponds to the monomeric replicative form 
(Rf/n) and the upper band to the duplex replicative form (Rfd). In the absence of 
helper virus, AAV DNA from infected U20S cells was difficult to detect by southerm 
blot. However in the presence of co-infecting helper virus, (even at lowest MOI) 
AAV DNA and its replication intermediates were observed. The ratio of different 
species of AAV DNA and replication intermediates was different for each helper 
virus. Furthermore this ratio and the amount of DNA reflects the MOI of helper virus 
used. In the case of Adenovirus, we observed that with regard to the three MOIs used.
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the quantity o f ss AAV DNA increased with increasing MOL The quantity of Rfw 
remained fairly constant and the RTof form was only visible upon longer exposure. The 
MOI values of co-infecting HSVl highlighted a considerable increase in ss AAV 
DNA, which peaked at the mid MOI used with a corresponding peak in Rfw and Rfd  
species. At lower or higher MOI of eoinfecting HSVl there was considerable 
replication and indeed at all MOI values used HSV1 appeared to aid AAV replication 
more than Ad5 coinfection as determined by relative abundance of ss AAV DNA and 
replicative intermediates. It appears that Vv conferred the least replicative help to 
AAV when compared with Ad5 and HSV 1. Again the mid value MOI perhaps gave 
the optimum output of newly-synthesised AAV DNA, the three replicative forms of 
which appeared in approximately equal ratios. In summary figure 3.2.1 provides a 
visual representation of helper virus-mediated AAV DNA replication.
Helper viruses disrupt the aggregation of AAV DNA into nuclear foci
We have already demonstrated that in non-permissive conditions, i.e. in the absence 
of helper viruses, that AAV DNA rapidly accumulates into intranuclear foci that 
eolocalise with DNA damage-related proteins. These foci are reminiscent of DNA 
damage-induced nuclear foci. We wanted to examine whether similar foci 
accumulated upon AAV and helper virus coinfection. As such U20S cells grown on 
glass coverslips were co-infeeted with Ad5, HSVl or Vaccinia virus with AAV and 
cultured for 24 hours. In situ hybridisation techniques were employed to visualise 
both AAV DNA and helper virus DNA. Figures 3.2.2, 3.2.3 and 3.2.4 provide a 
comparison of AAV infection alone with that of helper virus coinfections.
Figure 3.2.2 compares AAV infection alone with that of an Ad5 coinfection. When 
AAV infects cells the DNA appears restricted to intranuclear foci, which we have 
shown in previous experiments, directly eolocalise with DNA damage related proteins 
(see Figure 3.1.1). However when cultured in coinfection with Adenovirus, the AAV 
DNA was no longer confined to punctuate foci but rather appeared throughout the 
nucleus. The number of cells infected with AAV appeared less than infection with 
AAV alone. Since similar amounts of AAV were used it is likely that the number o f 
cells infected with AAV was the same here as AAV infection alone. Yet it seems that 
fewer cells demonstrate AAV DNA foci even in the absence of any apparent
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replication. Figure 3.2.3 compares AAV infeetion with HSVl-AAV eo-infections. In 
a similar way to Adenovirus co-infections, we see that in the presence of HSV 1, AAV 
was no longer confined to discrete intranuclear foei but rather AAV DNA was found 
throughout mueh of the nucleus. Furthermore, while the number of cells 
demonstrating significant replication of AAV DNA was considerable for HSV 1 - AAV 
coinfections (greater than in the context of Ad5-AAV coinfections, in aggrement with 
the southern blot data of figure 3.2.1) even cells that appeared to have low quantities 
of AAV DNA did not have observable intranuclear foci. Figure 3.2.4 compares AAV 
infections with Vv-AAV co-infections. It is clear that the help to AAV replication by 
Vv was not as significant as the help derived from HSVl or Ad5 coinfection and this 
is again in agreement with the data shown in the southern blot of figure 3.2.1. 
However, when replication was observed, AAV DNA was not confined to discrete 
intranuclear foci but rather is dispersed diffusely within the nucleus. It is noteworthy 
also that in addition to the lower levels o f AAV replieation when compared to HSV 1 
or Ad5 coinfected cells, there were considerably more cells that while positive for 
both Vv DNA and AAV DNA did nevertheless display AAV DNA in nuelear foci in 
the absence of apparent replieation. This may be a reflection of the fact that unlike 
Ad5 or HSVl, Vv replication is cytoplasmic, associating with endoplasmic reticulum 
compartments (279). There are few demonstrations of in situ hybridisation of Vv 
DNA during replication and while reportedly strictly cytoplasmic the data presented 
here appears to demonstrate some nuclear loealisation of Vv DNA in U20S cells.
It is also of note that when the localisation of AAV DNA and helper virus DNA is 
compared, one appears almost totally excluded from the region of the other. This is 
apparent in the combined in situ hybridisation fluorescence images of coinfections 
highlighted in figures 3.2.2, 3.2.3 and 3.2.4. The localisation of helper virus 
replication centres and AAV replication centres is of some dispute. In the past, some 
evidence has supported the notion that AAV and helper virus replication 
compartments overlap (115, 262, 297). However a more recent study using indirect 
visualisation techniques has suggested that AAV and HSVl replication compartments 
are distinct (102). Here we show direct evidence for exclusion of three different 
helper viral DNAs from AAV DNA by direct in situ hybridisation.
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The observation that in permissive conditions, AAV DNA is not retained in nuclear 
foci led us to the hypothesis that elements o f the DNA damage-like foci and the DNA 
damage response may be factors that restrict AAV’s autonomous replication. Since 
the primary sensors o f DNA damage are the PIKK proteins, ATM, ATR and DNA- 
PK we wanted to examine whether signalling from these enzymes plays a role in 
inhibiting AAV replication.
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Figure 3.2.1
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Figure 3.2.1. Adenovirus, Herpes simplex virus (HSV) and Vaccinia 
virus facilitate AAV replication. L a n e s  1 a n d  2 ind ica te  m o c k  infec ted  
U 2 0 S  and  AAV in fe c te d  U 2 0 S  resp e c t iv e ly .  All o th e r  l a n e s  w e r e  
in fec ted  with AAV a t  a n  MOI of 2 0 0 0  in com bina tion  with increas ing  
a m o u n ts  of h e lp e r  v iru s  a t M OIs of 5. 15 a n d  30. T h e  m e m b r a n e  w a s  
p ro b ed  with a  rad io lab e l led  anti-AAV DNA p ro b e .  S in g le -s t ra n d e d  AAV 
DNA (ssA A V  DNA). m o n o m e r ic  rep lica tive  fo rm s  (R Fm ) a n d  dup lex  
replicative fo rm s  (RFd) a re  h igh lighted .
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Figure 3.2.2
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Figure 3.2.2. AAV DNA Is not restricted to discrete foci In Adenovirus 
(Ad6) and AAV coinfections. U 2 0 S  cells w e r e  cu ltu red  on g la s s  c o ve rs l ip s  
and  in fec ted  with AAV (MOI 2 0 0 0 )  a lo n e  or AAV (MOI 20 0 0 )  a n d  A d5 (MOI 
15) to g e th e r .  Cells  w e re  cu ltu red  for 24  h o u rs  an d  h a rv e s te d  a n d  p r o c e s s e d  
for in situ hybridisation. B io tiny lated  AAV p ro b e s  w e re  u s e d  to d e te c t  AAV 
DNA a n d  d e te c te d  u s ing  s trep tav id in  c o n ju g a te d  A lexa-594  in com bina tion  
with V accin ia  v irus  specif ic  d ig -labelled  p r o b e s  tha t  w e r e  v isu a l is e d  u s in g  
FITC c o n ju g a te d  anti-Dig im m unolabelling , DAPI sta in  h ighlights  DNA a n d  th e  
s c a le  r e p r e s e n t s  1 0 ^ m .
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Figure 3.2.3
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Figure 3.2.3. AAV DNA Is not restricted to discrete foci In Herpes 
simplex virus (HSV) and AAV coinfections. U 2 0 S  cells  w e r e  c u l tu red  on 
g la s s  c o v e rs l ip s  a n d  in fec ted  with AAV (MOI 2 0 0 0 )  a lo n e  or AAV (MOI 
2000)  a n d  H SV  (MOI 15) to g e th e r .  C e l ls  w e r e  cu ltu red  for 24  h o u r s  a n d  
h a r v e s t e d  a n d  p r o c e s s e d  fo r  in situ hybr id isation . Biotinylated AAV p r o b e s  
w e re  u s e d  to d e te c t  AAV DNA a n d  d e t e c t e d  u s ing  s trep tav id in  c o n ju g a te d  
A lexa-594 in com bina tion  with H SV  specif ic  d ig -labelled  p ro b e s  th a t  w e r e  
v isu a l is e d  u s ing  F IT C  c o n ju g a te d  anti-Dig im m unolabelling . DAPI sta in  
h ighlights DNA a n d  th e  s c a l e  r e p r e s e n t s  10 ^tm.
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Figure 3.2.4
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Figure 3.2.4. AAV DNA is not restricted to discrete foci in Vaccinia virus 
(Vv) and AAV coinfections. U 2 0 S  cells  w e r e  cu ltured  on g la s s  covers l ip s  and  
infected  with AAV a lo n e  (MOI 2000) or AAV (MOI 2000) a n d  W  (MOI 15) 
together .  C ells  w e r e  cu ltu red  for 24 h o u rs  a n d  h a rv e s te d  a n d  p r o c e s s e d  for in 
situ hybridisation. Biotinylated AAV p ro b e s  w e r e  u s e d  to d e te c t  AAV DNA a n d  
d e te c te d  u s in g  s treptavidin  c o n ju g a te d  A lexa-594  in com bination  with Vv 
specific dig-labelled p r o b e s  th a t  w e re  v isu a l ise d  us ing  FITC c o n ju g a te d  anti-Dig 
im m unolabelling. DAPI sta in  highlights DNA a n d  th e  s c a le  r e p r e s e n t s  10 /xm.
140
Helper viruses decrease PIKK protein levels
We considered the levels of ATM, ATR and DNA-PK as well as the activation status 
of ATM (via serine 1981 phosphorylation) by western blotting. Whole cell lysates of 
AAV, Ad5, HSVl or Vv infected cells were taken at 24 and 48 hours as well as 
coinfected cultures at the 48-hour time point. Figure 3.2.5 displays the result of 
western blotting of these lysates using anti-ATM antibodies and antibodies that 
recognise ATM proteins phosphorylated at serine 1981, indicative of ATM activation 
by auto-phosphorylation. Levels of ATM protein appeared considerably raised upon 
infection with AAV while coinfections did not show a dramatic increase of ATM 
protein and in the case of an HSVl and AAV coinfection, the levels of ATM were 
drastically decreased below that o f control, uninfected U20S cells. AAV-infected 
U20S cells showed significant activation of ATM as interpreted by levels of 
phosphorylation, though uninfected U 20S cells also appeared to exhibit ATM 
phosphorylation. While the reasons for this are not clear, it is important to note that 
helper virus-AAV coinfected cultures o f Ad5 or Vv showed little if any 
phosphorylation of ATM. HSV-AAV coinfections appeared to activate ATM to a 
similar degree to that of AAV alone.
When we consider ATR (Figure 3.2.6) we observed that levels of ATR were 
considerably decreased in all coinfected cultures when compared with AAV alone or 
uninfected controls. Similarly, levels o f DNA-PK were profoundly decreased by AAV 
coinfection with Ad5 or HSVl when compared with AAV-infected U20S and 
uninfected controls (Figure 3.2.6).
In summary we see that in the context of helper virus-AAV coinfections there is a 
decrease in at least one if not all o f the PIKK protein levels or activation shown in 
figures 3.2.5 and 3.2.6 when compared to AAV infections alone or uninfected 
controls. This suggests that one unified way in which helper viruses may modulate the 
cellular environment to render it permissive for AAV replication is by manipulation 
of PIKK proteins and / or signalling.
141
Figure 3.2.5
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Figure 3.2.6 -  Effect of AAV, Adenovirus, HSV, Vaccinia virus and helper 
vIrus-AAV coinfections on ATM and ATM phosphorylation of serine 1981
at 24 and 48 hours post infection. T h e  first lan e  r e p r e s e n t s  an un in fec ted  
control. L a n e s  labe l led  '+' d e n o te  4 8  hou r  co in fec tions  of th e  r e sp e c t iv e  h e lp e r  
virus with AAV.
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Figure 3.2.6
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Figure 3.2.6 -  Effect of AAV, Adenovirus, HSV, Vaccinia virus and 
helper virus-AAV coinfections on ATR and DNA-PK at 24 and 48 
hours post infection. T h e  first l a n e  r e p r e s e n t s  an un in fe c te d  control. 
L a n e s  labelled '+* d e n o te  4 8  hou r  co in fe c t io n s  of r e s p e c t iv e  h e lp e r  virus 
with AAV.
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Biochemical inhibition of PIKK protein function aids AAV replication
To establish whether ATM, ATR and DNA-PK signalling were repressors of AAV 
replication we chose to examine whether chemical inhibitors of their kinase activity 
would augment AAV replication. We used the chemical wortmannin, NU7027 
(Calbiochem) a DNA-PK inhibitor, and caffeine, to inhibit a combination of activities 
(Figure 3.2.7). Wortmannin is used at the lower concentration of 20 \xM to inhibit 
ATM and DNA-PK. At the higher concentration o f 150 piM wortmannin inhibits 
ATM, DNA-PK and ATR (41). We found that while high concentrations of 
wortmannin appeared to promote an increase in the amount of ss AAV DNA this did 
not coincide with the appearance o f any replicative intermediates. However, the 
physiologically effective concentration range o f DNA-PK inhibitor (10 pM) and 2 
pM caffeine generated not only an increase in the amount o f ss AAV DNA but also 
resulted in the generation o f replicative intermediates. Caffeine is a broad range 
inhibitor of all PIKK protein activity and other unspecified cellular functions while 
the DNA-PK inhibitor, NU7027 is considered to be a specific inhibitor of DNA-PK 
function and it is with this drug treatment that we see the most significant increase to 
the quantity of AAV DNA. The inclusion of DNA extracts from Ad5-AAV 
coinfections was shown as a positive control and appears significantly over-exposed 
since it was necessary to expose the other portions of the blot for considerably longer.
Molecular inhibition of PIKK protein function
While the biochemical inhibition of PIKK protein signalling, particularly the 
inhibition o f DNA-PK appears to permit some replication of AAV we wanted to 
ensure that observed replication was not a consequence of drug-induced genotoxic 
stress for example. As such we sought to employ short interfering RNA (siRNA) and 
Tetracycline inducible systems to either silence expression or promote expression of 
kinase dead dominant-negative proteins respectively with the aim to inhibit ATM, 
ATR and DNA-PK function. Difficulty was encountered in terms of siRNA-mediated 
expression silencing of both ATM and ATR. Furthermore the expression of kinase 
dead ATM also required some optimisation and the results are far from satisfactory 
(figure 3.2.8A). While the results for siRNA mediated silencing of DNA-PK have 
proven more fruitful the results from these experiments remain preliminary and are 
only indicative.
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Figure 3.2.8A demonstrates the expression of either flag-tagged wild-type ATM 
(ATMwt) or kinase dead ATM (ATMkd). Although the levels of the proteins were not 
as high as we had hoped for, these cells were infected with AAV and cultured for 48 
hours. Total DNA extractions were performed and equal quantities of DNA were 
loaded onto either an agarose gel or slot blot apparatus. DNA was transferred to nylon 
membrane and radiolabelled anti-AAV probes were used to probe for AAV DNA 
species. Figure 3.2.8B shows the appearance o f the monomeric replicative form of 
AAV DNA in the presence of ATMkd. This suggests that inhibition of ATM may 
help AAV replication. This is reinforced by slot-blot data in figure 3.2.8C. The slot 
blot image has been subject to phosphorimager analysis and the intensity of signal is 
plotted graphically. As demonstrated in the graph, there is some increase in AAV 
DNA in both ATM wt and kd expressing cells though a greater increase in the 
quantity of AAV DNA occurs in the presence of ATMkd protein. It is clear that 
ATMwt and ATMkd experiments require further optimisation and for the experiment 
to be repeated under more ideal conditions before any conclusions be drawn.
Figure 3.2.9A demonstrates the expression silencing of DNA-PK in U20S cells. Cells 
in which siDNA-PK had been employed to reduce DNA-PK expression as well as 
siCONTROL transfected cells were infected with AAV. Cells were infected 24 hours 
post transfection and cultured for 48 hours. Total DNA extractions were performed 
and equal quantities of DNA were loaded onto agarose gels and transferred to nylon 
membrane for southern blotting as described above (Figure 3.2.9B). Southern blotting 
illustrates a considerable increase in quantities o f the ss AAV DNA also with the 
appearance of monomeric replicative forms in siDNA-PK treated cells. This implies a 
significant role for DNA-PK in the inhibition of AAV replication.
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Figure 3.2.7
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Figure 3.2.7. Caffeine treatment and DNA-PK Inhibitor of U20S cells 
promotes AAV replication. L a n e  n u m b e r s  r e p r e s e n t  t r e a tm e n t s  highlighted 
a b o v e .  C ells  w e r e  d ru g  t r e a te d  fo r  2 4  h o u r s  prior to  AAV infection. C e lls  w e re  
c u ltu red  in th e  p r e s e n c e  of AAV a n d  d ru g  fo r  a  further  4 8  h o u rs .  Total DNA 
e x tra c t io n s  w e r e  p e r f o m e d  a n d  e q u a l  q u a n ti t ie s  of DNA lo a d e d  on to  a  0 .6 2 5 %  
a g a r o s e  gel. DNA w a s  t r a n s fe r r e d  to  nylon m e m b r a n e  a n d  s u b je c t  to s o u th e rn  
blotting with rad io labe l led .  anti-AAV p r o b e s .  S ing le  s t r a n d e d  AAV DNA (ssA A V  
DNA). m o n o m e r ic  rep lica tive  fo rm s  (R F m ) a n d  duplex  rep lica tive  fo rm s  (R Fd) 
a re  h igh ligh ted  accord ing ly .
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Figure 3.2.8 
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Figure 3.2.8. Expression of ATMkd in U20S cells enhances replication 
of AAV. (A) U 2 0 S  ce lls  w e r e  t r a n s f e c t e d  with an  e m p ty  e x p re s s io n  v e c to r  
(c) or a  v e c to r .h a r b o u r in g  th e  w ild -type  ATM g e n e  (ATMwt) or a  k in a s e  d e a d  
m u ta n t  ATM (ATMkd). O n e  day  p o s t  t ra n s fe c t io n ,  ce lls  w e re  in fec ted  with 
AAV a n d  cu ltu red  fo r  4 8  h o u r s .  Half of th e  ce lls  w e r e  ly sed  a n d  s u b je c t  to  
protein  ex trac t ion  a n d  quantif ication; a n  eq u a l  quan ti ty  of protein w a s  lo a d e d  
on to  e a c h  la n e .  P ro te in  w a s  t r a n s fe r r e d  to n i trocellu lose  m e m b r a n e  a n d  
s u b je c t  to  w e s te rn  b lotting with an ti-FLA G  a n t ib o d ie s .  (B) T h e  o th e r  half of 
ce lls  w e r e  s u b je c t  to  to ta l DNA ex trac tion  a n d  an  eq u a l  quan ti ty  of DNA w a s  
lo a d e d  o n to  e a c h  la n e  of a  0 .6 2 5 %  a g a r o s e  gel. DNA w a s  t ra n s fe r re d  to  
nylon m e m b r a n e  a n d  s u b je c t  to  s o u th e rn  blotting with a  rad io labe l led  anti- 
AAV DNA p ro b e .  (C) In para lle l  e q u a l  q u an ti t ie s  of DNA w e re  lo a d e d  o n to  a  
slot blot a n d  t r a n s f e r r e d  to nylon m e m b r a n e  s u b je c t  to s o u th e rn  blotting 
u s ing  a  rad io lab e l led  anti-AAV DNA p ro b e .  R F m  in d ic a te s  th e  m o n o m e r ic  
replicative form a n d  ssA A V  DNA r e p r e s e n t s  th e  s in g le -s t ra n d e d  AAV DNA.
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Figure 3.2.9. Expression of siDNA-PK in U20S cells enhances 
replication of AAV. (A) U 2 0 S  ce lls  w e r e  t r a n s fe c te d  with s iC O N T R O L  
DNA or SiRNA d irec ted  a g a in s t  D N A -R K cs. O n e  d a y  p o s t  t ra n s fe c t io n ,  cells 
w e re  in fec ted  with AAV a n d  c u l tu re d  for 4 8  h o u rs .  Half of th e  ce lls  w e re  
ly sed  a n d  su b jec t  to  p ro te in  ex tra c t io n  a n d  quantification; a n  e q u a l  quantity  
of protein w a s  lo a d e d  on to  e a c h  la n e .  P ro te in  w a s  t r a n s fe r re d  to 
n itrocellu lose  m e m b r a n e  a n d  s u b je c t  to w e s te r n  blotting with anti-DNA -PK 
a n tib o d ie s  a n d  tubulin to  d e m o n s t r a t e  e q u a l  loading . (B) T h e  o th e r  half of 
cells  w e r e  su b je c t  to  to ta l DNA ex trac tion  a n d  a n  equa l  quan ti ty  of DNA 
w a s  lo a d e d  on to  e a c h  la n e  of a  0 .6 2 5 %  a g a r o s e  gel. DNA w a s  t r a n s fe r r e d  
to nylon m e m b r a n e  a n d  s u b je c t  to  s o u th e rn  blotting with a  rad io labe l led  
anti-AAV DNA p ro b e .  R F m  in d ic a te s  t h e  m o n o m e r ic  replicative form a n d  
ssAAV DNA r e p r e s e n t s  t h e  s in g le - s t r a n d e d  AAV DNA.
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Helper viruses attenuate AAV-induced hyperphosphorylation of RPA
While data addressing the question of whether the PIKK proteins inhibit AAV 
replication remain preliminary, it appears to point in the direction DNA-PK and 
perhaps ATM as inhibitory factors. These initial experiments, both biochemical and 
molecular, pinpoint DNA-PK as being of particular importance. If helper viruses do 
facilitate AAV replication, in part by the inhibition of PIKK activity, we wanted to 
consider downstream elements o f PIKK signalling that might be ultimately 
responsible for AAV restriction. We have already demonstrated that AAV induces the 
hyperphosphorylation o f RPA (Figure 3.1.1). RPA is a target substrate of both ATM 
and DNA-PK kinase activity in vivo. Therefore, we wanted to examine whether helper 
viruses might prevent the generation o f hyperphosphorylated RPA by the inhibition of 
PIKK protein signalling. To this end, U 20S cells were infected with AAV, Ad5, 
HSVl, Vv or AAV in combination with helper virus. Protein extracts were examined 
by immunoblotting using an anti-RPA antibody that recognises all species of RPA 
(Figure 3.2.10). The upper band observed following AAV infection represents 
hyperphosphorylated RPA and this is absent from extracts of Ad5, HSVl or Vv 
infected cells or AAV-helper virus coinfections. This result supported the notion that 
helper viruses prevent the phosphorylation o f RPA. This encourages the hypothesis 
that phosphorylated RPA inhibits AAV replication.
A mutant form of RPA-34 can act as a dominant negative
One way in which to verify whether AAV replication is inhibited by 
hyperphosphorylation of RPA is by the direct prevention of hyperphosphorylated 
RPA species' generation in the context o f an AAV infection. AAV requires 
unphosphory 1 ated RPA for replication and so it is not possible to simply prevent 
expression of RPA. Furthermore, RPA is absolutely required for cell survival also. 
RPA functions as a heterotrimeric complex and it is the N-terminus 32 kDa subunit 
that is particularly phosphorylated in response to DNA damage. To date there is no 
known dominant negative form of RPA that can inhibit RPA phosphorylation in cells. 
We wanted to know if expression of a mutant form of the 32 kDa subunit lacking the 
region of the N-terminus that is the substrate for phosphorylation would prevent the 
generation of the hyperphosphorylated RPA complex following DNA damage. As 
such we sought to express a mutant form to act in a dominant negative manner. In 
2004 Binz et al. produced a series o f RPA-32 mutants to express in bacteria and
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analysed their DNA binding affinities (30). One such mutant, RPA32A33 lacked the 
phosphorylation domain but retained much of its DNA binding capabilities. As such 
we considered that this mutant might retain its ability to function in the context of the 
cellular RPA heterotrimer in terms of replication but may prevent the 
hyperphosphorylation o f RPA in response to DNA damage. The mutant DNA 
sequence o f RPA32 was amplified from the original construct using PCR. Restriction 
sites were added at either end to facilitate directional cloning into a mammalian 
expression vector. When expressed in U 20S cells, the protein was only tolerated at 
low levels. Cells were transfected with either 1 p.g (+) or 2.5 |ig (++) of RPA32A33 
and then irradiated with 5 J/m^ UV (Figure 3.2.11). The figure clearly demonstrates 
that following UV irradiation, control cells generated considerable levels of 
hyperphosphorylated RPA. However, expression of the RPA32A33 mutant protein 
prevented this. This suggests that this mutant can function as a dominant-negative in 
vivo, preventing the generation o f hyperphosphorylated RPA in response to DNA 
damage. Furthermore, while cells irradiated with 5 J/m^ UV appeared arrested or 
dying, the RPA32A33 continued to cycle. We must further verify if cells do indeed 
continue to replicate their DNA in the presence o f DNA damage when expressing this 
mutant. If this is the case, this mutant will prove a powerful tool for examining the 
inhibitory role o f hyperphosphorylated RPA separately from dephosphorylated RPA, 
which we know to be required for AAV replication (200). AAV infection o f cells 
expressing such a mutant will allow us to determine the involvement o f RPA 
phosphorylation in AAV replication.
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Figure 3.2.10
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Figure 3.2.10. AAV Infection results In the hyper phosphorylation of RPA 
protein. C ells  w e r e  in fe c te d  a n d  h a r v e s t e d  at 24  a n d  4 8  h o u r s  p o s t  infection 
a n d  total p ro te in  ex trac t ion  p e r f o r m e d .  E q u a l  qu a n ti t ie s  of total protein  w e r e  
lo a d e d  o n to  e a c h  la n e .  T h e  firs t  l a n e  r e p r e s e n t s  an  u n in fe c te d  control. L a n e s  
labe l led  '+ ' d e n o te  a  4 8  h o u r  co in fec tion  with AAV. T h e  m e m b r a n e  w a s  p ro b e d  
u s ing  a n  a n t i -R P A  a n tib o d y  th a t  r e c o g n i s e s  all R P A  s p e c i e s .  R P A p p  d e n o te s  
th e  h y p e rp h o s p h o r y la te d  form  of t h e  p ro te in .
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Figure 3.2.11
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Figure 3.2.11. Transfection with RPA32A33 mutant prevents 
hyperphosphoryiation of RPA in response to UV irradiation.
W e s te rn  a n a ly s i s  of R P A . U 2 0 S  ce lls  w e r e  t r a n s f e c te d  with a n  e m p ty  
v e c to r  (c) or  a  v e c to r  h a rb o u r in g  t h e  R P A 3 2 A 3 3  m u ta n t  in tw o  quan ti t ie s ,  
IfjiQ (+) or 2 .5  Atg (++). O n e - d a y  p o s t  t ra n s fe c t io n  ce lls  w e re  i r rad ia ted  
with 5 J / n f  UV or m o c k  t r e a te d .  T ubu lin  im m unob lo t t ing  d e m o n s t r a t e s  
load ing  of t h e  p ro te in .
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Section 4 Discussion
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Viral Interactions with the DNA Damage Response
We are only just beginning to understand the complex cellular response that takes 
place in the event o f DNA damage. Damage to the cellular DNA can take place as a 
consequence of both exogenous and endogenous events; from UV-induced DNA 
lesions to mistakes during replication. However, when we consider multicellular 
organisms we must consider that each cell takes responsibility for the fidelity with 
which it passes on its vital genetic information to daughter cells. To do this cells 
employ a complex array of signalling proteins and pathways to detect, repair and 
replicate their DNA. In the event that the faithful transfer of the cellular genome to 
progeny cells be jeopardised, these cells also have the potential to undergo 
programmed cell death. The strict coordination o f these pathways is pivotal to normal 
life.
The cellular DNA damage response is carefully honed to be able to detect not simply 
DNA damage, but to distinguish between lesion types and respond with appropriate 
repair mechanisms. The complexity required to perform these functions whilst 
ensuring the accurate replication o f the cellular genome is of course phenomenal. It is 
not surprising then that the presence of viral DNA and replication intermediates in the 
nucleus of a host cell would not go un-noticed. It has only been relatively recently that 
the interactions between viruses and cellular DNA damage responses have been truly 
appreciated. For some viruses, DNA damage responses appear to be detrimental and
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as such, some viruses have evolved methods by which to evade such responses while 
conversely other viruses appear to benefit from DNA damage repair and signalling 
components. There are few reports o f RNA virus interactions with DNA damage 
response though retroviruses, and particularly their integration steps have warranted 
several reports focusing on elements o f DNA recombination machinery. However, 
there are numerous reports regarding DNA viruses and their interactions with DNA 
damage machinery. Adenovirus targets several components of the MRN complex for 
degradation since the MRN complex in conjunction with other components o f the 
cellular DNA repair machinery recognise the linear, double-stranded DNA genome o f 
the virus as broken DNA ends to be recombined (261). If Adenovirus did not produce 
proteins to manipulate the localisation and degradation of M re ll, newly replicated 
Adenovirus genomes would be processed by cellular repair factors leading to 
circularised concatemer molecules that cannot be packaged into viral genomes. As our 
knowledge and understanding o f cellular DNA damage responses increases, so too 
does our recognition of viral interactions with them.
Unlike viruses whose interactions with cellular DNA damage responses may to some 
degree be seen as part of the viral lifecycle, the AAV-induced DNA damage 
responses that we discuss here do not involve viral proteins that arise from viral 
transcription or incoming viral particles (220). The ability of AAV DNA to induce G2 
arrest, activate p53 signalling or induce p84N5-dependent apoptosis is entirely 
dependent upon the structure of the AAV DNA alone.
AAV DNA is a single-stranded structure with hairpin loop formation at either end as a 
consequence o f palindromic repeat sequences (28). The AAV DNA enters the nucleus 
o f a cell by a process that is not fully understood but requires viral uncoating and 
translocation through the nuclear envelope. Although the precise time frame within 
which the AAV DNA engages the cellular DNA damage machinery has not yet been 
investigated, it is clear that within 24 hours a DNA damage response is activated. An 
ATR and Chk2-mediated G2 arrest is observed within 24 hours (129, 220). This 
response coincides with an inhibition o f cyclin B/cdc2 activity and the activation o f 
p53 and its downstream targets including p21 and pRb as demonstrated here. When in 
situ hybridisation was employed to visualise AAV DNA within the nucleus during 
this period, the AAV DNA was seen to be present in foci that also contained RPA and
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TopBPl (Figure 3 .L IA  and 3.1.1B). Since the formation of such foci and the 
hyperphosphoryiation o f RPA are both consistent with an activated DNA damage 
response, our observations imply that AAV DNA is the stimulus for such responses.
AAV Activation of p53 Signalling; the p53-p21-pRb pathway
The DNA damage-induced activation o f p53 was one of the discoveries that prompted 
p53’s christening as ‘guardian o f the genome’ (Lane 1992). Many forms o f cellular 
stress lead to the activation o f p53, which is essentially determined by the measurable 
stabilisation o f cellular levels of p53 and by the phosphorylation status of key residues 
of p53 protein. Activation o f p53 in response to DNA damage occurs as a 
consequence o f several routes o f signalling, ATM and ATR signalling via Chkl and 
Chk2 for example. In p53 serine 15 and serine 20 are considered key sites of ATM 
and ATR-dependent phosphorylation. Here we demonstrate that the AAV-induced 
DNA damage response leads to the activation o f p53 as demonstrated by the increased 
phosphorylation of serine 15 (Figure 3.1.3). Since serine 15 phosphorylation of p53 is 
considered to be indicative o f ATM and ATR activity this data reinforces previous 
observations that the AAV-induced G2 arrest is at least an ATR-mediated DNA 
damage response (129). The activation o f p53 is crucial for the cell to survive this. 
Cells that lack p53 will also arrest at the G2/M transition but they do not emerge from 
this arrest. Instead they undergo apoptosis. Although activated p53 in these cells 
stimulates the expression of several of its target genes such as 14-3-3a and p21, only 
p21 appears to be crucial for protecting cells from cell death (220).
There are several reports o f p21 playing a protective role in response to DNA damage 
(286, 287). Protection from AAV-induced cell death by p21 may in part be a 
reflection o f the role of p21 in maintaining G2 arrest (31, 276), Blagosklonny et al 
2000). In the absence of p21, cells may still be capable of undergoing arrest but this 
arrest may not be sustained (36). Since arrest may be a period in which cells have the 
opportunity to repair DNA damage, p21’s protective role may be to allow for DNA 
repair. In the absence of p21’s ability to sustain G2/M phase arrest cells may enter 
into mitosis in the presence of DNA damage leading to mitotic catastrophe; an 
unprogrammed form of cell death (95). p21 may also exert its protective properties by 
preventing DNA replication in the light of DNA damage. This hypothesis stems from 
the observation that following DNA damage, cells without p21 may appear to
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undergo cell cycle arrest at G2 but continue to synthesise their DNA without 
intervening mitosis leading to cells with abnormal DNA content (aneupolidy) (121, 
286). In such cases cell death invariably occurs. This may be deemed as a 
consequence o f mitotic catastrophe, as cells enter mitosis with DNA damage or 
genomic imbalance (43) or apoptosis in response to genomic instability (276). Indeed, 
the loss o f p21 has been shown to sensitize tumours to radiation (300) and cisplatin 
cytotoxicity (311).
We observe a response induced by AAV that is very much reminiscent of the well- 
characterised p53-mediated signal transduction associated with DNA damage 
responses i.e. the induction o f p21 gene transcription. Initial experiments demonstrate 
the importance o f p53 and p2I in preventing cell death following AAV infection. 
Although the apparent protective role of p53 in this context may be contrary to 
preconceived ideas regarding p53 activity, the demonstration that p21 may prevent 
cell death supports the protective role of p53 in response to DNA damage. However, 
it was also clear that neither p53 nor p2I alone were sufficient to protect cells from 
AAV-induced apoptosis. As such we examined the signalling components 
downstream of p53 and p2I.
p21 inhibits CDKs and thus cell cycle progression. One o f the fundamental targets of 
cyclin-CDK complexes is pRb (1). We demonstrate that AAV activates not only p53 
leading to the increased expression of p21 but that this also leads to the activation of 
pRb. By inhibition o f pRb expression in the context of functional p53 and p21 the 
data highlighted in figure 3.1.8 demonstrates that pRb is also required for the 
resistance of cells to AAV-induced cell death. While the activation of pRb is 
important in terms of restricting progression through the cell cycle, such activation 
may also function to suppress E2F from inducing apoptosis (65). However, in 
addition to pro-apoptotic targets o f E2F transactivation, E2F also stimulates the 
transcription o f repair proteins (224). As such it is unlikely that pRb exerts its 
protective role through E2F transcription inhibition. The ability of pRb to suppress 
cell death may be via its ability to inhibit the activity of c-Jun N-terminal kinase 
(JNK) (143). This infers a further role for p53 signalling as p53 itself has been shown 
to directly inhibit JNK-mediated cell death (165). In summary, while p53 signalling is 
a well-characterised in terms of induction o f apoptosis, we know that several aspects
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of p53-p21-pRb pathway may function in the protection against cell death in response 
to DNA damage. The importance of p53 signalling and more specifically the 
competent signal transduction that can lead to the activation (dephosphorylation) of 
pRb following the activation of p53 became clear with regard to preventing AAV- 
induced cell death. From this observation it was our objective to understand the 
mechanism of cell death induction and how this may be connected to p53 signalling to 
confer a protective role to this pro-apoptotic mediator.
AAV Activation of p84N5
The process o f apoptosis in mammalian cells in mediated almost exclusively by two 
well-characterised pathways, the intrinsic and the extrinsic pathways. The 
fundamental difference is that the intrinsic pathway is activated by a stimulus from 
within the cell while the extrinsic pathway is activated in response to external stimuli. 
Despite their differences both pathways are carried out by defined groups o f caspase 
proteins in distinct cascades. The family o f caspase enzymes are cysteine proteases 
that facilitate the proteolytic cleavage o f cellular proteins upon activation o f an 
apoptotic programme (226) The intrinsic pathway is mediated by the mitochondria 
(289) and involves the activation o f caspase 9 and subsequently a cascade of caspase 
activation that converges on the activation of caspase-3. However the binding of 
extracellular death ligands leads to the activation o f the initiator caspase, caspase-8 
then followed by the activation o f the effector caspase, caspase-3 (167). In mammals 
the initiator caspases and effector caspases are grouped as follows, caspases-2, -8, -9, 
and 10 represent initiator caspases while caspases-3, -6 and -7  are known as the 
effector caspases. The initiator caspases are auto-activated leading to the activation of 
downstream effector caspases. Caspase activation coincides with the cleavage o f pro- 
caspase proteins.
In our efforts to identify the apoptotic mediator o f AAV-induced cell death, we 
examined caspase activation since, as described, the profile of caspase activation can 
be indicative o f the nature of apoptotic cell death. Based on the identification o f the 
activation of at least caspase-3 and -6  in response to AAV, and the demonstrated 
presiding importance of caspase-6, it was possible to refine the search for apoptotic 
mediator to a few significant points. The role o f caspase-6 in terms o f apoptosis is not
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well defined. It remains unclear whether capsase-6 is activated prior to or as a 
consequence o f caspase-3 activation. Our results suggested a role for caspease-6 that 
may not require caspase-3 and as such it allowed further refinement of the search for a 
the apoptotic mediator o f AAV-induced cell death. The reports o f caspase-6 activation 
and targets are few but o f particular significance is the involvement of caspase-6 in 
cell death mediated by death effector domain (DED)-containing proteins (235). The 
DED is a protein/protein interaction domain found predominantly in proteins involved 
in apoptotic signalling. One such protein known as DEDD has been shown to localise 
to nucleoli substructures, activate caspase-6 and inhibit RNA polymerase I. We 
considered other such proteins, in particular the p84N5 protein.
The literature base for p84N5 is relatively small but there are several key observations 
that have been made regarding p84N5-induced apoptosis, which highlights a 
remarkable similarity to AAV-induced cell death. Here we show that AAV induces a 
G2 arrest, which precedes apoptosis and that apoptosis is associated with the 
activation of caspase-6. In the case o f p84N5-induced cell death it was observed that 
prior to the onset o f apoptosis, a G2/M phase cell-cycle checkpoint was also observed 
(76). p84N5 contains a region o f significant similarity to the death domain region 
containing proteins that are involved in apoptotic signalling and indeed the ability of 
p84N5 to induce apoptosis is dependent upon the intact nature of such a death 
domain. Furthermore, direct evidence associates the activation of caspase-6 with 
p84N5-induced apoptosis (77). The process o f p84N5-mediated apoptosis coincides 
with the cleavage o f full-length p84N5. While the process of p84N5 cleavage has not 
been fully investigated it is hypothesised to be a consequence of caspase-dependent 
proteolysis by consideration o f specific caspase cleavage sites (271).
However, one of the most profound connections, which allowed us to bridge the gap 
between the apparent protective role o f p53 signalling and AAV-mediated cell death 
was the report that activated pRb is a potent inhibitor of p84N5’s apoptotic activity 
(75). Upon further investigation we found that AAV does indeed activate p84N5 and 
furthermore in the absence of p84N5 activity, cells demonstrate resistance to AAV- 
induced cell death. As such the data supported a model in which two pathways are 
activated by the AAV-induced DNA damage response. The balance of these two 
pathways dictates life or death for the cell. The model details that upon AAV
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infection, the AAV DNA is introduced to the nucleus. The cell recognises the AAV 
DNA as a DNA lesion and as such a DNA damage response takes place. 
Consequently at least two pathways are activated. Firstly, p53 activation takes place 
leading to the increased expression o f p21, which in turn promotes the activation of 
pRb by dephosphorylation. In parallel a second signalling pathway is set in motion to 
activate the apoptotic activity o f p84N5.
In cells in which the p53-p21-pRb signalling pathway is complete, this stream of 
signalling causes transient cell cycle arrest and p84N5 activation is prevented by 
hypophosphorylated pRb. However, in the absence of functional p53 signalling that 
would normally result in the activation o f pRb, p84N5 activation is unrestrained and 
as such is able to initiate an apoptotic cascade that leads to the activation of caspase-6 
and subsequently cell death. However it must be highlighted that there are certain 
unresolved issues that remain to be addressed. These include a full analysis of all key 
caspases and their potential role in the cell death observed here. Furthermore a 
thorough analysis o f the phosphorylation status of pRb in Saos cells and the ability of 
activated pRb to inhibit p84N5 has not been addressed here but rather in previous 
work by other groups (75). In the interest o f completion it would be beneficial to more 
thoroughally address these issues in accompaniment to the data presented here.
Furthermore, while UV-AAV was used for the experiments described above to 
prevent viral transcription it would be interesting to consider whether a artificially 
manufactured non-UV irradiated hairpin DNA or similar structure to the AAV 
genome lacking coding regions may produce a similar effect.
p53 signalling and inhibition of cell death
Cellular stress such as DNA damage can lead to genetic changes, which by their very 
nature will be passed on from generation to generation of the cell. This is the very 
foundation upon which cancer builds; the cumulative amass of mutations. As such it 
is pivotal that 'incidents’ that could generate mutation are dealt with at the point when 
still detectable i.e. at the point o f DNA damage. This is the fundamental role of p53 as 
a tumour suppressor, to respond to DNA damage and deal with it accordingly. In the 
light o f potential damage to the cellular genome it is without a doubt that the safest 
option is to remove the potentially compromised cell by inducing cell death, thus
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protecting the whole organism in the long-term. This is the long-standing, well- 
documented pro-apoptotic activity of p53. Experimental evidence supports the notion 
o f p53's over-riding pro-apoptotic propensity by observing the outcome of drug- 
treatment or radiation-induced lesion generation. It is without a doubt that such 
treatments yield multiple lesions o f various types to the cellular genome. In these 
instances p53 activation leads to cell death, but what is the outcome of p53 activation 
when levels o f damage are low? Can p53 modulate its activity to accommodate 
varying degrees o f damage and thus risk? The possibility that this may be the case has 
recently emerged and there is increasing evidence that p53 may promote cell survival 
in the light of DNA damage. Our data support such a notion in which p53 signalling 
may prevent apoptosis. It is important to appreciate the complex modulation of life 
and death that p53 co-ordinates. p53’s role as a pivot between the two warrants more 
thorough investigation. To do so, it is likely that we will need to refine our methods 
for inducing a DNA damage response. As such AAV represents an interesting tool 
since introducing AAV DNA as the substrate for a DNA damage response does not 
cause damage to the cellular genome in any way and can be titrated to introduce a 
approximately defined number o f ‘lesions’. As a tool to generate a DNA damage 
response, AAV can be more easily controlled within an experimental context.
The outcome of p53 signalling is likely to be dependent on the balance of 
transcription-dependent and more controversially, the transcription-independent roles 
of p53. Various groups have considered the role of p53 transcription in determining 
the outcome of DNA damage signalling in terms of survival versus apoptosis. Speidel 
et al 2006 considered the up-regulation o f pro-apoptotic mediators such as Bax, PIG3 
and PUMA as well as anti-apoptotic targets upon p53 activation. They found that 
within the scope o f their study, the transcriptional targets o f p53 did not change 
regardless o f dose of damaging agent but that the outcome was swayed towards 
apoptosis by events independent o f p53 transcription. Their work and that of others in 
which the role of p21 in terms of cell survival has been further considered support the 
concept that p53 activation sets a balanced stage that pivots the outcome for cell 
mortality between survival and death. The non-transcription roles of p53 may also 
contribute to the balance between life and death. For instance p53 has been shown to 
induce apoptosis independently from its ability to affect gene expression. It is 
reported that p53 is able to localise to the mitochondria and directly bind apoptotic
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inhibitors and as such may be actively involved in apoptotic signalling from the 
mitochondria (173). Alternatively, p53 may harbour direct roles in DNA repair via 
inherent exonuclease activity (194) and an ability to bind damaged DNA in a manner 
distinct from its transactivational DNA binding activity (146, 221, 299).
While both the transcriptional and non-transcriptional roles of p53 may determine the 
outcome of DNA damage responses there is clear evidence for cell type specificity in 
determining the outcome o f p53 signalling. For example it has been observed that p53 
is not induced to the same degree between tissue types and furthermore even when 
p53 is stabilised to the same degree between two different cell types the levels o f cell 
death may not be the same between the two (168). Such tissue specific responses to 
p53 is considered to be in part, due to differences in expression of downstream factors 
involved in p53’s regulation o f cell fate (32). There is also evidence for tissue-specific 
expression of p53 inhibitors that may also manipulate signalling toward apoptosis in 
certain tissues (231).
Cell-cycle arrest in response to DNA damage is considered an opportunity to repair 
DNA damage and poses a mechanism by which p53 may be actively participating in 
promoting cell survival. Such a notion is compounded by observations that p53- 
dependent expression of genes involved in DNA repair such as GADD45 and ERCC3 
(86, 252), may promote cell survival via repair in response to DNA damage (251). 
The concept that p53’s ability to induce cell-cycle arrest is a method by which p53 
can encourage cell survival is supported by the work presented here in which we 
demonstrate that it is the p21-inducing activity of p53 that actually prevents apoptosis 
by p84N5.
p84N5’s role in human cancer
As described earlier, the literature available regarding p84N5 is somewhat limited. 
However one might expect that this may change as we begin to understand more 
thoroughly the links between DNA damage and apoptosis. Making such connections 
can often be hindered by variations in nomenclature. p84N5 is also known as Thocl 
or H prl, whose role in transcription has been extensively investigated. As might be 
suggested by the inconsistency of identification, the two roles of p84N5 as both
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apoptotic mediator and alternatively as RNA processing factor have thus far been 
considered rather independently. However, it is likely that these two roles are linked 
and perhaps p84N5 is pivotal in integrating signalling between the process o f 
transcription and the DNA damage surveillance machinery. The following section 
will discuss the current evidence for such a premise and highlight the role that such a 
hypothesis may generate for p84N5 in terms o f tumorigenesis.
Thocl / Hprl or p84N5 as we shall continue to refer to it here is part o f the 
evolutionarily conserved RNA TREX (Transcription/Export) complex. In yeast, the 
TREX complex links transcription with messenger ribonucleoprotein biogenesis, 
RNA processing and RNA export for a subset o f genes (152). The TREX complex is 
required to aid the export o f spliced mRNA from the nucleus where maturation takes 
place, to the cytoplasm to allow mRNA translation (49). DNA damage causes DNA 
lesions that stall not only DNA replication but also RNA transcription. Blockage to 
transcription elongation has been shown to activate p53 in an ATR and RPA- 
dependent manner (69). Such studies suggest that ATR and RPA may also be 
recruited to regions of stalled RNA polymerase II, facilitating a transcription stress 
response (163). Although initially conceptual, the idea that the transcription 
machinery may be involved in DNA damage surveillance and the suppression of 
mutagenesis is proving to be new chapter in our understanding of DNA damage 
recognition. Indeed, the data presented here very pointedly highlights an area in which 
DNA damage responses and transcription control mechanisms overlap. In terms of the 
dual role of p84N5 one might consider the ability o f p84N5 to function in terms of 
both RNA processing and apoptotic signalling as a function o f the cleavage status of 
p84N5. For example, it may be that cleaved p84N5 demonstrates different protein 
interaction properties that mediate apoptotic function as oppose to RNA processing. 
Full-length p84N5's presence in an RNA-processing complex may function in a 
similar way to A TR's presence at the replication fork. In the absence o f DNA 
damage, full-length p84N5 aids in transcription and RNA export. Upon encountering 
a DNA lesion that stalls RNA polymerase, p84N5 may undergo post-translational 
modification, such as cleavage. As such p84N5 may no-longer function in RNA 
processing mechanisms but rather as an apoptotic mediator. The ability o f only 
dephosphorylated pRb to prevent p84N5-mediated apoptosis suggests that p84N5 
may be primed for apoptotic activity during S phase, monitoring replication and DNA
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integrity through transcription The suggestion that transcription might act as a DNA 
damage dosimeter (164) is an interesting hypothesis and perhaps relies on elements of 
the transcriptional machinery recognising DNA damage and signalling to DNA- 
damage response pathways. The identification here o f a pro-apoptotic factor, p84N5, 
that integrates transcription control via the TREX complex with DNA damage 
signalling via p53 represents a candidate mediator o f such function. Particularly since 
we show here that functional p53 signalling is required to prevent apoptosis via 
p84N5.
Such a role for p53 is certainly contrary to the dogma o f p53 function, but as our 
appreciation for the ‘fine-tuning' o f responses to DNA damage evolves so must our 
perception of the elements involved in executing such function. The role o f p53 is of 
course pivotal to maintaining genome integrity, without which cancer is invariably the 
outcome. Perhaps this intermediary role o f p84N5 provides a mechanism by which 
mutagenesis can be avoided when principle ‘guardians’ o f integrity fail i.e. in the 
absence of functional p53. Particularly if we consider the role o f tumour genotype- 
dependent therapy and the fact that p53-/- tumours can be rather resistant to treatment 
when many of our chemotherapeutic agents rely heavily upon the competency o f the 
DNA damage response machinery. The proposition that moving our chemotherapeutic 
focus toward the transcription machinery may provide alternative, clinically relevant 
solutions has already been made (68). Indeed, the increased efficacy o f certain 
treatments that also inhibit transcription has been observed but specific targets have 
not been thoroughly examined. Should this be the case, p84N5 and other members of 
the transcription regulatory machinery may find themselves in the spotlight for cancer 
therapeutics.
The status of p84N5 in human cancers has only recently been considered. One study 
has linked the human TREX complex to breast carcinoma (107). The work suggests 
that increased p84N5 expression is linked to an increase in tumour size, progression 
and metastatic state. The authors demonstrated that siRNA-mediated silencing of 
p84N5 abrogates nuclear export o f mRNA and decreases cellular proliferation. Such a 
result is not entirely unexpected since growth and proliferation are intrinsically linked 
to a requirement for protein production and thus efficient transcription and translation, 
presumably facilitated by the TREX complex and thus p84N5. Perhaps an increase in
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p84N5 expression reflects the disrupted growth pattern inherent in a tumour and its 
microenvironment or perhaps it is causally related to tumorigenesis.
To begin to address the question o f how p84N5 may contribute to a cancer state, the 
requirements for p84N5 by isogenic normal cells and oncogene-transformed cells has 
been compared (151). The data delineates increased apoptosis of neoplastic cells 
depleted of p84N5 when compared to normal cells. Interestingly, normal cells become 
resistant to transformation upon depletion o f p84N5. Such data suggests that cancer 
cells not only require the increased expression o f  p84N5 for survival but also that 
p84N5 be required for the very initial stages o f transformation.
Our data suggests that upon activation o f a DNA damage response induced by AAV, 
the levels o f p84N5 appear to rise (Figure 3.1.12). Perhaps this is akin to the 
stabilisation of p53 protein upon activation o f a DNA damage response. As such it 
may be the case that the increased expression o f p84N5 in metastatic breast carcinoma 
cells reflects the presence o f DNA damage signalling. The activation of DNA damage 
signalling in early tumorigenesis is a recently highlighted phenomenon (20, 104, 283) 
thought to act as an early barrier to tumorigesis. It is likely to be activated by aberrant 
DNA replication or the attenuated to repair DNA lesions that may occur through 
replication. It is of course important to understand the dynamics of expression of 
proteins such as p84N5 whose expression appears to be increased in response to 
tumorigenesis. In doing so we will have a clearer picture of how to approach 
manipulation o f p84N5 or integrated pathways in terms o f beneficial therapeutic 
techniques.
Cancer therapy: p53 signalling and p84 - the check and balance
The data presented here describes a check and balance system between p53 signalling 
and p84N5's pro-apoptotic activation that directly demonstrates a mechanism in 
which p53’s induction of cell cycle checkpoint activators can prevent apoptosis. One 
might speculate that this mechanism prevails when damage signalling is low and thus 
additional signals are not present to sway the balance in favour of apoptosis by 
alternative mechanisms. This reinforces the view of p53 as pivot and provides an 
added dimension for understanding how p53 may orchestrate its role as ‘guardian of 
the genome’.
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Furthermore, understanding the role of p84N5 as a member of the DNA damage 
surveillance pathways and its involvement in response to damage signalling will 
undoubtedly provide insight into the somewhat undeveloped area o f how 
transcription, RNA processing and translation machinery are incorporated in the cell 
to survey and preserve genome integrity.
Our observations may not have been possible if it were not for the subtle way in 
which AAV can generate DNA damage signalling in a cell without causing DNA 
damage and without modulating the emerging DNA damage response. These 
observations are important in that they may pave the way for the generation of drugs 
that specifically target the activation o f p84N5, particularly in the context of tumours 
lacking functional p53 or pRb. These observations may also provide some insight into 
the frequently observed increase in apoptosis o f cells lacking p53, p21 or pRb, the 
principle that underlies many o f the current chemotherapeutic agents (48). However, 
the status o f p53 protein is rarely considered in terms o f therapy administration. 
Perhaps this is because o f the unclear outcome of p53 signalling in response to DNA 
damage in terms of tissue context and overlapping pro-apoptotic and pro-survival 
roles as discussed above. The many instances in which the absence of p53 may 
sensitise cells to cell death may complicate the clinical relevance of p53 status in 
terms of cancer therapeutic intervention (45, 92, 113, 182, 220, 302, 308). However a 
clearer appreciation o f how p53 can protect cells from cell death may provide more 
appropriate therapeutic targets that could circumvent our reliance on p53 activity for 
therapeutic efficacy.
The development in our understanding o f how AAV can selectively mediate the death 
of cells that lack functional p53-p21-pRb signalling may also add some appeal to the 
pursuit o f developing AAV as a delivery system for a DNA damage response in 
cancer therapy directly. The pursuit o f oncolytic viruses once had considerable 
momentum until certain tragic events lead to shunning of such avenues by many of 
the large pharmaceutical companies (180). The principle of oncolytic viruses lies in 
the ability of the engineered virus to replicate only in cancer cells leading to cell death 
of the infected, cancerous cell. The benefits o f such a therapy theoretically lie in the 
transmissibility and selectivity o f the virus and lysis. Viruses that have been
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engineered for use in such a way include Adenoviruses and Vaccinia virus 
derivatives. These viruses are commonly recognised as pathogenic entities and the 
reservations regarding their use in human cancer therapeutics are reasonable. 
However, the potential use o f AAV’s DNA damage inducing potential and selective 
killing of p53-p21-pRb defective cells has not been considered. The potential uses of 
AAV in terms of oncolytic therapy will be considered more in the following chapter.
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Chapter 2 AAV-induced DNA damage signalling as a potential 
factor restricting autonomous replication of AAV
• Helper virus-mediated AAV replication and PIKK protein disruption
• Hyperphosphorylated RPA as a key inhibitor of viral replication
• Viral restriction and oncolytic therapy
H elper virus-mediated AAV replication and PIKK protein disruption
It has long been recognised that AAV replication requires coinfection with a helper 
virus to augment replication. While there are specific helper viral proteins that are 
considered required for this, there appears to be no common mechanism that lends 
help or rather, the cellular restriction factors that ultimately inhibit AAV replication 
hav e not been identified. The autonomous Parvoviruses must wait for cells to enter S 
phase when the cellular factors required by the viruses for replication become 
available. It is clear that among the necessary helper virus functions the ability of 
proteins such as Adenovirus El A to push cells into S phase, providing cellular 
replication factors does indeed 'help ' AAV. However, the question remains, what 
prevents AAV from replicating as the autonomous Parvoviruses during the cells' S 
phase, w ithout a helper virus?
AAV DNA is ver\ quickly recognised by the cellular DNA damage machinery. As 
one might expect, the single-stranded DNA-binding protein RPA binds to the AAV 
genom e but most importantly appears in the hyperphosphorylated form. RPA is a 
heterotrimeric protein consisting o f three subunits. RPA70, 32 and 14. 
Phosphorylation o f the 32 kDa subunit occurs in a cell cycle dependent manner as a 
consequence of CDK activity (72). RPA phosphorylation correlates with the G l/S  
transition, replication and M phase and appears dephosphorylated at the end of M 
phase. Additional sites within the N-terminus of the 32 kDa subunit are 
phosphorv lated following DNA damage to generate hyperphosphorylated RPA. RPA 
is a substrate for DNA-damage dependent phosphorylation by the PIKK proteins; the 
family which includes ATM. ATR and DNA-PK. all of which have been shown to 
phosphorylate RPA in vitro and/ or in vivo (30). Hyperphosphoryiation appears to be 
involved in the signalling o f DNA damage and recruitment o f other repair factors. 
Indeed RPA has been implicated in the activation o f ATR (320) and interacts with 
several cellular proteins including p53. BRCAl and nucleolin (54. 83. 290). As such
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hyperphosphoryiation can play a role in the direction o f DNA-damage induced foci 
formation. We show directly that both AAV DNA and hyperphosphorylated RPA 
colocalise and we also demonstrate the colocalisation o f TopBPl to RPA in similar 
foci following AAV infection (Figures 3.1.1 A and 3 .1 .IB). The DNA damage related 
proteins that associate with AAV DNA in infected cells has been further characterised 
to also include DNA polymerase delta. ATR and the 9/1/1 complex (129).
In non-permissive cells AAV DNA appears restricted to punctate intranuclear foci 
and we wanted to consider if such foci formation was a contributing factor to 
inhibition of AAV replication. When we examined permissive helper virus-AAV 
coinfected cells. AAV DNA did not appear restricted to discrete foci and the number 
o f cells exhibiting such foci was significantly reduced, even in cells that did not 
exhibit a significant increase in the quantity o f AAV DNA. Since PIKK proteins are 
pivotal in the generation o f hyperphosphorylated RPA. and also are members o f DNA 
damage-induced foci we considered whether the helper viruses manipulated ATM. 
ATR and DNA-PK levels or the activation o f ATM. Adenovirus has previously been 
shown to redistribute and degrade components o f the MRN complex and very recently 
such degradation has been implicated in helping replication and transduction of 
recombinant AAV (238). Furthermore the Herpes virus protein ICPO has been shown 
to decrease the expression o f the catalytic subunit o f DNA-PK; DNA-PKcs (147). As 
such it seemed reasonable to examine whether Ad5. HSVl and Vv affect the levels o f 
the PIKK proteins. We found that infection with either of these very different helper 
viruses had some impact on a combination o f ATM. ATR or DNA-PK levels and the 
activation of ATM.
These observations reinforced the hypothesis that PIKK proteins may restrict AAV 
replication. As such we undertook a series o f biochemical studies, the result o f which 
highlighted the importance of DNA-PK in particular. Whilst in the process of 
verifying these observation using direct molecular approaches, the involvement o f 
DNA-PK in inhibiting AAV replication has been further emphasised. The observation 
that H SVl. in these studies, demonstrates the most profound augmentation of AAV 
replication may be a reflection o f the ability o f ICPO to degrade DNA-PK specifically. 
DNA-PK has been shown to be involved in AAV genome processing and viral
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persistence (53). Choi et al found that when using self-complimentary recombinant 
AAV (scAAV), the activity of ATM and DNA-PKcs was required for efficient 
conversion o f the genome into a double-stranded circular form in non-dividing cells 
(53). Perhaps the ATM and DNA-PK enhanced circularisation activity inhibits AAV 
genome amplification or perhaps promotes genome integration. A focus of further 
work will be to examine these possibilities more thoroughly.
Hyperphosphory lated RFA as a key inhibitor of viral replication
We observed that all o f the helper viruses examined in this study promoted a decrease 
in levels of a combination o f PIKK family protein or activation. We questioned 
whether helper virus disruption o f PIKK proteins ultimately prevents the 
hyperphosphoryiation o f RPA and that hyperphosphorylated RPA may be the key 
element in restricting AAV replication and indeed a restriction factor that helper 
viruses have evolved to overcome. Like cellular DNA replication, RPA is required for 
AAV replication, but it is conceivable that hyperphosphorylated RPA may be 
restrictive since hyperphosphorylated species function less efficiently in DNA 
replication and instead promote repair and recombination events (206). We examined 
the phosphory lated species o f RPA generated in response to AAV infection as oppose 
to helper virus infection or coinfection. We found that hyperphosphory lated RPA was 
generated in response to AAV infection (reiterating the immunofluorescence data 
already shown) but not in response to Ad5. HSV or Vv infection or helper virus-AAV 
coinfections. This lends gravity to the proposition that helper viruses prevent the 
generation of hyperphosphorylated forms o f RPA and that this may represent a 
restriction factor for AAV replication. We have generated a novel system for effective 
inhibition of hyperphosphory lated RPA in response to DNA damage whilst retaining 
the replicative functions o f RPA. This tool will prove crucial in ultimately answering 
the question o f whether hyperphosphorylated RPA inhibits AAV replication.
The possibility o f a dual role for DNA-PK and RPA in terms o f AAV restriction must 
not be dismissed. RPA has been also shown to interact with key members of the non- 
homologous end-joining machinery including DNA-PK. RPA dissociates from DNA- 
PK in the event o f DNA damage (241). It is thought that RPA may remain bound to 
single strand DNA. such as that generated during replication, and that encountering a 
double strand break may activate DNA-PK resulting in phosphorylation of RPA
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leading to dissociation o f RPA from the Ku-DNA-PKcs complex, perhaps promoting 
non-homologous end-joining. AAV DNA may present an ideal substrate for the 
activation o f DNA-PK and thus the hyperphosphoryiation o f RPA since it is both a 
single-stranded hairpin loop with a double-stranded portion. Furthermore, since AAV 
DNA is almost invariably processed into a double stranded form even in the absence 
of significant replication, blunt double-strand break-like structures may also represent 
a substrate tor the activation o f DNA-PK. As such the activation of DNA-PK may 
simultaneously lead to detrimental viral processing and the generation o f RPA species 
that are not beneficial to DNA replication.
Viral restriction and oncolytic therapy
Understanding the factors that restrict AAV replication may seem to be interesting 
from a purely academic viewpoint. However, when we consider the potential for 
oncolytic therapy in cancer treatment one might envisage how the two chapters 
discussed here may intertwine. On one hand we have presented a mechanism by 
which a non-pathogenic virus can cause a DNA-damage response that culminates in 
death o f cells that, like many cancer cells, harbour defects in the p53-p21-pRb 
pathway. On the other hand we discuss factors that restrict that same virus from 
replicating. When we consider that one o f the fundamental stumbling blocks to cancer 
therapy and particularly oncolytic cancer therapy is transmission and penetration 
within a target tissue it is clear that wild-type AAV could not function as a 
transmissible entity (this issue is quite separate from the potential uses of recombinant 
A A Vs in gene therapy). However, in terms o f tissue penetration it has been shown 
that AAV may be able to penetrate a solid tissue mass considerably more efficiently 
than Adenovirus for example (87). This is likely a consequence o f the size of AAV. 
one of the smallest DNA viruses reported.
However, if AAV could also replicate to some degree, and as demonstrated here. 
selecti\ely induce cell death in cancer cells. AAV may in this way prove a novel tool 
for penetrating and destroying cancerous tissue. Our current experiments will clarify 
the role of both DNA-PK and / or hyperphosphory lated RPA in terms of inhibition of 
AAV replication. 1 here are numerous DNA-PK inhibitors available that inhibit DNA- 
PK activity specifically with considerable efficacy (see Calbiochem). fhe implication
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of their use to enhance AAV replication may be translated to the concept of their 
restricted use in the locale o f cancerous cells in combination with AAV infection. 
Alternatively, the inhibition of hyperphosphory iation o f RPA may yield a more potent 
augmentation o f AAV replication. Experiments conducted in the course o f this work 
have shown that very low levels o f caffeine can be used to inhibit the 
hyperphosphoryiation o f RPA in response to DNA damage (2 pM) while higher 
concentrations appear to actually cause hyperphosphoryiation, perhaps as a cause of 
replicative stress (Figure 4.2.1). Caffeine inhibition o f RPA hyperphosphoryiation 
most likely occurs as a consequence o f inhibition o f PIKK kinase activity. Low-level 
caffeine treatment to facilitate AAV replication may be of little detrimental 
physiological consequence. This combined with the restricted replication o f a non- 
pathogenic virus, transporting a DNA damage response to selectively kill cancerous 
cells via p84N5 may be an intriguing avenue to pursue in the fields of oncolytic 
therapy.
Our data thus far also highlights the potential role o f PIKK signalling and / or the 
hyperphosphory iation o f RPA in inhibition o f viruses such as Adenoviruses. Herpes 
viruses and the Pox family virus. Vaccinia virus. These viruses remain of pathological 
significance and so perhaps exploring the mechanisms by which these viruses may 
overcome inhibition by PIKK proteins or hyperphosphorylated RPA may provide 
novel anti-viral targets. Furthermore, several dérivâtes o f Adenovirus for example 
have already been generated for use in oncolytic therapy. Perhaps caffeine treatment 
or DNA-PK inhibitors for example would be useful adjuvants along side such therapy 
to increase treatment efficacv.
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AAV Infected U20S treated 
with PI3K Inhibitors
C AAV 1 2 3 4 5 6
RPA
Figure 4.2.1. AAV cau ses the hyperphosphoryiation of 
RPA, which can be Inhibited using 2mM caffeine. The
first lane to the left is an uninfected control. The adjacent 
lane shows the hyperphosphoryiation of RPA that occurs 
following AAV infection. The following lanes were treated 
as follows with PI3K inhibitor drugs for 3 hours prior to 
infection.
Lane 1 -  2mM caffeine. Lane 2 -  4mM caffeine. Lane 3 -  
6mM caffeine. Lane 4 - 4mM caffeine + 30/xM wortmannin, 
Lane 5- 4mM caffeine + lOptM DNA-PK inhibitor. Lane 6 
4mM caffeine + 30/^U wortmannin + 10 DNA-PK 
inhibitor.
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